UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For The Quarterly Period Ended March 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 814-00702
HERCULES CAPITAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Maryland |
|
74-3113410 |
(State or Jurisdiction of Incorporation or Organization) |
|
(IRS Employer Identification Number) |
400 Hamilton Ave., Suite 310 Palo Alto, California (Address of Principal Executive Offices) |
|
94301 (Zip Code) |
|
(650) 289-3060
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Shares, par value $0.001 per share |
HTGC |
New York Stock Exchange |
6.25% Notes due 2033 |
HCXY |
New York Stock Exchange |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
Emerging growth company |
|
☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
||||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
On May 2, 2022, there were 123,879,248 shares outstanding of the Registrant’s common stock, $0.001 par value.
HERCULES CAPITAL, INC.
FORM 10-Q TABLE OF CONTENTS
|
3 |
|||
Item 1. |
|
|
|
3 |
|
|
|
|
3 |
|
|
Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (unaudited) |
|
4 |
|
|
|
|
5 |
|
|
Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited) |
|
6 |
|
|
Consolidated Schedule of Investments as of March 31, 2022 (unaudited) |
|
7 |
|
|
Consolidated Schedule of Investments as of December 31, 2021 |
|
18 |
|
|
|
29 |
|
Item 2. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
61 |
Item 3. |
|
|
|
77 |
Item 4. |
|
|
|
78 |
|
|
79 |
||
Item 1. |
|
|
79 |
|
Item 1A. |
|
|
|
79 |
Item 2. |
|
|
|
80 |
Item 3. |
|
|
80 |
|
Item 4. |
|
|
|
80 |
Item 5. |
|
|
|
80 |
Item 6. |
|
|
|
81 |
|
|
86 |
||
PART I: FINANCIAL INFORMATION
In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Capital, Inc. and its wholly owned subsidiaries, unless the context otherwise requires.
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
(in thousands, except per share data)
|
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Investments, at fair value: |
|
|
|
|
|
|
||
Non-control/Non-affiliate investments (cost of $2,492,877 and $2,293,398, respectively) |
|
$ |
2,511,227 |
|
|
$ |
2,351,560 |
|
Control investments (cost of $85,358 and $84,039, respectively) |
|
|
76,277 |
|
|
|
73,504 |
|
Affiliate investments (cost of $8,167 and $13,547, respectively) |
|
|
4,830 |
|
|
|
9,458 |
|
Total investments, at fair value (cost of $2,586,402 and $2,390,984, respectively) |
|
|
2,592,334 |
|
|
|
2,434,522 |
|
Cash and cash equivalents |
|
|
59,330 |
|
|
|
133,115 |
|
Restricted cash |
|
|
3,127 |
|
|
|
3,150 |
|
Interest receivable |
|
|
19,648 |
|
|
|
17,365 |
|
Right of use asset |
|
|
6,142 |
|
|
|
6,761 |
|
Other assets |
|
|
10,966 |
|
|
|
5,100 |
|
Total assets |
|
$ |
2,691,547 |
|
|
$ |
2,600,013 |
|
|
|
|
|
|
|
|
||
Liabilities |
|
|
|
|
|
|
||
Debt (net of debt issuance costs - Note 5) |
|
$ |
1,323,995 |
|
|
$ |
1,236,303 |
|
Accounts payable and accrued liabilities |
|
|
27,228 |
|
|
|
47,781 |
|
Operating lease liability |
|
|
6,876 |
|
|
|
7,382 |
|
Total liabilities |
|
$ |
1,358,099 |
|
|
$ |
1,291,466 |
|
|
|
|
|
|
|
|
||
Net assets consist of: |
|
|
|
|
|
|
||
Common stock, par value |
|
$ |
124 |
|
|
$ |
117 |
|
Capital in excess of par value |
|
|
1,178,019 |
|
|
|
1,091,907 |
|
Total distributable earnings |
|
|
155,305 |
|
|
|
216,523 |
|
Total net assets |
|
$ |
1,333,448 |
|
|
$ |
1,308,547 |
|
Total liabilities and net assets |
|
$ |
2,691,547 |
|
|
$ |
2,600,013 |
|
|
|
|
|
|
|
|
||
Shares of common stock outstanding ($0.001 par value and 200,000,000 authorized) |
|
|
123,194 |
|
|
|
116,619 |
|
Net asset value per share |
|
$ |
10.82 |
|
|
$ |
11.22 |
|
See notes to consolidated financial statements
3
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Investment income: |
|
|
|
|
|
|
||
Interest income |
|
|
|
|
|
|
||
Non-control/Non-affiliate investments |
|
$ |
60,090 |
|
|
$ |
62,982 |
|
Control investments |
|
|
1,115 |
|
|
|
799 |
|
Affiliate investments |
|
|
1,047 |
|
|
|
1 |
|
Total interest income |
|
|
62,252 |
|
|
|
63,782 |
|
Fee income |
|
|
|
|
|
|
||
Non-control/Non-affiliate investments |
|
|
2,889 |
|
|
|
4,969 |
|
Control investments |
|
|
16 |
|
|
|
8 |
|
Total fee income |
|
|
2,905 |
|
|
|
4,977 |
|
Total investment income |
|
|
65,157 |
|
|
|
68,759 |
|
Operating expenses: |
|
|
|
|
|
|
||
Interest |
|
|
11,647 |
|
|
|
14,750 |
|
Loan fees |
|
|
1,842 |
|
|
|
2,800 |
|
General and administrative |
|
|
3,818 |
|
|
|
3,596 |
|
Tax expenses |
|
|
712 |
|
|
|
1,438 |
|
Employee compensation |
|
|
|
|
|
|
||
Compensation and benefits |
|
|
8,329 |
|
|
|
9,804 |
|
Stock-based compensation |
|
|
4,424 |
|
|
|
2,744 |
|
Total employee compensation |
|
|
12,753 |
|
|
|
12,548 |
|
Total gross operating expenses |
|
|
30,772 |
|
|
|
35,132 |
|
Expenses allocated to the Adviser Subsidiary |
|
|
(1,402 |
) |
|
|
(933 |
) |
Total net operating expenses |
|
|
29,370 |
|
|
|
34,199 |
|
Net investment income |
|
|
35,787 |
|
|
|
34,560 |
|
Net realized gain (loss) and net change in unrealized appreciation (depreciation): |
|
|
|
|
|
|
||
Net realized gain (loss) |
|
|
|
|
|
|
||
Non-control/Non-affiliate investments |
|
|
(2,467 |
) |
|
|
7,770 |
|
Affiliate investments |
|
|
3,772 |
|
|
|
— |
|
Loss on debt extinguishment |
|
|
(3,686 |
) |
|
|
— |
|
Total net realized gain (loss) |
|
|
(2,381 |
) |
|
|
7,770 |
|
Net change in unrealized appreciation (depreciation) |
|
|
|
|
|
|
||
Non-control/Non-affiliate investments |
|
|
(38,949 |
) |
|
|
18,022 |
|
Control investments |
|
|
1,454 |
|
|
|
1,702 |
|
Affiliate investments |
|
|
753 |
|
|
|
2,109 |
|
Total net change in unrealized appreciation (depreciation) |
|
|
(36,742 |
) |
|
|
21,833 |
|
Total net realized gain (loss) and net change in unrealized appreciation (depreciation) |
|
|
(39,123 |
) |
|
|
29,603 |
|
Net increase (decrease) in net assets resulting from operations |
|
$ |
(3,336 |
) |
|
$ |
64,163 |
|
|
|
|
|
|
|
|
||
Net investment income before investment gains and losses per common share: |
|
|||||||
Basic |
|
$ |
0.30 |
|
|
$ |
0.30 |
|
Change in net assets resulting from operations per common share: |
|
|
|
|
|
|
||
Basic |
|
$ |
(0.03 |
) |
|
$ |
0.56 |
|
Diluted |
|
$ |
(0.03 |
) |
|
$ |
0.55 |
|
Weighted average shares outstanding |
|
|
|
|
|
|
||
Basic |
|
|
118,296 |
|
|
|
114,304 |
|
Diluted |
|
|
118,296 |
|
|
|
114,803 |
|
Distributions paid per common share: |
|
|
|
|
|
|
||
Basic |
|
$ |
0.48 |
|
|
$ |
0.37 |
|
See notes to consolidated financial statements
4
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS
(unaudited)
(dollars and shares in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
Capital in |
|
|
Distributable |
|
|
|
|
|||||
|
Common Stock |
|
|
excess |
|
|
Earnings |
|
|
Net |
|
||||||||
For the Three Months Ended March 31, 2022 |
Shares |
|
|
Par Value |
|
|
of par value |
|
|
(loss) |
|
|
Assets |
|
|||||
Balance as of December 31, 2021 |
|
116,619 |
|
|
$ |
117 |
|
|
$ |
1,091,907 |
|
|
$ |
216,523 |
|
|
$ |
1,308,547 |
|
Net increase (decrease) in net assets resulting from operations |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(3,336 |
) |
|
|
(3,336 |
) |
Public offering, net of offering expenses |
|
4,860 |
|
|
|
5 |
|
|
|
85,244 |
|
|
|
— |
|
|
|
85,249 |
|
Issuance of common stock due to stock option exercises |
|
37 |
|
|
|
— |
|
|
|
454 |
|
|
|
— |
|
|
|
454 |
|
Retired shares from net issuance |
|
(2 |
) |
|
|
— |
|
|
|
(32 |
) |
|
|
— |
|
|
|
(32 |
) |
Issuance of common stock under restricted stock plan |
|
765 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
Retired shares for restricted stock vesting |
|
(126 |
) |
|
|
— |
|
|
|
(3,694 |
) |
|
|
— |
|
|
|
(3,694 |
) |
Distributions reinvested in common stock |
|
60 |
|
|
|
— |
|
|
|
1,025 |
|
|
|
— |
|
|
|
1,025 |
|
Issuance of common stock from conversion of 2022 Convertible Notes |
|
981 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
Distributions |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(57,882 |
) |
|
|
(57,882 |
) |
Stock-based compensation (1) |
|
— |
|
|
|
— |
|
|
|
3,117 |
|
|
|
— |
|
|
|
3,117 |
|
Balance as of March 31, 2022 |
|
123,194 |
|
|
$ |
124 |
|
|
$ |
1,178,019 |
|
|
$ |
155,305 |
|
|
$ |
1,333,448 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
Capital in |
|
|
Distributable |
|
|
|
|
|||||
|
|
Common Stock |
|
|
excess |
|
|
Earnings |
|
|
Net |
|
||||||||
For the Three Months Ended March 31, 2021 |
|
Shares |
|
|
Par Value |
|
|
of par value |
|
|
(loss) |
|
|
Assets |
|
|||||
Balance as of December 31, 2020 |
|
|
114,726 |
|
|
$ |
115 |
|
|
$ |
1,158,198 |
|
|
$ |
133,391 |
|
|
$ |
1,291,704 |
|
Net increase (decrease) in net assets resulting from operations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
64,163 |
|
|
|
64,163 |
|
Public offering, net of offering expenses |
|
|
— |
|
|
|
— |
|
|
|
(195 |
) |
|
|
— |
|
|
|
(195 |
) |
Issuance of common stock due to stock option exercises |
|
|
222 |
|
|
|
— |
|
|
|
2,745 |
|
|
|
— |
|
|
|
2,745 |
|
Retired shares from net issuance |
|
|
(50 |
) |
|
|
— |
|
|
|
(603 |
) |
|
|
— |
|
|
|
(603 |
) |
Issuance of common stock under restricted stock plan |
|
|
924 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
Retired shares for restricted stock vesting |
|
|
(121 |
) |
|
|
— |
|
|
|
(3,181 |
) |
|
|
— |
|
|
|
(3,181 |
) |
Distributions reinvested in common stock |
|
|
67 |
|
|
|
— |
|
|
|
1,040 |
|
|
|
— |
|
|
|
1,040 |
|
Distributions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(42,795 |
) |
|
|
(42,795 |
) |
Stock-based compensation (1) |
|
|
— |
|
|
|
— |
|
|
|
2,516 |
|
|
|
— |
|
|
|
2,516 |
|
Balance as of March 31, 2021 |
|
|
115,768 |
|
|
$ |
116 |
|
|
$ |
1,160,519 |
|
|
$ |
154,759 |
|
|
$ |
1,315,394 |
|
See notes to consolidated financial statements
5
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
For the Three Months Ended March 31, |
|
|||||
|
2022 |
|
|
2021 |
|
||
Cash flows used in operating activities: |
|
|
|
|
|
||
Net increase (decrease) in net assets resulting from operations |
$ |
(3,336 |
) |
|
$ |
64,163 |
|
Adjustments to reconcile net increase in net assets resulting from |
|
|
|
|
|
||
Purchases of investments |
|
(351,601 |
) |
|
|
(355,333 |
) |
Fundings allocated to Adviser Funds |
|
61,081 |
|
|
|
48,353 |
|
Principal and fee payments received on investments |
|
96,311 |
|
|
|
209,747 |
|
Proceeds from the sale of investments |
|
8,816 |
|
|
|
12,973 |
|
Net unrealized (appreciation) depreciation |
|
36,742 |
|
|
|
(21,833 |
) |
Net realized (gain) loss |
|
(1,305 |
) |
|
|
(7,770 |
) |
Accretion of paid-in-kind principal |
|
(4,976 |
) |
|
|
(2,475 |
) |
Accretion of loan discounts |
|
(972 |
) |
|
|
(1,176 |
) |
Accretion of loan discount on convertible notes |
|
112 |
|
|
|
168 |
|
Accretion of loan exit fees |
|
(5,709 |
) |
|
|
(5,744 |
) |
Change in loan income, net of collections |
|
3,535 |
|
|
|
13,414 |
|
Unearned fees related to unfunded commitments |
|
1,037 |
|
|
|
(1,505 |
) |
Loss on debt extinguishment |
|
3,686 |
|
|
|
— |
|
Amortization of debt issuance costs |
|
1,371 |
|
|
|
2,156 |
|
Depreciation and amortization |
|
54 |
|
|
|
94 |
|
Stock-based compensation and amortization of restricted stock grants (1) |
|
3,117 |
|
|
|
2,516 |
|
Change in operating assets and liabilities: |
|
|
|
|
|
||
Interest receivable |
|
(2,289 |
) |
|
|
(1,520 |
) |
Other assets |
|
(13,229 |
) |
|
|
1,849 |
|
Accrued liabilities |
|
(21,067 |
) |
|
|
(8,496 |
) |
Net cash provided by (used in) operating activities |
|
(188,622 |
) |
|
|
(50,419 |
) |
|
|
|
|
|
|
||
Cash flows used in investing activities: |
|
|
|
|
|
||
Purchases of capital equipment |
|
(50 |
) |
|
|
(12 |
) |
Net cash used in investing activities |
|
(50 |
) |
|
|
(12 |
) |
|
|
|
|
|
|
||
Cash flows provided by (used in) financing activities: |
|
|
|
|
|
||
Issuance of common stock |
|
86,184 |
|
|
|
— |
|
Offering expenses |
|
(935 |
) |
|
|
(195 |
) |
Retirement of employee shares, net |
|
(3,272 |
) |
|
|
(1,039 |
) |
Distributions paid |
|
(56,857 |
) |
|
|
(41,755 |
) |
Issuance of debt |
|
535,500 |
|
|
|
342,218 |
|
Repayment of debt |
|
(441,000 |
) |
|
|
(397,727 |
) |
Debt issuance costs |
|
(4,140 |
) |
|
|
(1,842 |
) |
Fees paid for credit facilities and debentures |
|
(616 |
) |
|
|
(35 |
) |
Net cash provided by (used in) financing activities |
|
114,864 |
|
|
|
(100,375 |
) |
Net increase (decrease) in cash, cash equivalents, and restricted cash |
|
(73,808 |
) |
|
|
(150,806 |
) |
Cash, cash equivalents, and restricted cash at beginning of period |
|
136,265 |
|
|
|
237,622 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
62,457 |
|
|
$ |
86,816 |
|
|
|
|
|
|
|
||
Supplemental disclosures of cash flow information and non-cash investing and financing activities: |
|
||||||
Interest paid |
$ |
19,010 |
|
|
$ |
17,359 |
|
Income tax, including excise tax, paid |
$ |
7,119 |
|
|
$ |
3,488 |
|
Distributions reinvested |
$ |
1,025 |
|
|
$ |
1,040 |
|
The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:
|
For the Three Months Ended March 31, |
|
|||||
(Dollars in thousands) |
2022 |
|
|
2021 |
|
||
Cash and cash equivalents |
$ |
59,330 |
|
|
$ |
74,987 |
|
Restricted cash |
|
3,127 |
|
|
|
11,829 |
|
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows |
$ |
62,457 |
|
|
$ |
86,816 |
|
See “Note 2 – Summary of Significant Accounting Policies” for a description of restricted cash and cash equivalents.
See notes to consolidated financial statements
6
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Cytracom Holdings LLC |
|
Senior Secured |
February 2025 |
3-month LIBOR + 9.31% or Floor rate of 10.31% |
|
$ |
8,978 |
|
|
$ |
8,793 |
|
|
$ |
8,678 |
|
|
(11)(16)(17) |
Rocket Lab Global Services, LLC |
|
Senior Secured |
June 2024 |
PRIME + 4.90% or Floor rate of 8.15%, PIK Interest 1.25%, 3.25% Exit Fee |
|
$ |
88,819 |
|
|
|
88,839 |
|
|
|
90,873 |
|
|
(13)(15) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
97,632 |
|
|
|
99,551 |
|
|
|
||||
Subtotal: Communications & Networking (7.47%)* |
|
|
|
|
|
|
97,632 |
|
|
|
99,551 |
|
|
|
||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Grove Collaborative, Inc. |
|
Senior Secured |
April 2025 |
PRIME + 5.50% or Floor rate of 8.75%, 6.75% Exit Fee |
|
$ |
23,520 |
|
|
|
23,351 |
|
|
|
25,813 |
|
|
(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
23,351 |
|
|
|
25,813 |
|
|
|
||||
Subtotal: Consumer & Business Products (1.94%)* |
|
|
|
|
|
|
23,351 |
|
|
|
25,813 |
|
|
|
||||
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gibraltar Business Capital, LLC |
|
Unsecured |
September 2026 |
FIXED 14.50% |
|
$ |
15,000 |
|
|
|
14,674 |
|
|
|
13,628 |
|
|
(7) |
|
|
Unsecured |
September 2026 |
FIXED 11.50% |
|
$ |
10,000 |
|
|
|
9,830 |
|
|
|
9,329 |
|
|
(7) |
Total Gibraltar Business Capital, LLC |
|
|
|
|
|
$ |
25,000 |
|
|
|
24,504 |
|
|
|
22,957 |
|
|
|
Hercules Adviser LLC |
|
Unsecured |
May 2023 |
FIXED 5.00% |
|
$ |
10,150 |
|
|
|
10,150 |
|
|
|
10,150 |
|
|
(7) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
34,654 |
|
|
|
33,107 |
|
|
|
||||
Subtotal: Diversified Financial Services (2.48%)* |
|
|
|
|
|
|
34,654 |
|
|
|
33,107 |
|
|
|
||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Chemocentryx, Inc. |
|
Senior Secured |
December 2022 |
PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee |
|
$ |
18,951 |
|
|
|
20,083 |
|
|
|
20,083 |
|
|
(10) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
20,083 |
|
|
|
20,083 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Albireo Pharma, Inc. |
|
Senior Secured |
July 2024 |
PRIME + 5.90% or Floor rate of 9.15%, 6.95% Exit Fee |
|
$ |
10,000 |
|
|
|
10,277 |
|
|
|
10,325 |
|
|
(10)(11) |
Aldeyra Therapeutics, Inc. |
|
Senior Secured |
October 2023 |
PRIME + 3.10% or Floor rate of 8.60%, 6.95% Exit Fee |
|
$ |
15,000 |
|
|
|
15,697 |
|
|
|
15,633 |
|
|
|
Applied Genetic Technologies Corporation |
|
Senior Secured |
April 2024 |
PRIME + 6.50% or Floor rate of 9.75%, 6.95% Exit Fee |
|
$ |
20,000 |
|
|
|
20,564 |
|
|
|
20,421 |
|
|
|
Aveo Pharmaceuticals, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 6.40% or Floor rate of 9.65%, 6.95% Exit Fee |
|
$ |
40,000 |
|
|
|
41,037 |
|
|
|
40,882 |
|
|
(11)(14) |
Axsome Therapeutics, Inc. |
|
Senior Secured |
October 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 5.82% Exit Fee |
|
$ |
50,000 |
|
|
|
49,669 |
|
|
|
49,204 |
|
|
(10)(12) |
Bicycle Therapeutics PLC |
|
Senior Secured |
October 2024 |
PRIME + 5.60% or Floor rate of 8.85%, 5.00% Exit Fee |
|
$ |
24,000 |
|
|
|
24,352 |
|
|
|
24,568 |
|
|
(5)(10)(11)(12) |
BiomX, INC |
|
Senior Secured |
September 2025 |
PRIME + 5.70% or Floor rate of 8.95%, 6.55% Exit Fee |
|
$ |
9,000 |
|
|
|
9,028 |
|
|
|
8,930 |
|
|
(5)(10)(11) |
BridgeBio Pharma, Inc. |
|
Senior Secured |
November 2026 |
FIXED 9.00%, 2.00% Exit Fee |
|
$ |
38,149 |
|
|
|
37,663 |
|
|
|
37,663 |
|
|
(13)(16) |
Cellarity, Inc. |
|
Senior Secured |
June 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 3.75% Exit Fee |
|
$ |
30,000 |
|
|
|
29,524 |
|
|
|
29,524 |
|
|
(14) |
Center for Breakthrough Medicines Holdings, LLC |
|
Senior Secured |
May 2024 |
PRIME + 5.50% or Floor rate of 8.75%, 7.50% Exit Fee |
|
$ |
5,000 |
|
|
|
5,097 |
|
|
|
5,097 |
|
|
|
Century Therapeutics, Inc. |
|
Senior Secured |
April 2024 |
PRIME + 6.30% or Floor rate of 9.55%, 3.95% Exit Fee |
|
$ |
10,000 |
|
|
|
10,117 |
|
|
|
10,343 |
|
|
(11) |
Chemocentryx, Inc. |
|
Senior Secured |
February 2025 |
PRIME + 3.25% or Floor rate of 8.50%, 7.15% Exit Fee |
|
$ |
5,000 |
|
|
|
5,178 |
|
|
|
5,076 |
|
|
(10) |
Codiak Biosciences, Inc. |
|
Senior Secured |
October 2025 |
PRIME + 5.00% or Floor rate of 8.25%, 5.50% Exit Fee |
|
$ |
25,000 |
|
|
|
25,531 |
|
|
|
25,191 |
|
|
(11) |
See notes to consolidated financial statements
7
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Corium, Inc. |
|
Senior Secured |
September 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 7.75% Exit Fee |
|
$ |
132,675 |
|
|
$ |
132,127 |
|
|
$ |
133,126 |
|
|
(15) |
Eloxx Pharmaceuticals, Inc. |
|
Senior Secured |
April 2025 |
PRIME + 6.25% or Floor rate of 9.50%, 6.55% Exit Fee |
|
$ |
12,500 |
|
|
|
12,518 |
|
|
|
12,329 |
|
|
(14) |
enGene, Inc. |
|
Senior Secured |
July 2025 |
PRIME + 5.00% or Floor rate of 8.25%, 6.35% Exit Fee |
|
$ |
7,000 |
|
|
|
6,909 |
|
|
|
6,909 |
|
|
(5)(10) |
G1 Therapeutics, Inc. |
|
Senior Secured |
November 2026 |
PRIME + 5.90% or Floor rate of 9.15%, 9.86% Exit Fee |
|
$ |
58,125 |
|
|
|
58,070 |
|
|
|
58,070 |
|
|
(10)(11)(12)(14)(16) |
Geron Corporation |
|
Senior Secured |
October 2024 |
PRIME + 5.75% or Floor rate of 9.00%, 6.55% Exit Fee |
|
$ |
32,500 |
|
|
|
32,896 |
|
|
|
32,852 |
|
|
(10)(12) |
Hibercell, Inc. |
|
Senior Secured |
May 2025 |
PRIME + 5.40% or Floor rate of 8.65%, 4.95% Exit Fee |
|
$ |
17,000 |
|
|
|
17,107 |
|
|
|
17,036 |
|
|
(14) |
Humanigen, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.50% or Floor rate of 8.75%, 6.75% Exit Fee |
|
$ |
20,000 |
|
|
|
20,333 |
|
|
|
19,972 |
|
|
(9)(10) |
Kaleido Biosciences, Inc. |
|
Senior Secured |
January 2024 |
PRIME + 6.10% or Floor rate of 9.35%, 7.55% Exit Fee |
|
$ |
5,776 |
|
|
|
6,937 |
|
|
|
1,880 |
|
|
(12) |
Locus Biosciences, Inc. |
|
Senior Secured |
July 2025 |
PRIME + 6.10% or Floor rate of 9.35%, 4.95% Exit Fee |
|
$ |
8,000 |
|
|
|
8,012 |
|
|
|
7,956 |
|
|
(14) |
Nabriva Therapeutics |
|
Senior Secured |
June 2023 |
PRIME + 4.30% or Floor rate of 9.80%, 6.95% Exit Fee |
|
$ |
5,000 |
|
|
|
5,544 |
|
|
|
5,499 |
|
|
(5)(10) |
Phathom Pharmaceuticals, Inc. |
|
Senior Secured |
October 2026 |
PRIME + 2.25% or Floor rate of 5.50%, PIK Interest 3.35%, 7.50% Exit Fee |
|
$ |
87,848 |
|
|
|
87,147 |
|
|
|
85,646 |
|
|
(10)(12)(13)(14)(15)(16) |
Redshift Bioanalytics, Inc. |
|
Senior Secured |
April 2025 |
PRIME + 4.25% or Floor rate of 7.50%, 3.80% Exit Fee |
|
$ |
1,500 |
|
|
|
1,472 |
|
|
|
1,472 |
|
|
(14) |
Scynexis, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.80% or Floor rate of 9.05%, 3.95% Exit Fee |
|
$ |
18,667 |
|
|
|
18,431 |
|
|
|
18,349 |
|
|
(12) |
Seres Therapeutics, Inc. |
|
Senior Secured |
October 2024 |
Prime + 6.40% or Floor rate of 9.65%, 4.98% Exit Fee |
|
$ |
37,500 |
|
|
|
38,263 |
|
|
|
38,263 |
|
|
(12) |
Syndax Pharmaceutics Inc. |
|
Senior Secured |
April 2024 |
PRIME + 6.00% or Floor rate of 9.25%, 4.99% Exit Fee |
|
$ |
20,000 |
|
|
|
20,695 |
|
|
|
20,661 |
|
|
(12)(16) |
Tarsus Pharmaceuticals, Inc. |
|
Senior Secured |
February 2027 |
PRIME + 5.20% or Floor rate of 8.45%, 4.75% Exit Fee |
|
$ |
8,250 |
|
|
|
8,218 |
|
|
|
8,218 |
|
|
(10)(16) |
TG Therapeutics, Inc. |
|
Senior Secured |
January 2026 |
PRIME + 2.15% or Floor rate of 5.40%, PIK Interest 3.45%, 5.95% Exit Fee |
|
$ |
51,751 |
|
|
|
50,980 |
|
|
|
50,980 |
|
|
(10)(12)(13) |
uniQure B.V. |
|
Senior Secured |
December 2025 |
PRIME + 4.70% or Floor rate of 7.95%, 7.28% Exit Fee |
|
$ |
77,500 |
|
|
|
79,086 |
|
|
|
79,086 |
|
|
(5)(10)(11)(12)(15) |
Unity Biotechnology, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 6.10% or Floor rate of 9.35%, 6.25% Exit Fee |
|
$ |
20,000 |
|
|
|
20,807 |
|
|
|
20,983 |
|
|
|
Valo Health, LLC |
|
Senior Secured |
May 2024 |
PRIME + 6.45% or Floor rate of 9.70%, 3.85% Exit Fee |
|
$ |
11,500 |
|
|
|
11,606 |
|
|
|
11,541 |
|
|
(11) |
X4 Pharmaceuticals, Inc. |
|
Senior Secured |
July 2024 |
PRIME + 3.75% or Floor rate of 8.75%, 8.80% Exit Fee |
|
$ |
32,500 |
|
|
|
33,392 |
|
|
|
33,262 |
|
|
(11)(12) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
954,284 |
|
|
|
946,947 |
|
|
|
||||
Subtotal: Drug Discovery & Development (72.52%)* |
|
|
|
|
|
|
974,367 |
|
|
|
967,030 |
|
|
|
||||
Healthcare Services, Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Better Therapeutics, Inc. |
|
Senior Secured |
August 2025 |
PRIME + 5.70% or Floor rate of 8.95%, 5.95% Exit Fee |
|
$ |
8,000 |
|
|
|
8,007 |
|
|
|
7,932 |
|
|
(14)(16) |
Blue Sprig Pediatrics, Inc. |
|
Senior Secured |
November 2026 |
1-Month LIBOR + 5.00% or Floor rate of 6.00%, PIK Interest 4.45% |
|
$ |
25,301 |
|
|
|
24,946 |
|
|
|
24,946 |
|
|
(13)(16) |
Carbon Health Technologies, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.60% or Floor rate of 8.85%, 4.61% Exit Fee |
|
$ |
46,125 |
|
|
|
46,099 |
|
|
|
46,099 |
|
|
(12)(16)(18) |
Equality Health, LLC |
|
Senior Secured |
February 2026 |
PRIME + 6.25% or Floor rate of 9.50%, PIK Interest 1.55% |
|
$ |
35,582 |
|
|
|
35,254 |
|
|
|
35,176 |
|
|
(12)(13)(16) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
114,306 |
|
|
|
114,153 |
|
|
|
||||
Subtotal: Healthcare Services, Other (8.56%)* |
|
|
|
|
|
|
114,306 |
|
|
|
114,153 |
|
|
|
||||
See notes to consolidated financial statements
8
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capella Space Corp. |
|
Senior Secured |
November 2024 |
PRIME + 5.00% or Floor rate of 8.25%, PIK Interest 1.10%, 4.00% Exit Fee |
|
$ |
20,080 |
|
|
$ |
19,903 |
|
|
$ |
19,469 |
|
|
(13)(14)(18) |
Yipit, LLC |
|
Senior Secured |
September 2026 |
1-month LIBOR + 9.08% or Floor rate of 10.08% |
|
$ |
31,875 |
|
|
|
31,291 |
|
|
|
30,730 |
|
|
(16)(17) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
51,194 |
|
|
|
50,199 |
|
|
|
||||
Subtotal: Information Services (3.76%)* |
|
|
|
|
|
|
51,194 |
|
|
|
50,199 |
|
|
|
||||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Nextroll, Inc. |
|
Senior Secured |
June 2022 |
1-month LIBOR + 9.28% or Floor rate of 10.28%, 3.50% Exit Fee |
|
$ |
21,715 |
|
|
|
22,377 |
|
|
|
22,377 |
|
|
(12)(13)(18) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
22,377 |
|
|
|
22,377 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
AppDirect, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 5.90% or Floor rate of 9.15%, 7.95% Exit Fee |
|
$ |
30,790 |
|
|
|
31,592 |
|
|
|
32,371 |
|
|
|
Carwow LTD |
|
Senior Secured |
December 2024 |
PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 1.45%, 4.95% Exit Fee |
|
£ |
21,250 |
|
|
|
28,846 |
|
|
|
28,005 |
|
|
(5)(10)(13) |
Convoy, Inc. |
|
Senior Secured |
March 2026 |
PRIME + 3.20% or Floor rate of 6.45%, PIK Interest 1.95%, 4.55% Exit Fee |
|
$ |
78,000 |
|
|
|
76,210 |
|
|
|
76,210 |
|
|
(15)(18) |
ePayPolicy Holdings, LLC |
|
Senior Secured |
December 2024 |
3-month LIBOR + 8.50% or Floor rate of 9.50% |
|
$ |
8,117 |
|
|
|
7,971 |
|
|
|
8,117 |
|
|
(11) |
Rhino Labs, Inc. |
|
Senior Secured |
March 2024 |
PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 2.25% |
|
$ |
16,219 |
|
|
|
15,892 |
|
|
|
15,998 |
|
|
(13)(14) |
RVShare, LLC |
|
Senior Secured |
December 2026 |
1-month LIBOR + 5.50% or Floor rate of 6.50%, PIK Interest 4.00% |
|
$ |
18,116 |
|
|
|
17,771 |
|
|
|
17,771 |
|
|
(13)(14)(16) |
SeatGeek, Inc. |
|
Senior Secured |
June 2023 |
PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50% |
|
$ |
60,683 |
|
|
|
60,160 |
|
|
|
60,765 |
|
|
(13) |
Skyword, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.90%, 4.00% Exit Fee |
|
$ |
12,486 |
|
|
|
12,749 |
|
|
|
12,590 |
|
|
(13) |
Tectura Corporation |
|
Senior Secured |
July 2024 |
PIK Interest 5.00% |
|
$ |
10,680 |
|
|
|
240 |
|
|
|
— |
|
|
(7)(8)(13) |
|
|
Senior Secured |
July 2024 |
FIXED 8.25% |
|
$ |
8,250 |
|
|
|
8,250 |
|
|
|
8,250 |
|
|
(7) |
|
|
Senior Secured |
July 2024 |
PIK Interest 5.00% |
|
$ |
13,023 |
|
|
|
13,023 |
|
|
|
97 |
|
|
(7)(8)(13) |
Total Tectura Corporation |
|
|
|
|
|
$ |
31,953 |
|
|
|
21,513 |
|
|
|
8,347 |
|
|
|
Thumbtack, Inc. |
|
Senior Secured |
April 2026 |
PRIME + 4.95% or Floor rate of 8.20%, PIK Interest 1.50%, 3.95% Exit Fee |
|
$ |
10,000 |
|
|
|
9,863 |
|
|
|
9,863 |
|
|
(12)(16) |
Veem, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 4.00% or Floor rate of 7.25%, PIK Interest 1.25% |
|
$ |
5,000 |
|
|
|
4,882 |
|
|
|
4,882 |
|
|
(16) |
Worldremit Group Limited |
|
Senior Secured |
February 2025 |
1-month LIBOR + 9.25% or Floor rate of 10.25%, 3.00% Exit Fee |
|
$ |
103,000 |
|
|
|
101,970 |
|
|
|
100,214 |
|
|
(5)(10)(12)(15)(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
389,419 |
|
|
|
375,133 |
|
|
|
||||
Greater than 5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Houzz, Inc. |
|
Convertible Debt |
May 2028 |
PIK Interest 5.50% |
|
$ |
20,960 |
|
|
|
20,960 |
|
|
|
20,725 |
|
|
(9)(13) |
Subtotal: Greater than 5 Years Maturity |
|
|
|
|
|
|
20,960 |
|
|
|
20,725 |
|
|
|
||||
Subtotal: Internet Consumer & Business Services (31.36%)* |
|
|
|
|
|
|
432,756 |
|
|
|
418,235 |
|
|
|
||||
Manufacturing Technology |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Bright Machines, Inc. |
|
Senior Secured |
November 2022 |
PRIME + 5.70% or Floor rate of 8.95%, 6.95% Exit Fee |
|
$ |
15,000 |
|
|
|
15,138 |
|
|
|
15,138 |
|
|
(11)(18) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
15,138 |
|
|
|
15,138 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
MacroFab, Inc. |
|
Senior Secured |
March 2026 |
PRIME + 4.35% or Floor rate of 7.60%, PIK Interest 1.25%, 4.50% Exit Fee |
|
$ |
10,000 |
|
|
|
9,630 |
|
|
|
9,630 |
|
|
(16) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
9,630 |
|
|
|
9,630 |
|
|
|
||||
Subtotal: Manufacturing Technology (1.86%)* |
|
|
|
|
|
|
24,768 |
|
|
|
24,768 |
|
|
|
||||
See notes to consolidated financial statements
9
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Medical Devices & Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Lucira Health, Inc. |
|
Senior Secured |
February 2026 |
PRIME + 5.50% or Floor rate of 8.75%, 5.25% Exit Fee |
|
$ |
15,000 |
|
|
$ |
14,803 |
|
|
$ |
14,803 |
|
|
|
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
14,803 |
|
|
|
14,803 |
|
|
|
||||
Subtotal: Medical Devices & Equipment (1.11%)* |
|
|
|
|
|
|
14,803 |
|
|
|
14,803 |
|
|
|
||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Fungible, Inc. |
|
Senior Secured |
December 2024 |
PRIME + 5.00% or Floor rate of 8.25%, 4.95% Exit Fee |
|
$ |
20,000 |
|
|
|
19,208 |
|
|
|
19,208 |
|
|
(14)(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
19,208 |
|
|
|
19,208 |
|
|
|
||||
Subtotal: Semiconductors (1.44%)* |
|
|
|
|
|
|
19,208 |
|
|
|
19,208 |
|
|
|
||||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Delphix Corp. |
|
Senior Secured |
February 2023 |
PRIME + 5.50% or Floor rate of 10.25%, 7.00% Exit Fee |
|
$ |
60,000 |
|
|
|
62,177 |
|
|
|
62,177 |
|
|
(12)(15)(18) |
Khoros (p.k.a Lithium Technologies) |
|
Senior Secured |
October 2022 |
6-month LIBOR + 8.00% or Floor rate of 9.00% |
|
$ |
56,208 |
|
|
|
55,953 |
|
|
|
55,953 |
|
|
(16) |
Pymetrics, Inc. |
|
Senior Secured |
October 2022 |
PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 1.75%, 4.00% Exit Fee |
|
$ |
9,509 |
|
|
|
9,760 |
|
|
|
9,846 |
|
|
(13) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
127,890 |
|
|
|
127,976 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
3GTMS, LLC |
|
Senior Secured |
February 2025 |
6-month LIBOR + 9.28% or Floor rate of 10.28% |
|
$ |
10,833 |
|
|
|
10,658 |
|
|
|
10,465 |
|
|
(16)(17) |
Agilence, Inc. |
|
Senior Secured |
October 2026 |
1-Month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
9,377 |
|
|
|
9,125 |
|
|
|
9,125 |
|
|
(16) |
Annex Cloud |
|
Senior Secured |
February 2027 |
BSBY + 9.00% or Floor rate of 10.00% |
|
$ |
8,500 |
|
|
|
8,263 |
|
|
|
8,263 |
|
|
(16) |
Brain Corporation |
|
Senior Secured |
April 2025 |
PRIME + 3.70% or Floor rate of 6.95%, PIK Interest 1.00%, 3.95% Exit Fee |
|
$ |
15,041 |
|
|
|
14,953 |
|
|
|
14,953 |
|
|
(13)(14)(16) |
Campaign Monitor Limited |
|
Senior Secured |
November 2025 |
6-month LIBOR + 8.90% or Floor rate of 9.9% |
|
$ |
33,000 |
|
|
|
32,488 |
|
|
|
33,000 |
|
|
(18) |
Ceros, Inc. |
|
Senior Secured |
September 2026 |
6-month LIBOR + 8.89% or Floor rate of 9.89% |
|
$ |
17,978 |
|
|
|
17,495 |
|
|
|
17,154 |
|
|
(16)(17) |
CloudBolt Software, Inc. |
|
Senior Secured |
October 2024 |
PRIME + 6.70% or Floor rate of 9.95%, 2.95% Exit Fee |
|
$ |
10,000 |
|
|
|
9,966 |
|
|
|
10,040 |
|
|
(11)(12)(18) |
Copper CRM, Inc |
|
Senior Secured |
March 2025 |
Prime + 4.50% or Floor rate of 8.25%, PIK Interest 1.95%, 4.50% Exit Fee |
|
$ |
10,000 |
|
|
|
9,884 |
|
|
|
9,884 |
|
|
|
Cybermaxx Intermediate Holdings, Inc. |
|
Senior Secured |
August 2026 |
6-month LIBOR + 9.28% or Floor rate of 10.28% |
|
$ |
8,000 |
|
|
|
7,809 |
|
|
|
7,670 |
|
|
(16) |
Dashlane, Inc. |
|
Senior Secured |
July 2025 |
PRIME + 3.05% or Floor rate of 7.55%, PIK Interest 1.10%, 7.10% Exit Fee |
|
$ |
20,776 |
|
|
|
21,909 |
|
|
|
21,751 |
|
|
(11)(13)(16)(18) |
Demandbase, Inc. |
|
Senior Secured |
August 2025 |
PRIME + 5.25% or Floor rate of 8.50%, 2.33% Exit Fee |
|
$ |
22,500 |
|
|
|
22,088 |
|
|
|
21,941 |
|
|
(16)(18) |
Enmark Systems, Inc. |
|
Senior Secured |
September 2026 |
6-month LIBOR + 6.83% or Floor rate of 7.83%, PIK Interest 2.19% |
|
$ |
8,088 |
|
|
|
7,894 |
|
|
|
7,740 |
|
|
(11)(13)(16)(17) |
Esentire, Inc. |
|
Senior Secured |
May 2024 |
3-month LIBOR + 9.96% or Floor rate of 10.96% |
|
$ |
21,000 |
|
|
|
20,728 |
|
|
|
20,687 |
|
|
(5)(10)(11)(17) |
Esme Learning Solutions, Inc. |
|
Senior Secured |
February 2025 |
PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 1.50%, 3.00% Exit Fee |
|
$ |
5,007 |
|
|
|
4,775 |
|
|
|
4,770 |
|
|
(13) |
Gryphon Networks Corp. |
|
Senior Secured |
January 2026 |
3-month LIBOR + 9.69% or Floor rate of 10.69% |
|
$ |
5,232 |
|
|
|
5,112 |
|
|
|
5,124 |
|
|
(11)(16) |
Ikon Science Limited |
|
Senior Secured |
October 2024 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
6,825 |
|
|
|
6,648 |
|
|
|
6,663 |
|
|
(5)(10)(16)(17) |
See notes to consolidated financial statements
10
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Imperva, Inc. |
|
Senior Secured |
January 2027 |
3-month LIBOR + 7.75% or Floor rate of 8.75% |
|
$ |
20,000 |
|
|
$ |
19,857 |
|
|
$ |
19,997 |
|
|
(18) |
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) |
|
Senior Secured |
July 2023 |
3-month SOFR + 10.15% or Floor rate of 11.15% |
|
$ |
10,957 |
|
|
|
10,751 |
|
|
|
10,711 |
|
|
(17) |
Logicworks |
|
Senior Secured |
January 2024 |
PRIME + 7.50% or Floor rate of 10.75% |
|
$ |
12,000 |
|
|
|
11,878 |
|
|
|
11,979 |
|
|
(12) |
Mixpanel, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 1.80%, 3.00% Exit Fee |
|
$ |
20,523 |
|
|
|
20,443 |
|
|
|
21,172 |
|
|
(12)(13)(18) |
Mobile Solutions Services |
|
Senior Secured |
December 2025 |
6-month LIBOR + 9.87% or Floor rate of 10.87% |
|
$ |
5,500 |
|
|
|
5,359 |
|
|
|
5,292 |
|
|
(16)(17) |
|
|
Senior Secured |
December 2025 |
6-month LIBOR + 9.06% or Floor rate of 10.06% |
|
$ |
12,168 |
|
|
|
11,875 |
|
|
|
11,821 |
|
|
(16)(17) |
Total Mobile Solutions Services |
|
|
|
|
|
$ |
17,668 |
|
|
|
17,234 |
|
|
|
17,113 |
|
|
|
Nuvolo Technologies Corporation |
|
Senior Secured |
July 2025 |
PRIME + 5.25% or Floor rate of 8.50%, 2.04% Exit Fee |
|
$ |
17,500 |
|
|
|
17,454 |
|
|
|
17,460 |
|
|
(12)(16)(18) |
Pollen, Inc. |
|
Senior Secured |
November 2023 |
PRIME + 4.75% or Floor rate of 8.00%, PIK Interest 0.50%, 4.50% Exit Fee |
|
$ |
7,467 |
|
|
|
7,570 |
|
|
|
7,412 |
|
|
(13) |
|
|
Senior Secured |
November 2023 |
PRIME + 5.25% or Floor rate of 8.50%, PIK Interest 1.35%, 4.50% Exit Fee |
|
$ |
13,085 |
|
|
|
13,124 |
|
|
|
13,257 |
|
|
(13)(14) |
Total Pollen, Inc. |
|
|
|
|
|
$ |
20,552 |
|
|
|
20,694 |
|
|
|
20,669 |
|
|
|
ShadowDragon, LLC |
|
Senior Secured |
December 2026 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
6,000 |
|
|
|
5,835 |
|
|
|
5,835 |
|
|
(16)(17) |
Tact.ai Technologies, Inc. |
|
Senior Secured |
February 2024 |
PRIME + 4.00% or Floor rate of 8.75%, PIK Interest 2.00%, 5.50% Exit Fee |
|
$ |
5,211 |
|
|
|
5,359 |
|
|
|
5,297 |
|
|
(13) |
ThreatConnect, Inc. |
|
Senior Secured |
May 2026 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
11,116 |
|
|
|
10,817 |
|
|
|
10,777 |
|
|
(12)(16)(17) |
Udacity, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 4.50% or Floor rate of 7.75%, PIK Interest 2.00%, 3.00% Exit Fee |
|
$ |
51,150 |
|
|
|
51,037 |
|
|
|
52,112 |
|
|
(12)(13) |
VideoAmp, Inc. |
|
Senior Secured |
February 2025 |
PRIME + 3.70% or Floor rate of 6.95%, PIK Interest 1.25%, 5.25% Exit Fee |
|
$ |
62,587 |
|
|
|
60,917 |
|
|
|
60,917 |
|
|
(13)(14)(18) |
Zimperium, Inc. |
|
Senior Secured |
July 2024 |
6-month LIBOR + 8.95% or Floor rate of 9.95% |
|
$ |
17,452 |
|
|
|
17,151 |
|
|
|
17,111 |
|
|
(12)(17) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
479,222 |
|
|
|
480,380 |
|
|
|
||||
Subtotal: Software (45.62%)* |
|
|
|
|
|
|
607,112 |
|
|
|
608,356 |
|
|
|
||||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Impossible Foods, Inc. |
|
Senior Secured |
July 2022 |
PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee |
|
$ |
8,714 |
|
|
|
13,133 |
|
|
|
13,133 |
|
|
(12) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
13,133 |
|
|
|
13,133 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Pineapple Energy LLC |
|
Senior Secured |
December 2024 |
PIK Interest 10.00% |
|
$ |
3,000 |
|
|
|
3,000 |
|
|
|
2,986 |
|
|
(6)(13) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
3,000 |
|
|
|
2,986 |
|
|
|
||||
Subtotal: Sustainable and Renewable Technology (1.21%)* |
|
|
|
|
|
|
16,133 |
|
|
|
16,119 |
|
|
|
||||
Total: Debt Investments (179.34%)* |
|
|
|
|
|
$ |
2,410,284 |
|
|
$ |
2,391,342 |
|
|
|
||||
See notes to consolidated financial statements
11
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
|
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Equity Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Peerless Network Holdings, Inc. |
|
Equity |
10/21/2020 |
Common Stock |
|
|
3,328 |
|
|
$ |
— |
|
|
$ |
18 |
|
|
|
|
|
Equity |
4/11/2008 |
Preferred Series A |
|
|
1,135,000 |
|
|
|
1,230 |
|
|
|
6,242 |
|
|
|
Total Peerless Network Holdings, Inc. |
|
|
|
|
|
|
1,138,328 |
|
|
|
1,230 |
|
|
|
6,260 |
|
|
|
Subtotal: Communications & Networking (0.47%)* |
|
|
|
|
|
1,230 |
|
|
|
6,260 |
|
|
|
|||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) |
|
Equity |
4/30/2010 |
Common Stock |
|
|
42,989 |
|
|
|
128 |
|
|
|
362 |
|
|
|
Subtotal: Consumer & Business Products (0.03%)* |
|
|
|
|
|
128 |
|
|
|
362 |
|
|
|
|||||
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gibraltar Business Capital, LLC |
|
Equity |
3/1/2018 |
Common Stock |
|
|
830,000 |
|
|
|
1,884 |
|
|
|
1,169 |
|
|
(7) |
|
|
Equity |
3/1/2018 |
Preferred Series A |
|
|
10,602,752 |
|
|
|
26,122 |
|
|
|
18,496 |
|
|
(7) |
Total Gibraltar Business Capital, LLC |
|
|
|
|
|
|
11,432,752 |
|
|
|
28,006 |
|
|
|
19,665 |
|
|
|
Hercules Adviser LLC |
|
Equity |
3/26/2021 |
Member Units |
|
|
1 |
|
|
|
35 |
|
|
|
14,544 |
|
|
(7) |
Newfront Insurance Holdings, Inc. |
|
Equity |
9/30/2021 |
Preferred Series D-2 |
|
|
210,282 |
|
|
|
403 |
|
|
|
538 |
|
|
|
Subtotal: Diversified Financial Services (2.61%)* |
|
|
|
|
|
28,444 |
|
|
|
34,747 |
|
|
|
|||||
Drug Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
AcelRx Pharmaceuticals, Inc. |
|
Equity |
12/10/2018 |
Common Stock |
|
|
176,730 |
|
|
|
1,329 |
|
|
|
51 |
|
|
(4) |
Aytu BioScience, Inc. |
|
Equity |
3/28/2014 |
Common Stock |
|
|
13,600 |
|
|
|
1,500 |
|
|
|
15 |
|
|
(4) |
BioQ Pharma Incorporated |
|
Equity |
12/8/2015 |
Preferred Series D |
|
|
165,000 |
|
|
|
500 |
|
|
|
120 |
|
|
|
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) |
|
Equity |
4/6/2015 |
Common Stock |
|
|
2,498 |
|
|
|
309 |
|
|
|
15 |
|
|
(4) |
Subtotal: Drug Delivery (0.02%)* |
|
|
|
|
|
3,638 |
|
|
|
201 |
|
|
|
|||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Albireo Pharma, Inc. |
|
Equity |
9/14/2020 |
Common Stock |
|
|
25,000 |
|
|
|
1,000 |
|
|
|
746 |
|
|
(4)(10) |
Applied Molecular Transport |
|
Equity |
4/6/2021 |
Common Stock |
|
|
1,000 |
|
|
|
42 |
|
|
|
8 |
|
|
(4)(10) |
Avalo Therapeutics, Inc. |
|
Equity |
8/19/2014 |
Common Stock |
|
|
119,087 |
|
|
|
1,000 |
|
|
|
86 |
|
|
(4) |
Aveo Pharmaceuticals, Inc. |
|
Equity |
7/31/2011 |
Common Stock |
|
|
190,179 |
|
|
|
1,715 |
|
|
|
1,063 |
|
|
(4) |
Bicycle Therapeutics PLC |
|
Equity |
10/5/2020 |
Common Stock |
|
|
98,100 |
|
|
|
1,871 |
|
|
|
4,304 |
|
|
(4)(5)(10) |
BridgeBio Pharma, Inc. |
|
Equity |
6/21/2018 |
Common Stock |
|
|
231,329 |
|
|
|
2,255 |
|
|
|
2,348 |
|
|
(4) |
Chemocentryx, Inc. |
|
Equity |
6/15/2020 |
Common Stock |
|
|
17,241 |
|
|
|
1,000 |
|
|
|
432 |
|
|
(4)(10) |
Concert Pharmaceuticals, Inc. |
|
Equity |
2/13/2019 |
Common Stock |
|
|
70,796 |
|
|
|
1,367 |
|
|
|
239 |
|
|
(4)(10) |
Dare Biosciences, Inc. |
|
Equity |
1/8/2015 |
Common Stock |
|
|
13,550 |
|
|
|
1,000 |
|
|
|
20 |
|
|
(4) |
Dynavax Technologies |
|
Equity |
7/22/2015 |
Common Stock |
|
|
20,000 |
|
|
|
550 |
|
|
|
217 |
|
|
(4)(10) |
Genocea Biosciences, Inc. |
|
Equity |
11/20/2014 |
Common Stock |
|
|
27,933 |
|
|
|
2,000 |
|
|
|
35 |
|
|
(4) |
Hibercell, Inc. |
|
Equity |
5/7/2021 |
Preferred Series B |
|
|
3,466,840 |
|
|
|
4,250 |
|
|
|
3,078 |
|
|
(14) |
Humanigen, Inc. |
|
Equity |
3/31/2021 |
Common Stock |
|
|
43,243 |
|
|
|
800 |
|
|
|
130 |
|
|
(4)(10) |
Kaleido Biosciences, Inc. |
|
Equity |
2/10/2021 |
Common Stock |
|
|
86,585 |
|
|
|
1,000 |
|
|
|
- |
|
|
(4) |
NorthSea Therapeutics |
|
Equity |
12/15/2021 |
Preferred Series C |
|
|
983 |
|
|
|
2,000 |
|
|
|
1,873 |
|
|
(5)(10) |
Paratek Pharmaceuticals, Inc. |
|
Equity |
2/26/2007 |
Common Stock |
|
|
76,362 |
|
|
|
2,744 |
|
|
|
227 |
|
|
(4) |
Rocket Pharmaceuticals, Ltd. |
|
Equity |
8/22/2007 |
Common Stock |
|
|
944 |
|
|
|
1,500 |
|
|
|
15 |
|
|
(4) |
Savara, Inc. |
|
Equity |
8/11/2015 |
Common Stock |
|
|
11,119 |
|
|
|
203 |
|
|
|
15 |
|
|
(4) |
Sio Gene Therapies, Inc. |
|
Equity |
2/2/2017 |
Common Stock |
|
|
16,228 |
|
|
|
1,269 |
|
|
|
11 |
|
|
(4)(10) |
Tricida, Inc. |
|
Equity |
2/28/2018 |
Common Stock |
|
|
68,816 |
|
|
|
863 |
|
|
|
566 |
|
|
(4) |
uniQure B.V. |
|
Equity |
1/31/2019 |
Common Stock |
|
|
17,175 |
|
|
|
332 |
|
|
|
310 |
|
|
(4)(5)(10)(15) |
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) |
|
Equity |
12/11/2020 |
Preferred Series B |
|
|
510,308 |
|
|
|
3,000 |
|
|
|
4,977 |
|
|
|
X4 Pharmaceuticals, Inc. |
|
Equity |
11/26/2019 |
Common Stock |
|
|
198,277 |
|
|
|
1,641 |
|
|
|
347 |
|
|
(4) |
Subtotal: Drug Discovery & Development (1.58%)* |
|
|
|
|
|
33,402 |
|
|
|
21,047 |
|
|
|
|||||
Electronics & Computer Hardware |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Skydio, Inc. |
|
Equity |
3/8/2022 |
Preferred Series E |
|
|
248,900 |
|
|
|
1,500 |
|
|
|
1,563 |
|
|
|
Subtotal: Electronics & Computer Hardware (0.12%)* |
|
|
|
|
|
1,500 |
|
|
|
1,563 |
|
|
|
|||||
Healthcare Services, Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
23andMe, Inc. |
|
Equity |
3/11/2019 |
Common Stock |
|
|
825,732 |
|
|
|
5,094 |
|
|
|
3,162 |
|
|
(4) |
Carbon Health Technologies, Inc. |
|
Equity |
3/30/2021 |
Preferred Series C |
|
|
217,880 |
|
|
|
1,687 |
|
|
|
1,267 |
|
|
|
Subtotal: Healthcare Services, Other (0.33%)* |
|
|
|
|
|
6,781 |
|
|
|
4,429 |
|
|
|
|||||
See notes to consolidated financial statements
12
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
|
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Planet Labs, Inc. |
|
Equity |
6/21/2019 |
Common Stock |
|
|
547,880 |
|
|
$ |
615 |
|
|
$ |
2,783 |
|
|
(4) |
Yipit, LLC |
|
Equity |
12/30/2021 |
Preferred Series E |
|
|
41,021 |
|
|
|
3,825 |
|
|
|
3,825 |
|
|
|
Zeta Global Corp. |
|
Equity |
11/20/2007 |
Common Stock |
|
|
295,861 |
|
|
|
- |
|
|
|
3,592 |
|
|
(4)(19) |
Subtotal: Information Services (0.76%)* |
|
|
|
|
|
4,440 |
|
|
|
10,200 |
|
|
|
|||||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Black Crow AI, Inc. affiliates |
|
Equity |
3/24/2021 |
Preferred Note |
|
|
3 |
|
|
|
3,000 |
|
|
|
3,000 |
|
|
(20) |
Brigade Group, Inc. |
|
Equity |
3/1/2013 |
Common Stock |
|
|
9,023 |
|
|
|
93 |
|
|
|
- |
|
|
|
Carwow LTD |
|
Equity |
12/15/2021 |
Preferred Series D-4 |
|
|
199,742 |
|
|
|
1,151 |
|
|
|
634 |
|
|
(5)(10) |
Contentful Global, Inc. |
|
Equity |
12/22/2020 |
Preferred Series C |
|
|
41,000 |
|
|
|
138 |
|
|
|
315 |
|
|
(5)(10) |
|
|
Equity |
11/20/2018 |
Preferred Series D |
|
|
108,500 |
|
|
|
500 |
|
|
|
875 |
|
|
(5)(10) |
Total Contentful Global, Inc. |
|
|
|
|
|
|
149,500 |
|
|
|
638 |
|
|
|
1,190 |
|
|
|
DoorDash, Inc. |
|
Equity |
12/20/2018 |
Common Stock |
|
|
81,996 |
|
|
|
945 |
|
|
|
9,609 |
|
|
(4) |
Lyft, Inc. |
|
Equity |
12/26/2018 |
Common Stock |
|
|
100,738 |
|
|
|
5,263 |
|
|
|
3,868 |
|
|
(4) |
Nerdy Inc. |
|
Equity |
9/17/2021 |
Common Stock |
|
|
100,000 |
|
|
|
1,000 |
|
|
|
444 |
|
|
(4)(19) |
Nextdoor.com, Inc. |
|
Equity |
8/1/2018 |
Common Stock |
|
|
1,019,255 |
|
|
|
4,854 |
|
|
|
5,783 |
|
|
(4)(19) |
OfferUp, Inc. |
|
Equity |
10/25/2016 |
Preferred Series A |
|
|
286,080 |
|
|
|
1,663 |
|
|
|
649 |
|
|
|
|
|
Equity |
10/25/2016 |
Preferred Series A-1 |
|
|
108,710 |
|
|
|
632 |
|
|
|
246 |
|
|
|
Total OfferUp, Inc. |
|
|
|
|
|
|
394,790 |
|
|
|
2,295 |
|
|
|
895 |
|
|
|
Oportun |
|
Equity |
6/28/2013 |
Common Stock |
|
|
48,365 |
|
|
|
577 |
|
|
|
695 |
|
|
(4) |
Reischling Press, Inc. |
|
Equity |
7/31/2020 |
Common Stock |
|
|
1,163 |
|
|
|
15 |
|
|
|
- |
|
|
|
Rhino Labs, Inc. |
|
Equity |
1/24/2022 |
Preferred Series B-2 |
|
|
7,063 |
|
|
|
1,000 |
|
|
|
734 |
|
|
|
Savage X Holding, LLC |
|
Equity |
4/30/2010 |
Class A Units |
|
|
42,137 |
|
|
|
13 |
|
|
|
238 |
|
|
|
Tectura Corporation |
|
Equity |
5/23/2018 |
Common Stock |
|
|
414,994,863 |
|
|
|
900 |
|
|
|
- |
|
|
(7) |
|
|
Equity |
6/6/2016 |
Preferred Series BB |
|
|
1,000,000 |
|
|
|
- |
|
|
|
- |
|
|
(7) |
Total Tectura Corporation |
|
|
|
|
|
|
415,994,863 |
|
|
|
900 |
|
|
|
- |
|
|
|
TFG Holding, Inc. |
|
Equity |
4/30/2010 |
Common Stock |
|
|
42,989 |
|
|
|
89 |
|
|
|
188 |
|
|
|
Uber Technologies, Inc. |
|
Equity |
12/1/2020 |
Common Stock |
|
|
32,991 |
|
|
|
317 |
|
|
|
1,177 |
|
|
(4) |
Subtotal: Internet Consumer & Business Services (2.13%)* |
|
|
|
|
|
22,150 |
|
|
|
28,455 |
|
|
|
|||||
Medical Devices & Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Coronado Aesthetics, LLC |
|
Equity |
10/15/2021 |
Common Units |
|
|
180,000 |
|
|
|
- |
|
|
|
28 |
|
|
(7) |
|
|
Equity |
10/15/2021 |
Preferred Series A-2 |
|
|
5,000,000 |
|
|
|
250 |
|
|
|
586 |
|
|
(7) |
Total Coronado Aesthetics, LLC |
|
|
|
|
|
|
5,180,000 |
|
|
|
250 |
|
|
|
614 |
|
|
|
Flowonix Medical Incorporated |
|
Equity |
11/3/2014 |
Preferred Series AA |
|
|
221,893 |
|
|
|
1,500 |
|
|
|
- |
|
|
|
Gelesis, Inc. |
|
Equity |
11/30/2009 |
Common Stock |
|
|
1,716,107 |
|
|
|
1,002 |
|
|
|
6,661 |
|
|
(4)(19) |
ViewRay, Inc. |
|
Equity |
12/16/2013 |
Common Stock |
|
|
36,457 |
|
|
|
333 |
|
|
|
143 |
|
|
(4) |
Subtotal: Medical Devices & Equipment (0.56%)* |
|
|
|
|
|
3,085 |
|
|
|
7,418 |
|
|
|
|||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Achronix Semiconductor Corporation |
|
Equity |
7/1/2011 |
Preferred Series C |
|
|
277,995 |
|
|
|
160 |
|
|
|
437 |
|
|
|
Subtotal: Semiconductors (0.03%)* |
|
|
|
|
|
160 |
|
|
|
437 |
|
|
|
|||||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
3GTMS, LLC. |
|
Equity |
8/9/2021 |
Common Stock |
|
|
1,000,000 |
|
|
|
1,000 |
|
|
|
920 |
|
|
|
CapLinked, Inc. |
|
Equity |
10/26/2012 |
Preferred Series A-3 |
|
|
53,614 |
|
|
|
51 |
|
|
|
12 |
|
|
|
Docker, Inc. |
|
Equity |
11/29/2018 |
Common Stock |
|
|
20,000 |
|
|
|
4,284 |
|
|
|
- |
|
|
|
Druva Holdings, Inc. |
|
Equity |
10/22/2015 |
Preferred Series 2 |
|
|
458,841 |
|
|
|
1,000 |
|
|
|
2,513 |
|
|
|
|
|
Equity |
8/24/2017 |
Preferred Series 3 |
|
|
93,620 |
|
|
|
300 |
|
|
|
538 |
|
|
|
Total Druva Holdings, Inc. |
|
|
|
|
|
|
552,461 |
|
|
|
1,300 |
|
|
|
3,051 |
|
|
|
HighRoads, Inc. |
|
Equity |
1/18/2013 |
Common Stock |
|
|
190 |
|
|
|
307 |
|
|
|
- |
|
|
|
Lightbend, Inc. |
|
Equity |
12/4/2020 |
Common Stock |
|
|
38,461 |
|
|
|
265 |
|
|
|
6 |
|
|
|
Palantir Technologies |
|
Equity |
9/23/2020 |
Common Stock |
|
|
1,418,337 |
|
|
|
8,669 |
|
|
|
19,474 |
|
|
(4) |
SingleStore, Inc. |
|
Equity |
11/25/2020 |
Preferred Series E |
|
|
580,983 |
|
|
|
2,000 |
|
|
|
1,516 |
|
|
|
|
|
Equity |
8/12/2021 |
Preferred Series F |
|
|
52,956 |
|
|
|
280 |
|
|
|
171 |
|
|
|
Total SingleStore, Inc. |
|
|
|
|
|
|
633,939 |
|
|
|
2,280 |
|
|
|
1,687 |
|
|
|
Sprinklr, Inc. |
|
Equity |
3/22/2017 |
Common Stock |
|
|
700,000 |
|
|
|
3,749 |
|
|
|
8,330 |
|
|
(4) |
Verana Health, Inc. |
|
Equity |
7/8/2021 |
Preferred Series E |
|
|
952,562 |
|
|
|
2,000 |
|
|
|
1,218 |
|
|
|
Subtotal: Software (2.60%)* |
|
|
|
|
|
23,905 |
|
|
|
34,698 |
|
|
|
|||||
See notes to consolidated financial statements
13
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
|
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Surgical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gynesonics, Inc. |
|
Equity |
1/18/2007 |
Preferred Series B |
|
|
219,298 |
|
|
$ |
250 |
|
|
$ |
- |
|
|
|
|
|
Equity |
6/16/2010 |
Preferred Series C |
|
|
656,538 |
|
|
|
282 |
|
|
|
- |
|
|
|
|
|
Equity |
2/8/2013 |
Preferred Series D |
|
|
1,991,157 |
|
|
|
712 |
|
|
|
- |
|
|
|
|
|
Equity |
7/14/2015 |
Preferred Series E |
|
|
2,786,367 |
|
|
|
429 |
|
|
|
- |
|
|
|
|
|
Equity |
12/18/2018 |
Preferred Series F |
|
|
1,523,693 |
|
|
|
118 |
|
|
|
- |
|
|
|
|
|
Equity |
12/18/2018 |
Preferred Series F-1 |
|
|
2,418,125 |
|
|
|
150 |
|
|
|
- |
|
|
|
Total Gynesonics, Inc. |
|
|
|
|
|
|
9,595,178 |
|
|
|
1,941 |
|
|
|
- |
|
|
|
Subtotal: Surgical Devices (0.00%)* |
|
|
|
|
|
1,941 |
|
|
|
- |
|
|
|
|||||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Impossible Foods, Inc. |
|
Equity |
5/10/2019 |
Preferred Series E-1 |
|
|
188,611 |
|
|
|
2,000 |
|
|
|
2,770 |
|
|
|
Modumetal, Inc. |
|
Equity |
6/1/2015 |
Common Stock |
|
|
1,035 |
|
|
|
500 |
|
|
|
- |
|
|
|
NantEnergy, LLC |
|
Equity |
8/31/2013 |
Common Units |
|
|
59,665 |
|
|
|
102 |
|
|
|
- |
|
|
|
Pineapple Energy LLC |
|
Equity |
12/10/2020 |
Common Stock |
|
|
498,978 |
|
|
|
5,167 |
|
|
|
1,844 |
|
|
(4)(6)(19) |
Pivot Bio, Inc. |
|
Equity |
6/28/2021 |
Preferred Series D |
|
|
593,080 |
|
|
|
4,500 |
|
|
|
2,310 |
|
|
|
Proterra, Inc. |
|
Equity |
5/28/2015 |
Common Stock |
|
|
457,841 |
|
|
|
543 |
|
|
|
3,443 |
|
|
(4) |
Subtotal: Sustainable and Renewable Technology (0.78%)* |
|
|
|
|
|
12,812 |
|
|
|
10,367 |
|
|
|
|||||
Total: Equity Investments (12.01%) |
|
|
|
|
$ |
143,616 |
|
|
$ |
160,184 |
|
|
|
|||||
Warrant Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Spring Mobile Solutions, Inc. |
|
Warrant |
4/19/2013 |
Common Stock |
|
|
2,834,375 |
|
|
$ |
418 |
|
|
$ |
- |
|
|
|
Subtotal: Communications & Networking (0.00%)* |
|
|
|
|
|
418 |
|
|
|
- |
|
|
|
|||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Grove Collaborative, Inc. |
|
Warrant |
4/30/2021 |
Common Stock |
|
|
83,625 |
|
|
|
433 |
|
|
|
311 |
|
|
|
Penumbra Brands, LLC |
|
Warrant |
6/3/2014 |
Common Stock |
|
|
1,662,441 |
|
|
|
228 |
|
|
|
- |
|
|
|
TechStyle, Inc. |
|
Warrant |
7/16/2013 |
Preferred Series B |
|
|
206,185 |
|
|
|
1,101 |
|
|
|
1,928 |
|
|
|
The Neat Company |
|
Warrant |
8/13/2014 |
Common Stock |
|
|
54,054 |
|
|
|
365 |
|
|
|
- |
|
|
|
Whoop, Inc. |
|
Warrant |
6/27/2018 |
Preferred Series C |
|
|
686,270 |
|
|
|
18 |
|
|
|
1,364 |
|
|
|
Subtotal: Consumer & Business Products (0.27%)* |
|
|
|
|
|
2,145 |
|
|
|
3,603 |
|
|
|
|||||
Drug Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aerami Therapeutics Holdings, Inc. |
|
Warrant |
9/30/2015 |
Common Stock |
|
|
110,882 |
|
|
|
74 |
|
|
|
- |
|
|
|
BioQ Pharma Incorporated |
|
Warrant |
10/27/2014 |
Common Stock |
|
|
459,183 |
|
|
|
1 |
|
|
|
- |
|
|
|
PDS Biotechnology Corporation |
|
Warrant |
8/28/2014 |
Common Stock |
|
|
3,929 |
|
|
|
390 |
|
|
|
- |
|
|
(4) |
Subtotal: Drug Delivery (0.00%)* |
|
|
|
|
|
465 |
|
|
|
- |
|
|
|
|||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Acacia Pharma Inc. |
|
Warrant |
6/29/2018 |
Common Stock |
|
|
201,330 |
|
|
|
304 |
|
|
|
1 |
|
|
(4)(5)(10) |
ADMA Biologics, Inc. |
|
Warrant |
12/21/2012 |
Common Stock |
|
|
89,750 |
|
|
|
295 |
|
|
|
1 |
|
|
(4) |
Albireo Pharma, Inc. |
|
Warrant |
6/8/2020 |
Common Stock |
|
|
5,311 |
|
|
|
61 |
|
|
|
61 |
|
|
(4)(10) |
Axsome Therapeutics, Inc. |
|
Warrant |
9/25/2020 |
Common Stock |
|
|
15,541 |
|
|
|
681 |
|
|
|
157 |
|
|
(4)(10) |
Brickell Biotech, Inc. |
|
Warrant |
2/18/2016 |
Common Stock |
|
|
9,005 |
|
|
|
119 |
|
|
|
- |
|
|
(4) |
Cellarity, Inc. |
|
Warrant |
12/8/2021 |
Preferred Series B |
|
|
100,000 |
|
|
|
287 |
|
|
|
207 |
|
|
(14) |
Century Therapeutics, Inc. |
|
Warrant |
9/14/2020 |
Common Stock |
|
|
16,112 |
|
|
|
37 |
|
|
|
39 |
|
|
(4) |
Concert Pharmaceuticals, Inc. |
|
Warrant |
6/8/2017 |
Common Stock |
|
|
61,273 |
|
|
|
178 |
|
|
|
3 |
|
|
(4)(10) |
Dermavant Sciences Ltd. |
|
Warrant |
5/31/2019 |
Common Stock |
|
|
223,642 |
|
|
|
101 |
|
|
|
256 |
|
|
(10)(12) |
enGene, Inc. |
|
Warrant |
12/30/2021 |
Preferred Series 3 |
|
|
84,714 |
|
|
|
64 |
|
|
|
29 |
|
|
(5)(10) |
Evofem Biosciences, Inc. |
|
Warrant |
6/11/2014 |
Common Stock |
|
|
7,806 |
|
|
|
267 |
|
|
|
- |
|
|
(4) |
Genocea Biosciences, Inc. |
|
Warrant |
4/24/2018 |
Common Stock |
|
|
41,176 |
|
|
|
165 |
|
|
|
1 |
|
|
(4) |
Motif Bio PLC |
|
Warrant |
1/27/2020 |
Common Stock |
|
|
121,337,041 |
|
|
|
282 |
|
|
|
- |
|
|
(10) |
Myovant Sciences, Ltd. |
|
Warrant |
10/16/2017 |
Common Stock |
|
|
73,710 |
|
|
|
460 |
|
|
|
181 |
|
|
(4)(10) |
Paratek Pharmaceuticals, Inc. |
|
Warrant |
6/27/2017 |
Common Stock |
|
|
432,240 |
|
|
|
546 |
|
|
|
127 |
|
|
(4) |
Phathom Pharmaceuticals, Inc. |
|
Warrant |
9/17/2021 |
Common Stock |
|
|
64,687 |
|
|
|
848 |
|
|
|
125 |
|
|
(4)(10)(14)(15) |
Redshift Bioanalytics, Inc. |
|
Warrant |
3/23/2022 |
Preferred Series E |
|
|
142,653 |
|
|
|
6 |
|
|
|
6 |
|
|
(14) |
Scynexis, Inc. |
|
Warrant |
5/14/2021 |
Common Stock |
|
|
106,035 |
|
|
|
296 |
|
|
|
110 |
|
|
(4) |
Stealth Bio Therapeutics Corp. |
|
Warrant |
6/30/2017 |
Common Stock |
|
|
500,000 |
|
|
|
158 |
|
|
|
- |
|
|
(4)(10) |
TG Therapeutics, Inc. |
|
Warrant |
2/28/2019 |
Common Stock |
|
|
231,613 |
|
|
|
1,033 |
|
|
|
767 |
|
|
(4)(10)(12) |
Tricida, Inc. |
|
Warrant |
3/27/2019 |
Common Stock |
|
|
31,352 |
|
|
|
280 |
|
|
|
12 |
|
|
(4) |
Valo Health, LLC |
|
Warrant |
6/15/2020 |
Common Units |
|
|
102,216 |
|
|
|
256 |
|
|
|
453 |
|
|
|
X4 Pharmaceuticals, Inc. |
|
Warrant |
3/18/2019 |
Common Stock |
|
|
108,334 |
|
|
|
673 |
|
|
|
30 |
|
|
(4) |
Yumanity Therapeutics, Inc. |
|
Warrant |
12/20/2019 |
Common Stock |
|
|
15,414 |
|
|
|
110 |
|
|
|
- |
|
|
(4) |
Subtotal: Drug Discovery & Development (0.19%)* |
|
|
|
|
|
7,507 |
|
|
|
2,566 |
|
|
|
|||||
See notes to consolidated financial statements
14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
|
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Electronics & Computer Hardware |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
908 Devices, Inc. |
|
Warrant |
3/15/2017 |
Common Stock |
|
|
49,078 |
|
|
$ |
101 |
|
|
$ |
370 |
|
|
(4) |
Skydio, Inc. |
|
Warrant |
11/8/2021 |
Common Stock |
|
|
622,255 |
|
|
|
557 |
|
|
|
2,424 |
|
|
|
Subtotal: Electronics & Computer Hardware (0.21%)* |
|
|
|
|
|
658 |
|
|
|
2,794 |
|
|
|
|||||
Healthcare Services, Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Vida Health, Inc. |
|
Warrant |
3/28/2022 |
Common Stock |
|
|
100,618 |
|
|
|
114 |
|
|
|
110 |
|
|
|
Subtotal: Healthcare Services, Other (0.01%)* |
|
|
|
|
|
114 |
|
|
|
110 |
|
|
|
|||||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capella Space Corp. |
|
Warrant |
10/21/2021 |
Common Stock |
|
|
176,200 |
|
|
|
207 |
|
|
|
- |
|
|
(14) |
INMOBI Inc. |
|
Warrant |
11/19/2014 |
Common Stock |
|
|
65,587 |
|
|
|
82 |
|
|
|
- |
|
|
(10) |
NetBase Solutions, Inc. |
|
Warrant |
8/22/2017 |
Preferred Series 1 |
|
|
60,000 |
|
|
|
356 |
|
|
|
449 |
|
|
|
Subtotal: Information Services (0.03%)* |
|
|
|
|
|
645 |
|
|
|
449 |
|
|
|
|||||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aria Systems, Inc. |
|
Warrant |
5/22/2015 |
Preferred Series G |
|
|
231,535 |
|
|
|
74 |
|
|
|
- |
|
|
|
Carwow LTD |
|
Warrant |
12/14/2021 |
Common Stock |
|
|
174,163 |
|
|
|
164 |
|
|
|
187 |
|
|
(5)(10) |
Cloudpay, Inc. |
|
Warrant |
4/10/2018 |
Preferred Series B |
|
|
6,763 |
|
|
|
54 |
|
|
|
240 |
|
|
(5)(10) |
Convoy, Inc. |
|
Warrant |
3/30/2022 |
Common Stock |
|
|
165,456 |
|
|
|
974 |
|
|
|
962 |
|
|
(15) |
First Insight, Inc. |
|
Warrant |
5/10/2018 |
Preferred Series B |
|
|
75,917 |
|
|
|
96 |
|
|
|
102 |
|
|
|
Houzz, Inc. |
|
Warrant |
10/29/2019 |
Common Stock |
|
|
529,661 |
|
|
|
20 |
|
|
|
53 |
|
|
|
Interactions Corporation |
|
Warrant |
6/16/2015 |
Preferred Series G-3 |
|
|
68,187 |
|
|
|
204 |
|
|
|
389 |
|
|
|
Landing Holdings Inc. |
|
Warrant |
3/12/2021 |
Common Stock |
|
|
11,806 |
|
|
|
116 |
|
|
|
- |
|
|
(14) |
Lendio, Inc. |
|
Warrant |
3/29/2019 |
Preferred Series D |
|
|
127,032 |
|
|
|
39 |
|
|
|
87 |
|
|
|
Rhino Labs, Inc. |
|
Warrant |
3/12/2021 |
Common Stock |
|
|
13,106 |
|
|
|
470 |
|
|
|
287 |
|
|
(14) |
RumbleON, Inc. |
|
Warrant |
4/30/2018 |
Common Stock |
|
|
5,139 |
|
|
|
87 |
|
|
|
20 |
|
|
(4) |
Savage X Holding, LLC |
|
Warrant |
6/27/2014 |
Class A Units |
|
|
206,185 |
|
|
|
- |
|
|
|
1,163 |
|
|
|
SeatGeek, Inc. |
|
Warrant |
6/12/2019 |
Common Stock |
|
|
1,379,761 |
|
|
|
842 |
|
|
|
3,664 |
|
|
|
ShareThis, Inc. |
|
Warrant |
12/14/2012 |
Preferred Series C |
|
|
493,502 |
|
|
|
547 |
|
|
|
- |
|
|
|
Skyword, Inc. |
|
Warrant |
8/23/2019 |
Preferred Series B |
|
|
444,444 |
|
|
|
83 |
|
|
|
2 |
|
|
|
Snagajob.com, Inc. |
|
Warrant |
4/20/2020 |
Common Stock |
|
|
600,000 |
|
|
|
16 |
|
|
|
114 |
|
|
(12) |
|
|
Warrant |
6/30/2016 |
Preferred Series A |
|
|
1,800,000 |
|
|
|
782 |
|
|
|
206 |
|
|
(12) |
|
|
Warrant |
8/1/2018 |
Preferred Series B |
|
|
1,211,537 |
|
|
|
62 |
|
|
|
119 |
|
|
(12) |
Total Snagajob.com, Inc. |
|
|
|
|
|
|
3,611,537 |
|
|
|
860 |
|
|
|
325 |
|
|
|
TFG Holding, Inc. |
|
Warrant |
6/27/2014 |
Common Stock |
|
|
206,185 |
|
|
|
- |
|
|
|
90 |
|
|
|
The Faction Group LLC |
|
Warrant |
11/3/2014 |
Preferred Series AA |
|
|
8,076 |
|
|
|
234 |
|
|
|
543 |
|
|
|
Thumbtack, Inc. |
|
Warrant |
5/1/2018 |
Common Stock |
|
|
267,225 |
|
|
|
844 |
|
|
|
783 |
|
|
|
Veem, Inc. |
|
Warrant |
3/31/2022 |
Common Stock |
|
|
98,428 |
|
|
|
126 |
|
|
|
126 |
|
|
|
Worldremit Group Limited |
|
Warrant |
2/11/2021 |
Preferred Series D |
|
|
77,215 |
|
|
|
129 |
|
|
|
704 |
|
|
(5)(10)(15) |
|
|
Warrant |
8/27/2021 |
Preferred Series E |
|
|
1,868 |
|
|
|
26 |
|
|
|
11 |
|
|
(5)(10)(15) |
Total Worldremit Group Limited |
|
|
|
|
|
|
79,083 |
|
|
|
155 |
|
|
|
715 |
|
|
|
Subtotal: Internet Consumer & Business Services (0.74%)* |
|
|
|
|
|
5,989 |
|
|
|
9,852 |
|
|
|
|||||
Manufacturing Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Bright Machines, Inc. |
|
Warrant |
3/31/2022 |
Common Stock |
|
|
196,335 |
|
|
|
151 |
|
|
|
151 |
|
|
|
MacroFab, Inc. |
|
Warrant |
3/23/2022 |
Common Stock |
|
|
1,111,111 |
|
|
|
528 |
|
|
|
525 |
|
|
|
Xometry, Inc. |
|
Warrant |
5/9/2018 |
Common Stock |
|
|
87,784 |
|
|
|
47 |
|
|
|
2,088 |
|
|
(4) |
Subtotal: Manufacturing Technology (0.21%)* |
|
|
|
|
|
726 |
|
|
|
2,764 |
|
|
|
|||||
Media/Content/Info |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Zoom Media Group, Inc. |
|
Warrant |
12/21/2012 |
Preferred Series A |
|
|
1,204 |
|
|
|
348 |
|
|
|
- |
|
|
|
Subtotal: Media/Content/Info (0.00%)* |
|
|
|
|
|
348 |
|
|
|
- |
|
|
|
|||||
Medical Devices & Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aspire Bariatrics, Inc. |
|
Warrant |
1/28/2015 |
Common Stock |
|
|
22,572 |
|
|
|
456 |
|
|
|
- |
|
|
|
Flowonix Medical Incorporated |
|
Warrant |
11/3/2014 |
Preferred Series AA |
|
|
155,325 |
|
|
|
362 |
|
|
|
- |
|
|
(12) |
|
|
Warrant |
9/21/2018 |
Preferred Series BB |
|
|
725,806 |
|
|
|
351 |
|
|
|
- |
|
|
(12) |
Total Flowonix Medical Incorporated |
|
|
|
|
|
|
881,131 |
|
|
|
713 |
|
|
|
- |
|
|
|
Intuity Medical, Inc. |
|
Warrant |
12/29/2017 |
Preferred Series B-1 |
|
|
3,076,323 |
|
|
|
294 |
|
|
|
90 |
|
|
|
Lucira Health, Inc. |
|
Warrant |
2/4/2022 |
Common Stock |
|
|
59,642 |
|
|
|
110 |
|
|
|
27 |
|
|
(4) |
Outset Medical, Inc. |
|
Warrant |
9/27/2013 |
Common Stock |
|
|
62,794 |
|
|
|
401 |
|
|
|
1,769 |
|
|
(4) |
Tela Bio, Inc. |
|
Warrant |
3/31/2017 |
Common Stock |
|
|
15,712 |
|
|
|
61 |
|
|
|
5 |
|
|
(4) |
Subtotal: Medical Devices & Equipment (0.14%)* |
|
|
|
|
|
2,035 |
|
|
|
1,891 |
|
|
|
|||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Achronix Semiconductor Corporation |
|
Warrant |
6/26/2015 |
Preferred Series D-2 |
|
|
750,000 |
|
|
|
99 |
|
|
|
1,173 |
|
|
|
Fungible, Inc. |
|
Warrant |
12/16/2021 |
Common Stock |
|
|
800,000 |
|
|
|
751 |
|
|
|
164 |
|
|
(14) |
Subtotal: Semiconductors (0.10%)* |
|
|
|
|
|
850 |
|
|
|
1,337 |
|
|
|
|||||
See notes to consolidated financial statements
15
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
|
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Bitsight Technologies, Inc. |
|
Warrant |
11/18/2020 |
Common Stock |
|
|
29,691 |
|
|
$ |
284 |
|
|
$ |
665 |
|
|
|
Brain Corporation |
|
Warrant |
10/4/2021 |
Common Stock |
|
|
194,629 |
|
|
|
165 |
|
|
|
90 |
|
|
(14) |
CloudBolt Software, Inc. |
|
Warrant |
9/30/2020 |
Common Stock |
|
|
211,342 |
|
|
|
117 |
|
|
|
47 |
|
|
|
Cloudian, Inc. |
|
Warrant |
11/6/2018 |
Common Stock |
|
|
477,454 |
|
|
|
71 |
|
|
|
18 |
|
|
|
Couchbase, Inc. |
|
Warrant |
4/25/2019 |
Common Stock |
|
|
105,350 |
|
|
|
462 |
|
|
|
806 |
|
|
(4) |
Dashlane, Inc. |
|
Warrant |
3/11/2019 |
Common Stock |
|
|
453,641 |
|
|
|
353 |
|
|
|
471 |
|
|
|
Delphix Corp. |
|
Warrant |
10/8/2019 |
Common Stock |
|
|
718,898 |
|
|
|
1,594 |
|
|
|
4,659 |
|
|
(15) |
Demandbase, Inc. |
|
Warrant |
8/2/2021 |
Common Stock |
|
|
579,898 |
|
|
|
480 |
|
|
|
448 |
|
|
|
DNAnexus, Inc. |
|
Warrant |
3/21/2014 |
Preferred Series C |
|
|
909,091 |
|
|
|
97 |
|
|
|
55 |
|
|
|
Esme Learning Solutions, Inc. |
|
Warrant |
1/27/2022 |
Common Stock |
|
|
56,765 |
|
|
|
198 |
|
|
|
121 |
|
|
|
Evernote Corporation |
|
Warrant |
9/30/2016 |
Common Stock |
|
|
62,500 |
|
|
|
106 |
|
|
|
26 |
|
|
|
Lightbend, Inc. |
|
Warrant |
2/14/2018 |
Preferred Series D |
|
|
89,685 |
|
|
|
131 |
|
|
|
- |
|
|
|
Mixpanel, Inc. |
|
Warrant |
9/30/2020 |
Common Stock |
|
|
82,362 |
|
|
|
252 |
|
|
|
452 |
|
|
|
Nuvolo Technologies Corporation |
|
Warrant |
3/29/2019 |
Common Stock |
|
|
70,000 |
|
|
|
172 |
|
|
|
288 |
|
|
|
Poplicus, Inc. |
|
Warrant |
5/28/2014 |
Common Stock |
|
|
132,168 |
|
|
|
- |
|
|
|
- |
|
|
|
Pymetrics, Inc. |
|
Warrant |
9/15/2020 |
Common Stock |
|
|
150,943 |
|
|
|
77 |
|
|
|
165 |
|
|
|
RapidMiner, Inc. |
|
Warrant |
11/28/2017 |
Preferred Series C-1 |
|
|
4,982 |
|
|
|
24 |
|
|
|
24 |
|
|
|
Reltio, Inc. |
|
Warrant |
6/30/2020 |
Common Stock |
|
|
69,120 |
|
|
|
215 |
|
|
|
335 |
|
|
|
SignPost, Inc. |
|
Warrant |
1/13/2016 |
Series Junior 1 Preferred |
|
|
474,019 |
|
|
|
314 |
|
|
|
- |
|
|
|
SingleStore, Inc. (p.k.a. memsql, Inc.) |
|
Warrant |
4/28/2020 |
Preferred Series D |
|
|
312,596 |
|
|
|
103 |
|
|
|
367 |
|
|
|
Tact.ai Technologies, Inc. |
|
Warrant |
2/13/2020 |
Common Stock |
|
|
1,041,667 |
|
|
|
206 |
|
|
|
116 |
|
|
|
Udacity, Inc. |
|
Warrant |
9/25/2020 |
Common Stock |
|
|
486,359 |
|
|
|
218 |
|
|
|
246 |
|
|
|
VideoAmp, Inc. |
|
Warrant |
1/21/2022 |
Common Stock |
|
|
152,048 |
|
|
|
1,275 |
|
|
|
756 |
|
|
(14) |
ZeroFox, Inc. |
|
Warrant |
5/7/2020 |
Preferred Series C-1 |
|
|
648,350 |
|
|
|
101 |
|
|
|
512 |
|
|
|
Zimperium, Inc. |
|
Warrant |
7/2/2021 |
Common Stock |
|
|
20,563 |
|
|
|
72 |
|
|
|
49 |
|
|
|
Subtotal: Software (0.80%)* |
|
|
|
|
|
7,087 |
|
|
|
10,716 |
|
|
|
|||||
Surgical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gynesonics, Inc. |
|
Warrant |
12/5/2012 |
Preferred Series C |
|
|
33,670 |
|
|
|
13 |
|
|
|
- |
|
|
|
TransMedics Group, Inc. |
|
Warrant |
11/7/2012 |
Common Stock |
|
|
64,440 |
|
|
|
139 |
|
|
|
831 |
|
|
(4) |
Subtotal: Surgical Devices (0.06%)* |
|
|
|
|
|
152 |
|
|
|
831 |
|
|
|
|||||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Agrivida, Inc. |
|
Warrant |
6/20/2013 |
Preferred Series D |
|
|
471,327 |
|
|
|
120 |
|
|
|
- |
|
|
|
Fulcrum Bioenergy, Inc. |
|
Warrant |
9/13/2012 |
Preferred Series C-1 |
|
|
280,897 |
|
|
|
274 |
|
|
|
784 |
|
|
|
Halio, Inc. |
|
Warrant |
4/22/2014 |
Preferred Series A |
|
|
325,000 |
|
|
|
155 |
|
|
|
149 |
|
|
|
|
|
Warrant |
4/7/2015 |
Preferred Series B |
|
|
131,883 |
|
|
|
63 |
|
|
|
51 |
|
|
|
Total Halio, Inc. |
|
|
|
|
|
|
456,883 |
|
|
|
218 |
|
|
|
200 |
|
|
|
Polyera Corporation |
|
Warrant |
12/11/2012 |
Preferred Series C |
|
|
311,609 |
|
|
|
338 |
|
|
|
- |
|
|
|
Subtotal: Sustainable and Renewable Technology (0.07%)* |
|
|
|
|
|
950 |
|
|
|
984 |
|
|
|
|||||
Total: Warrant Investments (2.84%)* |
|
|
|
|
|
30,089 |
|
|
|
37,897 |
|
|
|
|||||
Total Investments in Securities (14.85%)* |
|
|
|
|
$ |
173,705 |
|
|
$ |
198,081 |
|
|
|
|||||
Investment Funds & Vehicles Investments |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Forbion Growth Opportunities Fund I C.V. |
|
Investment Funds & Vehicles |
11/16/2020 |
|
|
|
|
|
|
2,413 |
|
|
|
2,911 |
|
|
(5)(10)(16) |
|
Total: Investment Funds & Vehicles Investments (0.22%)* |
|
|
|
|
$ |
2,413 |
|
|
$ |
2,911 |
|
|
|
|||||
Total: Investments (194.41%)* |
|
|
|
|
$ |
2,586,402 |
|
|
$ |
2,592,334 |
|
|
|
|||||
See notes to consolidated financial statements
16
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2022
(unaudited)
(dollars in thousands)
* Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
See notes to consolidated financial statements
17
`
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Cytracom Holdings LLC |
|
Senior Secured |
February 2025 |
3-month LIBOR + 9.31% or Floor rate of 10.31% |
|
$ |
9,000 |
|
|
$ |
8,802 |
|
|
$ |
8,725 |
|
|
(11)(16)(17) |
Rocket Lab Global Services, LLC |
|
Senior Secured |
June 2024 |
PRIME + 4.90% or Floor rate of 8.15%, PIK Interest 1.25%, 3.25% Exit Fee |
|
$ |
88,542 |
|
|
|
88,286 |
|
|
|
90,505 |
|
|
(13)(15) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
97,088 |
|
|
|
99,230 |
|
|
|
||||
Subtotal: Communications & Networking (7.58%)* |
|
|
|
|
|
|
97,088 |
|
|
|
99,230 |
|
|
|
||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Grove Collaborative, Inc. |
|
Senior Secured |
April 2025 |
PRIME + 5.50% or Floor rate of 8.75%, 6.75% Exit Fee |
|
$ |
23,520 |
|
|
|
23,162 |
|
|
|
23,298 |
|
|
(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
23,162 |
|
|
|
23,298 |
|
|
|
||||
Subtotal: Consumer & Business Products (1.78%)* |
|
|
|
|
|
|
23,162 |
|
|
|
23,298 |
|
|
|
||||
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Newfront Insurance Holdings, Inc. |
|
Convertible Note |
August 2022 |
PIK Interest 0.19% or Floor rate of 0.19% |
|
$ |
403 |
|
|
|
403 |
|
|
|
403 |
|
|
(9) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
403 |
|
|
|
403 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gibraltar Business Capital, LLC |
|
Unsecured |
September 2026 |
FIXED 14.50% |
|
$ |
15,000 |
|
|
|
14,662 |
|
|
|
13,818 |
|
|
(7) |
|
|
Unsecured |
September 2026 |
FIXED 11.50% |
|
$ |
10,000 |
|
|
|
9,823 |
|
|
|
9,394 |
|
|
(7) |
Total Gibraltar Business Capital, LLC |
|
|
|
|
|
$ |
25,000 |
|
|
|
24,485 |
|
|
|
23,212 |
|
|
|
Hercules Adviser LLC |
|
Unsecured |
May 2023 |
FIXED 5.00% |
|
$ |
8,850 |
|
|
|
8,850 |
|
|
|
8,850 |
|
|
(7) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
33,335 |
|
|
|
32,062 |
|
|
|
||||
Subtotal: Diversified Financial Services (2.48%)* |
|
|
|
|
|
|
33,738 |
|
|
|
32,465 |
|
|
|
||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Chemocentryx, Inc. |
|
Senior Secured |
December 2022 |
PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee |
|
$ |
18,951 |
|
|
|
20,036 |
|
|
|
20,036 |
|
|
(10) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
20,036 |
|
|
|
20,036 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Albireo Pharma, Inc. |
|
Senior Secured |
July 2024 |
PRIME + 5.90% or Floor rate of 9.15%, 6.95% Exit Fee |
|
$ |
10,000 |
|
|
|
10,229 |
|
|
|
10,268 |
|
|
(10)(11) |
Aldeyra Therapeutics, Inc. |
|
Senior Secured |
October 2023 |
PRIME + 3.10% or Floor rate of 8.60%, 6.95% Exit Fee |
|
$ |
15,000 |
|
|
|
15,639 |
|
|
|
15,653 |
|
|
|
Applied Genetic Technologies Corporation |
|
Senior Secured |
April 2024 |
PRIME + 6.50% or Floor rate of 9.75%, 6.95% Exit Fee |
|
$ |
20,000 |
|
|
|
20,416 |
|
|
|
20,339 |
|
|
|
Aveo Pharmaceuticals, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 6.40% or Floor rate of 9.65%, 6.95% Exit Fee |
|
$ |
40,000 |
|
|
|
40,842 |
|
|
|
40,776 |
|
|
(11)(14) |
Axsome Therapeutics, Inc. |
|
Senior Secured |
October 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 5.82% Exit Fee |
|
$ |
50,000 |
|
|
|
49,542 |
|
|
|
48,859 |
|
|
(10)(12) |
Bicycle Therapeutics PLC |
|
Senior Secured |
October 2024 |
PRIME + 5.60% or Floor rate of 8.85%, 5.00% Exit Fee |
|
$ |
24,000 |
|
|
|
24,271 |
|
|
|
24,454 |
|
|
(5)(10)(11)(12)(16) |
BiomX, INC |
|
Senior Secured |
September 2025 |
PRIME + 5.70% or Floor rate of 8.95%, 6.55% Exit Fee |
|
$ |
9,000 |
|
|
|
8,980 |
|
|
|
8,980 |
|
|
(5)(10)(11) |
BridgeBio Pharma, Inc. |
|
Senior Secured |
November 2026 |
FIXED 9.00%, 2.00% Exit Fee |
|
$ |
38,000 |
|
|
|
37,462 |
|
|
|
37,462 |
|
|
|
Cellarity, Inc. |
|
Senior Secured |
June 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 3.75% Exit Fee |
|
$ |
30,000 |
|
|
|
29,422 |
|
|
|
29,422 |
|
|
(14) |
Center for Breakthrough Medicines Holdings, LLC |
|
Senior Secured |
May 2023 |
PRIME + 5.50% or Floor rate of 8.75%, 7.50% Exit Fee |
|
$ |
5,000 |
|
|
|
5,005 |
|
|
|
5,005 |
|
|
|
Century Therapeutics |
|
Senior Secured |
April 2024 |
PRIME + 6.30% or Floor rate of 9.55%, 3.95% Exit Fee |
|
$ |
10,000 |
|
|
|
10,075 |
|
|
|
10,361 |
|
|
(11) |
See notes to consolidated financial statements
18
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Chemocentryx, Inc. |
|
Senior Secured |
February 2025 |
PRIME + 3.25% or Floor rate of 8.50%, 7.15% Exit Fee |
|
$ |
5,000 |
|
|
$ |
5,161 |
|
|
$ |
5,070 |
|
|
(10) |
Codiak Biosciences, Inc. |
|
Senior Secured |
October 2025 |
PRIME + 5.00% or Floor rate of 8.25%, 5.50% Exit Fee |
|
$ |
25,000 |
|
|
|
25,459 |
|
|
|
25,316 |
|
|
(11) |
Corium, Inc. |
|
Senior Secured |
September 2026 |
PRIME + 5.70% or Floor rate of 8.95%, 7.75% Exit Fee |
|
$ |
91,500 |
|
|
|
90,997 |
|
|
|
90,997 |
|
|
(15) |
Eloxx Pharmaceuticals, Inc. |
|
Senior Secured |
April 2025 |
PRIME + 6.25% or Floor rate of 9.50%, 6.55% Exit Fee |
|
$ |
12,500 |
|
|
|
12,443 |
|
|
|
12,443 |
|
|
(14) |
enGene, Inc. |
|
Senior Secured |
July 2025 |
PRIME + 5.00% or Floor rate of 8.25%, 6.35% Exit Fee |
|
$ |
7,000 |
|
|
|
6,858 |
|
|
|
6,858 |
|
|
(5)(10) |
G1 Therapeutics, Inc. |
|
Senior Secured |
November 2026 |
PRIME + 5.90% or Floor rate of 9.15%, 9.86% Exit Fee |
|
$ |
58,125 |
|
|
|
57,873 |
|
|
|
57,874 |
|
|
(10)(11)(12)(14)(16) |
Geron Corporation |
|
Senior Secured |
October 2024 |
PRIME + 5.75% or Floor rate of 9.00%, 6.55% Exit Fee |
|
$ |
32,500 |
|
|
|
32,704 |
|
|
|
32,744 |
|
|
(10)(12) |
Hibercell, Inc. |
|
Senior Secured |
May 2025 |
PRIME + 5.40% or Floor rate of 8.65%, 4.95% Exit Fee |
|
$ |
17,000 |
|
|
|
17,041 |
|
|
|
17,014 |
|
|
(14) |
Humanigen, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.50% or Floor rate of 8.75%, 6.75% Exit Fee |
|
$ |
20,000 |
|
|
|
20,235 |
|
|
|
19,985 |
|
|
(9)(10) |
Kaleido Biosciences, Inc. |
|
Senior Secured |
January 2024 |
PRIME + 6.10% or Floor rate of 9.35%, 7.55% Exit Fee |
|
$ |
22,500 |
|
|
|
23,505 |
|
|
|
23,384 |
|
|
(12) |
Locus Biosciences |
|
Senior Secured |
July 2025 |
PRIME + 6.10% or Floor rate of 9.35%, 4.95% Exit Fee |
|
$ |
8,000 |
|
|
|
7,977 |
|
|
|
7,900 |
|
|
(14) |
Nabriva Therapeutics |
|
Senior Secured |
June 2023 |
PRIME + 4.30% or Floor rate of 9.80%, 6.95% Exit Fee |
|
$ |
5,000 |
|
|
|
5,500 |
|
|
|
5,459 |
|
|
(5)(10) |
Phathom Pharmaceuticals, Inc. |
|
Senior Secured |
October 2026 |
PRIME + 2.25% or Floor rate of 5.50%, PIK Interest 3.35%, 7.50% Exit Fee |
|
$ |
87,116 |
|
|
|
86,075 |
|
|
|
86,075 |
|
|
(10)(12)(13)(14)(15)(16) |
Scynexis, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.80% or Floor rate of 9.05%, 3.95% Exit Fee |
|
$ |
16,000 |
|
|
|
15,826 |
|
|
|
15,778 |
|
|
|
Seres Therapeutics, Inc. |
|
Senior Secured |
November 2023 |
PRIME + 4.40% or Floor rate of 9.65%, 4.85% Exit Fee |
|
$ |
24,051 |
|
|
|
24,777 |
|
|
|
25,183 |
|
|
|
Syndax Pharmaceutics Inc. |
|
Senior Secured |
April 2024 |
PRIME + 6.00% or Floor rate of 9.25%, 4.99% Exit Fee |
|
$ |
20,000 |
|
|
|
20,646 |
|
|
|
20,653 |
|
|
(12)(16) |
TG Therapeutics, Inc. |
|
Senior Secured |
January 2026 |
PRIME + 2.15% or Floor rate of 5.40%, PIK Interest 3.45%, 5.95% Exit Fee |
|
$ |
51,450 |
|
|
|
50,470 |
|
|
|
50,470 |
|
|
(10) |
uniQure B.V. |
|
Senior Secured |
December 2025 |
PRIME + 4.70% or Floor rate of 7.95%, 7.28% Exit Fee |
|
$ |
77,500 |
|
|
|
78,755 |
|
|
|
78,755 |
|
|
(5)(10)(11)(12)(15) |
Unity Biotechnology, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 6.10% or Floor rate of 9.35%, 6.25% Exit Fee |
|
$ |
22,701 |
|
|
|
23,293 |
|
|
|
23,627 |
|
|
(9) |
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) |
|
Senior Secured |
May 2024 |
PRIME + 6.45% or Floor rate of 9.70%, 3.85% Exit Fee |
|
$ |
11,500 |
|
|
|
11,547 |
|
|
|
11,492 |
|
|
(11) |
X4 Pharmaceuticals, Inc. |
|
Senior Secured |
July 2024 |
PRIME + 3.75% or Floor rate of 8.75%, 8.80% Exit Fee |
|
$ |
32,500 |
|
|
|
34,140 |
|
|
|
34,085 |
|
|
(11)(12) |
Yumanity Therapeutics, Inc. |
|
Senior Secured |
January 2024 |
PRIME + 4.00% or Floor rate of 8.75%, 5.92% Exit Fee |
|
$ |
12,732 |
|
|
|
13,256 |
|
|
|
13,187 |
|
|
|
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
916,421 |
|
|
|
915,928 |
|
|
|
||||
Subtotal: Drug Discovery & Development (71.53%)* |
|
|
|
|
|
|
936,457 |
|
|
|
935,964 |
|
|
|
||||
Healthcare Services, Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Better Therapeutics, Inc. |
|
Senior Secured |
August 2025 |
PRIME + 5.70% or Floor rate of 8.95%, 5.95% Exit Fee |
|
$ |
8,000 |
|
|
|
7,966 |
|
|
|
7,966 |
|
|
(14)(16) |
Blue Sprig Pediatrics, Inc. |
|
Senior Secured |
November 2026 |
3-month LIBOR + 5.00% or Floor rate of 6.00%, PIK Interest 4.45% |
|
$ |
25,022 |
|
|
|
24,653 |
|
|
|
24,653 |
|
|
(13)(16) |
Carbon Health Technologies, Inc. |
|
Senior Secured |
March 2025 |
PRIME + 5.60% or Floor rate of 8.85%, 4.61% Exit Fee |
|
$ |
46,125 |
|
|
|
45,964 |
|
|
|
45,964 |
|
|
(16)(18) |
Equality Health, LLC |
|
Senior Secured |
February 2026 |
PRIME + 6.25% or Floor rate of 9.50%, PIK Interest 1.55% |
|
$ |
35,444 |
|
|
|
35,141 |
|
|
|
35,056 |
|
|
(12)(13)(16) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
113,724 |
|
|
|
113,639 |
|
|
|
||||
Subtotal: Healthcare Services, Other (8.68%)* |
|
|
|
|
|
|
113,724 |
|
|
|
113,639 |
|
|
|
||||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capella Space |
|
Senior Secured |
November 2024 |
PRIME + 5.00% or Floor rate of 8.25%, PIK Interest 1.10%, 4.00% Exit Fee |
|
$ |
20,025 |
|
|
|
19,751 |
|
|
|
19,424 |
|
|
(13)(14)(18) |
Yipit, LLC |
|
Senior Secured |
September 2026 |
1-month LIBOR + 9.08% or Floor rate of 10.08% |
|
$ |
45,900 |
|
|
|
45,022 |
|
|
|
45,022 |
|
|
(16)(17) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
64,773 |
|
|
|
64,446 |
|
|
|
||||
Subtotal: Information Services (4.93%)* |
|
|
|
|
|
|
64,773 |
|
|
|
64,446 |
|
|
|
||||
See notes to consolidated financial statements
19
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Nextroll, Inc. |
|
Senior Secured |
June 2022 |
PRIME + 3.75% or Floor rate of 7.00%, PIK Interest 2.95%, 3.50% Exit Fee |
|
$ |
21,555 |
|
|
$ |
22,164 |
|
|
$ |
22,164 |
|
|
(12)(13)(18) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
22,164 |
|
|
|
22,164 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
AppDirect, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 5.90% or Floor rate of 9.15%, 7.95% Exit Fee |
|
$ |
30,790 |
|
|
|
31,416 |
|
|
|
32,248 |
|
|
|
Carwow LTD |
|
Senior Secured |
December 2024 |
PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 1.45%, 4.95% Exit Fee |
|
£ |
21,250 |
|
|
|
28,632 |
|
|
|
28,632 |
|
|
(5)(10)(13) |
ePayPolicy Holdings, LLC |
|
Senior Secured |
December 2024 |
3-month LIBOR + 8.50% or Floor rate of 9.50% |
|
$ |
8,169 |
|
|
|
8,011 |
|
|
|
7,967 |
|
|
(11)(16) |
Houzz, Inc. |
|
Convertible Debt |
May 2028 |
PIK Interest 5.50% |
|
$ |
20,676 |
|
|
|
20,676 |
|
|
|
20,425 |
|
|
(9)(13) |
Rhino Labs, Inc. |
|
Senior Secured |
March 2024 |
PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 2.25% |
|
$ |
16,136 |
|
|
|
15,765 |
|
|
|
15,876 |
|
|
(13)(14) |
RVShare, LLC |
|
Senior Secured |
December 2026 |
1-month LIBOR + 5.50% or Floor rate of 6.50%, PIK Interest 4.00% |
|
$ |
15,000 |
|
|
|
14,701 |
|
|
|
14,701 |
|
|
(14)(16) |
SeatGeek, Inc. |
|
Senior Secured |
June 2023 |
PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50% |
|
$ |
60,607 |
|
|
|
59,983 |
|
|
|
60,316 |
|
|
(13) |
Skyword, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.90%, 4.00% Exit Fee |
|
$ |
12,426 |
|
|
|
12,665 |
|
|
|
12,521 |
|
|
(13) |
Tectura Corporation |
|
Senior Secured |
July 2024 |
PIK Interest 5.00% |
|
$ |
10,680 |
|
|
|
240 |
|
|
|
— |
|
|
(7)(8)(13) |
|
|
Senior Secured |
July 2024 |
FIXED 8.25% |
|
$ |
8,250 |
|
|
|
8,250 |
|
|
|
8,250 |
|
|
(7)(8) |
|
|
Senior Secured |
July 2024 |
PIK Interest 5.00% |
|
$ |
13,023 |
|
|
|
13,023 |
|
|
|
19 |
|
|
(7)(8)(13) |
Total Tectura Corporation |
|
|
|
|
|
$ |
31,953 |
|
|
|
21,513 |
|
|
|
8,269 |
|
|
|
Thumbtack, Inc. |
|
Senior Secured |
September 2023 |
PRIME + 3.45% or Floor rate of 8.95%, PIK Interest 1.50%, 3.95% Exit Fee |
|
$ |
25,618 |
|
|
|
25,965 |
|
|
|
26,372 |
|
|
(12)(13) |
Zepz (p.k.a. Worldremit Group Limited) |
|
Senior Secured |
February 2025 |
3-month LIBOR + 9.25% or Floor rate of 10.25%, 3.00% Exit Fee |
|
$ |
103,000 |
|
|
|
101,674 |
|
|
|
100,472 |
|
|
(5)(10)(12)(15)(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
341,001 |
|
|
|
327,799 |
|
|
|
||||
Subtotal: Internet Consumer & Business Services (26.74%)* |
|
|
|
|
|
|
363,165 |
|
|
|
349,963 |
|
|
|
||||
Manufacturing Technology |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Bright Machines, Inc. |
|
Senior Secured |
November 2022 |
PRIME + 5.70% or Floor rate of 8.95%, 6.95% Exit Fee |
|
$ |
15,000 |
|
|
|
14,995 |
|
|
|
14,995 |
|
|
(18) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
14,995 |
|
|
|
14,995 |
|
|
|
||||
Subtotal: Manufacturing Technology (1.15%)* |
|
|
|
|
|
|
14,995 |
|
|
|
14,995 |
|
|
|
||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Fungible Inc. |
|
Senior Secured |
December 2024 |
PRIME + 5.00% or Floor rate of 8.25%, 4.95% Exit Fee |
|
$ |
20,000 |
|
|
|
19,072 |
|
|
|
19,072 |
|
|
(14)(18) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
19,072 |
|
|
|
19,072 |
|
|
|
||||
Subtotal: Semiconductors (1.46%)* |
|
|
|
|
|
|
19,072 |
|
|
|
19,072 |
|
|
|
||||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Khoros (p.k.a Lithium Technologies) |
|
Senior Secured |
October 2022 |
6-month LIBOR + 8.00% or Floor rate of 9.00% |
|
$ |
56,208 |
|
|
|
55,834 |
|
|
|
55,834 |
|
|
(16) |
Pymetrics, Inc. |
|
Senior Secured |
October 2022 |
PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 1.75%, 4.00% Exit Fee |
|
$ |
9,667 |
|
|
|
9,845 |
|
|
|
9,845 |
|
|
(13) |
Regent Education |
|
Senior Secured |
January 2022 |
FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit Fee |
|
$ |
2,951 |
|
|
|
3,064 |
|
|
|
2,608 |
|
|
(8)(13) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
68,743 |
|
|
|
68,287 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
3GTMS, LLC. |
|
Senior Secured |
February 2025 |
6-Month LIBOR + 9.28% or Floor rate of 10.28% |
|
$ |
10,000 |
|
|
|
9,812 |
|
|
|
9,656 |
|
|
(16)(17) |
Agilence, Inc. |
|
Senior Secured |
October 2026 |
1-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
9,400 |
|
|
|
9,138 |
|
|
|
9,138 |
|
|
(16) |
See notes to consolidated financial statements
20
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Brain Corporation |
|
Senior Secured |
April 2025 |
PRIME + 3.70% or Floor rate of 6.95%, PIK Interest 1.00%, 3.95% Exit Fee |
|
$ |
10,016 |
|
|
$ |
9,943 |
|
|
$ |
9,943 |
|
|
(13)(14)(16) |
Campaign Monitor Limited |
|
Senior Secured |
November 2025 |
6-month LIBOR + 7.90% or Floor rate of 11.15% |
|
$ |
33,000 |
|
|
|
32,459 |
|
|
|
33,000 |
|
|
(18) |
Ceros, LLC |
|
Senior Secured |
September 2026 |
3-month LIBOR + 8.89% or Floor rate of 9.89% |
|
$ |
17,978 |
|
|
|
17,474 |
|
|
|
17,474 |
|
|
(16)(17) |
Cloud 9 Software |
|
Senior Secured |
April 2024 |
3-month LIBOR + 8.20% or Floor rate of 9.20% |
|
$ |
9,953 |
|
|
|
9,856 |
|
|
|
9,953 |
|
|
(12) |
CloudBolt Software, Inc. |
|
Senior Secured |
October 2024 |
PRIME + 6.70% or Floor rate of 9.95%, 2.95% Exit Fee |
|
$ |
10,000 |
|
|
|
9,923 |
|
|
|
10,035 |
|
|
(11)(12)(18) |
Cybermaxx Intermediate Holdings, Inc. |
|
Senior Secured |
August 2026 |
6-month LIBOR + 9.28% or Floor rate of 10.28% |
|
$ |
8,000 |
|
|
|
7,801 |
|
|
|
7,801 |
|
|
(16) |
Dashlane, Inc. |
|
Senior Secured |
July 2025 |
PRIME + 3.05% or Floor rate of 7.55%, PIK Interest 1.10%, 7.10% Exit Fee |
|
$ |
20,719 |
|
|
|
21,807 |
|
|
|
21,734 |
|
|
(11)(13)(16)(18) |
Delphix Corp. |
|
Senior Secured |
February 2023 |
PRIME + 5.50% or Floor rate of 10.25%, 5.00% Exit Fee |
|
$ |
60,000 |
|
|
|
61,736 |
|
|
|
62,345 |
|
|
(12)(15)(18) |
Demandbase, Inc. |
|
Senior Secured |
August 2025 |
PRIME + 5.25% or Floor rate of 8.50%, 2.00% Exit Fee |
|
$ |
16,875 |
|
|
|
16,463 |
|
|
|
16,463 |
|
|
(16)(18) |
Enmark Systems |
|
Senior Secured |
September 2026 |
6-Month LIBOR + 6.83% or Floor rate of 7.83%, PIK Interest 2.19% |
|
$ |
8,000 |
|
|
|
7,798 |
|
|
|
7,798 |
|
|
(11)(16)(17) |
Esentire, Inc. |
|
Senior Secured |
May 2024 |
3-month LIBOR + 9.96% or Floor rate of 10.96% |
|
$ |
21,000 |
|
|
|
20,699 |
|
|
|
20,750 |
|
|
(5)(10)(11)(17) |
Gryphon Networks Corp. |
|
Senior Secured |
January 2026 |
3-month LIBOR + 9.69% or Floor rate of 10.69% |
|
$ |
5,232 |
|
|
|
5,106 |
|
|
|
5,088 |
|
|
(11)(16) |
Ikon Science Limited |
|
Senior Secured |
October 2024 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
6,913 |
|
|
|
6,719 |
|
|
|
6,767 |
|
|
(5)(10)(16)(17) |
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) |
|
Senior Secured |
July 2023 |
3-month LIBOR + 10.14% or Floor rate of 11.14% |
|
$ |
8,571 |
|
|
|
8,403 |
|
|
|
8,375 |
|
|
(17) |
Logicworks |
|
Senior Secured |
January 2024 |
PRIME + 7.50% or Floor rate of 10.75% |
|
$ |
10,000 |
|
|
|
9,862 |
|
|
|
9,965 |
|
|
(12)(16) |
Mixpanel, Inc. |
|
Senior Secured |
August 2024 |
PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 1.80%, 3.00% Exit Fee |
|
$ |
20,431 |
|
|
|
20,292 |
|
|
|
21,030 |
|
|
(12)(13)(18) |
Mobile Solutions Services |
|
Senior Secured |
December 2025 |
6-month LIBOR + 9.87% or Floor rate of 10.87% |
|
$ |
19,074 |
|
|
|
18,575 |
|
|
|
18,834 |
|
|
(16)(17) |
Nuvolo Technologies Corporation |
|
Senior Secured |
July 2025 |
PRIME + 7.70% or Floor rate of 10.95%, 1.75% Exit Fee |
|
$ |
15,000 |
|
|
|
14,967 |
|
|
|
15,017 |
|
|
(12)(18) |
Pollen, Inc. |
|
Senior Secured |
November 2023 |
PRIME + 4.75% or Floor rate of 8.00%, PIK Interest 0.50%, 4.50% Exit Fee |
|
$ |
7,457 |
|
|
|
7,528 |
|
|
|
7,314 |
|
|
(13) |
|
|
Senior Secured |
November 2023 |
PRIME + 5.25% or Floor rate of 8.50%, PIK Interest 1.35%, 4.50% Exit Fee |
|
$ |
13,041 |
|
|
|
13,005 |
|
|
|
13,092 |
|
|
(13)(14) |
Total Pollen, Inc. |
|
|
|
|
|
$ |
20,498 |
|
|
|
20,533 |
|
|
|
20,406 |
|
|
|
Reltio, Inc. |
|
Senior Secured |
July 2023 |
PRIME + 5.70% or Floor rate of 8.95%, PIK Interest 1.70%, 4.95% Exit Fee |
|
$ |
10,248 |
|
|
|
10,336 |
|
|
|
10,542 |
|
|
(13)(18) |
ShadowDragon, LLC |
|
Senior Secured |
December 2026 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
6,000 |
|
|
|
5,828 |
|
|
|
5,828 |
|
|
(16)(17) |
Tact.ai Technologies, Inc. |
|
Senior Secured |
February 2024 |
PRIME + 4.00% or Floor rate of 8.75%, PIK Interest 2.00%, 5.50% Exit Fee |
|
$ |
5,185 |
|
|
|
5,305 |
|
|
|
5,245 |
|
|
(13) |
ThreatConnect, Inc. |
|
Senior Secured |
May 2026 |
3-month LIBOR + 9.00% or Floor rate of 10.00% |
|
$ |
11,144 |
|
|
|
10,831 |
|
|
|
10,859 |
|
|
(12)(16)(17) |
Udacity, Inc. |
|
Senior Secured |
September 2024 |
PRIME + 4.50% or Floor rate of 7.75%, PIK Interest 2.00%, 3.00% Exit Fee |
|
$ |
50,895 |
|
|
|
50,646 |
|
|
|
51,722 |
|
|
(12)(13) |
Zimperium, Inc. |
|
Senior Secured |
July 2024 |
1-month LIBOR + 8.95% or Floor rate of 9.95% |
|
$ |
15,633 |
|
|
|
15,347 |
|
|
|
15,347 |
|
|
(12)(17) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
437,659 |
|
|
|
441,115 |
|
|
|
||||
Greater than 5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Imperva, Inc. |
|
Senior Secured |
January 2027 |
3-month LIBOR + 7.75% or Floor rate of 8.75% |
|
$ |
20,000 |
|
|
|
19,851 |
|
|
|
20,000 |
|
|
(18) |
Subtotal: Greater than 5 Years Maturity |
|
|
|
|
|
|
19,851 |
|
|
|
20,000 |
|
|
|
||||
Subtotal: Software (40.46%)* |
|
|
|
|
|
|
526,253 |
|
|
|
529,402 |
|
|
|
||||
See notes to consolidated financial statements
21
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Maturity Date |
Interest Rate and Floor (1) |
|
Principal |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Impossible Foods, Inc. |
|
Senior Secured |
July 2022 |
PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee |
|
$ |
15,022 |
|
|
$ |
19,379 |
|
|
$ |
19,378 |
|
|
(12) |
Pineapple Energy LLC |
|
Senior Secured |
January 2022 |
FIXED 10.00% |
|
$ |
280 |
|
|
|
280 |
|
|
|
247 |
|
|
(6)(9)(16) |
Subtotal: Under 1 Year Maturity |
|
|
|
|
|
|
19,659 |
|
|
|
19,625 |
|
|
|
||||
1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Pineapple Energy LLC |
|
Senior Secured |
December 2023 |
PIK Interest 10.00% |
|
$ |
7,500 |
|
|
|
7,500 |
|
|
|
7,500 |
|
|
(6)(8)(13)(16) |
Subtotal: 1-5 Years Maturity |
|
|
|
|
|
|
7,500 |
|
|
|
7,500 |
|
|
|
||||
Subtotal: Sustainable and Renewable Technology (2.07%)* |
|
|
|
|
|
|
27,159 |
|
|
|
27,125 |
|
|
|
||||
Total: Debt Investments (168.86%)* |
|
|
|
|
|
$ |
2,219,586 |
|
|
$ |
2,209,599 |
|
|
|
||||
See notes to consolidated financial statements
22
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Equity Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Peerless Network Holdings, Inc. |
|
Equity |
10/21/2020 |
Common Stock |
|
3,328 |
|
|
$ |
— |
|
|
$ |
18 |
|
|
|
|
|
Equity |
4/11/2008 |
Preferred Series A |
|
1,135,000 |
|
|
|
1,230 |
|
|
|
6,242 |
|
|
|
Total Peerless Network Holdings, Inc. |
|
|
|
|
|
1,138,328 |
|
|
|
1,230 |
|
|
|
6,260 |
|
|
|
Subtotal: Communications & Networking (0.48%)* |
|
|
|
|
1,230 |
|
|
|
6,260 |
|
|
|
|||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) |
|
Equity |
4/30/2010 |
Common Stock |
|
42,989 |
|
|
|
128 |
|
|
|
447 |
|
|
|
Subtotal: Consumer & Business Products (0.03%)* |
|
|
|
|
128 |
|
|
|
447 |
|
|
|
|||||
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gibraltar Business Capital, LLC |
|
Equity |
3/1/2018 |
Common Stock |
|
830,000 |
|
|
|
1,884 |
|
|
|
1,225 |
|
|
(7) |
|
|
Equity |
3/1/2018 |
Preferred Series A |
|
10,602,752 |
|
|
|
26,122 |
|
|
|
19,393 |
|
|
(7) |
Total Gibraltar Business Capital, LLC |
|
|
11,432,752 |
|
|
|
28,006 |
|
|
|
20,618 |
|
|
|
|||
Hercules Adviser LLC |
|
Equity |
3/26/2021 |
Member Units |
|
1 |
|
|
|
35 |
|
|
|
11,990 |
|
|
(7) |
Subtotal: Diversified Financial Services (2.49%)* |
|
|
|
|
28,041 |
|
|
|
32,608 |
|
|
|
|||||
Drug Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
AcelRx Pharmaceuticals, Inc. |
|
Equity |
12/10/2018 |
Common Stock |
|
176,730 |
|
|
|
1,329 |
|
|
|
99 |
|
|
(4) |
Aytu BioScience, Inc. (p.k.a. Neos Therapeutics, Inc.) |
|
Equity |
3/28/2014 |
Common Stock |
|
13,600 |
|
|
|
1,500 |
|
|
|
18 |
|
|
(4) |
BioQ Pharma Incorporated |
|
Equity |
12/8/2015 |
Preferred Series D |
|
165,000 |
|
|
|
500 |
|
|
|
168 |
|
|
|
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) |
|
Equity |
4/6/2015 |
Common Stock |
|
2,498 |
|
|
|
309 |
|
|
|
20 |
|
|
(4) |
Subtotal: Drug Delivery (0.02%)* |
|
|
|
|
3,638 |
|
|
|
305 |
|
|
|
|||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Albireo Pharma, Inc. |
|
Equity |
9/14/2020 |
Common Stock |
|
25,000 |
|
|
|
1,000 |
|
|
|
582 |
|
|
(4)(10) |
Applied Molecular Transport |
|
Equity |
4/6/2021 |
Common Stock |
|
1,000 |
|
|
|
42 |
|
|
|
14 |
|
|
(4)(10) |
Avalo Therapeutics, Inc. (p.k.a. Cerecor, Inc.) |
|
Equity |
8/19/2014 |
Common Stock |
|
119,087 |
|
|
|
1,000 |
|
|
|
202 |
|
|
(4) |
Aveo Pharmaceuticals, Inc. |
|
Equity |
7/31/2011 |
Common Stock |
|
190,179 |
|
|
|
1,715 |
|
|
|
892 |
|
|
(4) |
Bicycle Therapeutics PLC |
|
Equity |
10/5/2020 |
Common Stock |
|
98,100 |
|
|
|
1,871 |
|
|
|
5,971 |
|
|
(4)(5)(10) |
BridgeBio Pharma, Inc. |
|
Equity |
6/21/2018 |
Common Stock |
|
231,329 |
|
|
|
2,255 |
|
|
|
3,859 |
|
|
(4) |
Chemocentryx, Inc. |
|
Equity |
6/15/2020 |
Common Stock |
|
17,241 |
|
|
|
1,000 |
|
|
|
628 |
|
|
(4)(10) |
Concert Pharmaceuticals, Inc. |
|
Equity |
2/13/2019 |
Common Stock |
|
70,796 |
|
|
|
1,367 |
|
|
|
223 |
|
|
(4)(10) |
Dare Biosciences, Inc. |
|
Equity |
1/8/2015 |
Common Stock |
|
13,550 |
|
|
|
1,000 |
|
|
|
27 |
|
|
(4) |
Dynavax Technologies |
|
Equity |
7/22/2015 |
Common Stock |
|
20,000 |
|
|
|
550 |
|
|
|
281 |
|
|
(4)(10) |
Genocea Biosciences, Inc. |
|
Equity |
11/20/2014 |
Common Stock |
|
27,933 |
|
|
|
2,000 |
|
|
|
32 |
|
|
(4) |
Hibercell, Inc. |
|
Equity |
5/7/2021 |
Preferred Series B |
|
3,466,840 |
|
|
|
4,250 |
|
|
|
3,264 |
|
|
(14) |
Humanigen, Inc. |
|
Equity |
3/31/2021 |
Common Stock |
|
43,243 |
|
|
|
800 |
|
|
|
161 |
|
|
(4)(10) |
Kaleido Biosciences, Inc. |
|
Equity |
2/10/2021 |
Common Stock |
|
86,585 |
|
|
|
1,000 |
|
|
|
207 |
|
|
(4) |
NorthSea Therapeutics |
|
Equity |
12/15/2021 |
Preferred Series C |
|
983 |
|
|
|
2,000 |
|
|
|
2,000 |
|
|
(5)(10) |
Paratek Pharmaceuticals, Inc. |
|
Equity |
2/26/2007 |
Common Stock |
|
76,362 |
|
|
|
2,744 |
|
|
|
343 |
|
|
(4) |
Rocket Pharmaceuticals, Ltd. |
|
Equity |
8/22/2007 |
Common Stock |
|
944 |
|
|
|
1,500 |
|
|
|
21 |
|
|
(4) |
Savara, Inc. |
|
Equity |
8/11/2015 |
Common Stock |
|
11,119 |
|
|
|
202 |
|
|
|
14 |
|
|
(4) |
Sio Gene Therapies, Inc. (p.k.a. Axovant Gene Therapies Ltd.) |
|
Equity |
2/2/2017 |
Common Stock |
|
16,228 |
|
|
|
1,269 |
|
|
|
21 |
|
|
(4)(10) |
Tricida, Inc. |
|
Equity |
2/28/2018 |
Common Stock |
|
68,816 |
|
|
|
863 |
|
|
|
658 |
|
|
(4) |
uniQure B.V. |
|
Equity |
1/31/2019 |
Common Stock |
|
17,175 |
|
|
|
332 |
|
|
|
356 |
|
|
(4)(5)(10)(15) |
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) |
|
Equity |
12/11/2020 |
Preferred Series B |
|
510,308 |
|
|
|
3,000 |
|
|
|
4,650 |
|
|
|
X4 Pharmaceuticals, Inc. |
|
Equity |
11/26/2019 |
Common Stock |
|
198,277 |
|
|
|
1,641 |
|
|
|
454 |
|
|
(4) |
Subtotal: Drug Discovery & Development (1.90%)* |
|
|
|
|
33,401 |
|
|
|
24,860 |
|
|
|
|||||
Healthcare Services, Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
23andMe, Inc. |
|
Equity |
3/11/2019 |
Common Stock |
|
825,732 |
|
|
|
5,094 |
|
|
|
5,500 |
|
|
(4) |
Carbon Health Technologies, Inc. |
|
Equity |
3/30/2021 |
Preferred Series C |
|
217,880 |
|
|
|
1,687 |
|
|
|
1,864 |
|
|
|
Subtotal: Healthcare Services, Other (0.56%)* |
|
|
|
|
6,781 |
|
|
|
7,364 |
|
|
|
|||||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Planet Labs, Inc. |
|
Equity |
6/21/2019 |
Common Stock |
|
547,880 |
|
|
|
615 |
|
|
|
3,369 |
|
|
(4) |
Yipit, LLC |
|
Equity |
12/30/2021 |
Preferred Series E |
|
41,021 |
|
|
|
3,825 |
|
|
|
3,825 |
|
|
|
Zeta Global Corp. |
|
Equity |
11/20/2007 |
Common Stock |
|
295,861 |
|
|
|
— |
|
|
|
2,220 |
|
|
(4)(19) |
Subtotal: Information Services (0.72%)* |
|
|
|
|
4,440 |
|
|
|
9,414 |
|
|
|
|||||
See notes to consolidated financial statements
23
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Black Crow AI, Inc. |
|
Equity |
3/24/2021 |
Preferred Series Seed |
|
872,797 |
|
|
$ |
1,000 |
|
|
$ |
1,120 |
|
|
(6) |
Black Crow AI, Inc. affiliates |
|
Equity |
3/24/2021 |
Preferred Note |
|
3 |
|
|
|
3,000 |
|
|
|
3,000 |
|
|
(20) |
Brigade Group, Inc. |
|
Equity |
3/1/2013 |
Common Stock |
|
9,023 |
|
|
|
93 |
|
|
|
— |
|
|
|
Carwow LTD |
|
Equity |
12/15/2021 |
Preferred Series D-4 |
|
199,742 |
|
|
|
1,151 |
|
|
|
608 |
|
|
(5)(10) |
Contentful Global, Inc. (p.k.a. Contentful, Inc.) |
|
Equity |
12/22/2020 |
Preferred Series C |
|
41,000 |
|
|
|
138 |
|
|
|
506 |
|
|
(5)(10) |
|
|
Equity |
11/20/2018 |
Preferred Series D |
|
108,500 |
|
|
|
500 |
|
|
|
1,388 |
|
|
(5)(10) |
Total Contentful Global, Inc. (p.k.a. Contentful, Inc.) |
|
|
149,500 |
|
|
|
638 |
|
|
|
1,894 |
|
|
|
|||
DoorDash, Inc. |
|
Equity |
12/20/2018 |
Common Stock |
|
81,996 |
|
|
|
945 |
|
|
|
12,209 |
|
|
(4) |
Lyft, Inc. |
|
Equity |
12/26/2018 |
Common Stock |
|
100,738 |
|
|
|
5,263 |
|
|
|
4,305 |
|
|
(4) |
Nerdy Inc. |
|
Equity |
9/17/2021 |
Common Stock |
|
100,000 |
|
|
|
1,000 |
|
|
|
450 |
|
|
(4) |
Nextdoor.com, Inc. |
|
Equity |
8/1/2018 |
Common Stock |
|
1,019,255 |
|
|
|
4,854 |
|
|
|
6,624 |
|
|
(4)(19) |
OfferUp, Inc. |
|
Equity |
10/25/2016 |
Preferred Series A |
|
286,080 |
|
|
|
1,663 |
|
|
|
1,791 |
|
|
|
|
|
Equity |
10/25/2016 |
Preferred Series A-1 |
|
108,710 |
|
|
|
632 |
|
|
|
680 |
|
|
|
Total OfferUp, Inc. |
|
|
|
|
|
394,790 |
|
|
|
2,295 |
|
|
|
2,471 |
|
|
|
Oportun |
|
Equity |
6/28/2013 |
Common Stock |
|
48,365 |
|
|
|
577 |
|
|
|
980 |
|
|
(4) |
Reischling Press, Inc. (p.k.a. Blurb, Inc.) |
|
Equity |
7/31/2020 |
Common Stock |
|
1,163 |
|
|
|
15 |
|
|
|
— |
|
|
|
Savage X Holding, LLC |
|
Equity |
4/30/2010 |
Class A Units |
|
42,137 |
|
|
|
13 |
|
|
|
71 |
|
|
|
Tectura Corporation |
|
Equity |
5/23/2018 |
Common Stock |
|
414,994,863 |
|
|
|
900 |
|
|
|
— |
|
|
(7) |
|
|
Equity |
6/6/2016 |
Preferred Series BB |
|
1,000,000 |
|
|
|
— |
|
|
|
— |
|
|
(7) |
Total Tectura Corporation |
|
|
415,994,863 |
|
|
|
900 |
|
|
|
— |
|
|
|
|||
TFG Holding, Inc. |
|
Equity |
4/30/2010 |
Common Stock |
|
42,989 |
|
|
|
89 |
|
|
|
216 |
|
|
|
Uber Technologies, Inc. (p.k.a. Postmates, Inc.) |
|
Equity |
12/1/2020 |
Common Stock |
|
32,991 |
|
|
|
318 |
|
|
|
1,383 |
|
|
(4) |
Subtotal: Internet Consumer & Business Services (2.70%)* |
|
|
|
|
22,151 |
|
|
|
35,331 |
|
|
|
|||||
Medical Devices & Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Coronado Aesthetics, LLC |
|
Equity |
10/15/2021 |
Common Units |
|
180,000 |
|
|
|
— |
|
|
|
65 |
|
|
(7) |
|
|
Equity |
10/15/2021 |
Preferred Series A-2 |
|
5,000,000 |
|
|
|
250 |
|
|
|
500 |
|
|
(7) |
Total Coronado Aesthetics, LLC |
|
|
5,180,000 |
|
|
|
250 |
|
|
|
565 |
|
|
|
|||
Flowonix Medical Incorporated |
|
Equity |
11/3/2014 |
Preferred Series AA |
|
221,893 |
|
|
|
1,500 |
|
|
|
— |
|
|
|
Gelesis, Inc. |
|
Equity |
11/30/2009 |
Common Stock |
|
227,013 |
|
|
|
— |
|
|
|
3,351 |
|
|
|
|
|
Equity |
12/30/2011 |
Preferred Series A-1 |
|
243,432 |
|
|
|
503 |
|
|
|
3,593 |
|
|
|
|
|
Equity |
12/31/2011 |
Preferred Series A-2 |
|
191,626 |
|
|
|
500 |
|
|
|
2,828 |
|
|
|
Total Gelesis, Inc. |
|
|
662,071 |
|
|
|
1,003 |
|
|
|
9,772 |
|
|
|
|||
Medrobotics Corporation |
|
Equity |
9/12/2013 |
Preferred Series E |
|
136,798 |
|
|
|
250 |
|
|
|
— |
|
|
|
|
|
Equity |
10/22/2014 |
Preferred Series F |
|
73,971 |
|
|
|
155 |
|
|
|
— |
|
|
|
|
|
Equity |
10/16/2015 |
Preferred Series G |
|
163,934 |
|
|
|
500 |
|
|
|
— |
|
|
|
Total Medrobotics Corporation |
|
|
374,703 |
|
|
|
905 |
|
|
|
— |
|
|
|
|||
ViewRay, Inc. |
|
Equity |
12/16/2013 |
Common Stock |
|
36,457 |
|
|
|
333 |
|
|
|
201 |
|
|
(4) |
Subtotal: Medical Devices & Equipment (0.81%)* |
|
|
|
|
3,991 |
|
|
|
10,538 |
|
|
|
|||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Achronix Semiconductor Corporation |
|
Equity |
7/1/2011 |
Preferred Series C |
|
277,995 |
|
|
|
160 |
|
|
|
725 |
|
|
|
Subtotal: Semiconductors (0.06%)* |
|
|
|
|
160 |
|
|
|
725 |
|
|
|
|||||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
3GTMS, LLC. |
|
Equity |
8/9/2021 |
Common Stock |
|
1,000,000 |
|
|
|
1,000 |
|
|
|
985 |
|
|
|
CapLinked, Inc. |
|
Equity |
10/26/2012 |
Preferred Series A-3 |
|
53,614 |
|
|
|
51 |
|
|
|
65 |
|
|
|
See notes to consolidated financial statements
24
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Docker, Inc. |
|
Equity |
11/29/2018 |
Common Stock |
|
20,000 |
|
|
$ |
4,284 |
|
|
$ |
3 |
|
|
|
Druva Holdings, Inc. (p.k.a. Druva, Inc.) |
|
Equity |
10/22/2015 |
Preferred Series 2 |
|
458,841 |
|
|
|
1,000 |
|
|
|
2,387 |
|
|
|
|
|
Equity |
8/24/2017 |
Preferred Series 3 |
|
93,620 |
|
|
|
300 |
|
|
|
529 |
|
|
|
Total Druva Holdings, Inc. (p.k.a. Druva, Inc.) |
|
|
552,461 |
|
|
|
1,300 |
|
|
|
2,916 |
|
|
|
|||
HighRoads, Inc. |
|
Equity |
1/18/2013 |
Common Stock |
|
190 |
|
|
|
307 |
|
|
|
— |
|
|
|
Lightbend, Inc. |
|
Equity |
12/4/2020 |
Common Stock |
|
38,461 |
|
|
|
265 |
|
|
|
5 |
|
|
|
Palantir Technologies |
|
Equity |
9/23/2020 |
Common Stock |
|
1,418,337 |
|
|
|
8,670 |
|
|
|
25,828 |
|
|
(4) |
SingleStore, Inc. (p.k.a. memsql, Inc.) |
|
Equity |
11/25/2020 |
Preferred Series E |
|
580,983 |
|
|
|
2,000 |
|
|
|
2,239 |
|
|
|
|
|
Equity |
8/12/2021 |
Preferred Series F |
|
52,956 |
|
|
|
279 |
|
|
|
240 |
|
|
|
Total SingleStore, Inc. (p.k.a. memsql, Inc.) |
|
|
633,939 |
|
|
|
2,279 |
|
|
|
2,479 |
|
|
|
|||
Sprinklr, Inc. |
|
Equity |
3/22/2017 |
Common Stock |
|
700,000 |
|
|
|
3,749 |
|
|
|
11,109 |
|
|
(4) |
Verana Health, Inc. |
|
Equity |
7/8/2021 |
Preferred Series E |
|
952,562 |
|
|
|
2,000 |
|
|
|
1,697 |
|
|
|
Subtotal: Software (3.45%)* |
|
|
|
|
23,905 |
|
|
|
45,087 |
|
|
|
|||||
Surgical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gynesonics, Inc. |
|
Equity |
1/18/2007 |
Preferred Series B |
|
219,298 |
|
|
|
250 |
|
|
|
9 |
|
|
|
|
|
Equity |
6/16/2010 |
Preferred Series C |
|
656,538 |
|
|
|
282 |
|
|
|
26 |
|
|
|
|
|
Equity |
2/8/2013 |
Preferred Series D |
|
1,991,157 |
|
|
|
712 |
|
|
|
81 |
|
|
|
|
|
Equity |
7/14/2015 |
Preferred Series E |
|
2,786,367 |
|
|
|
429 |
|
|
|
131 |
|
|
|
|
|
Equity |
12/18/2018 |
Preferred Series F |
|
1,523,693 |
|
|
|
118 |
|
|
|
123 |
|
|
|
|
|
Equity |
12/18/2018 |
Preferred Series F-1 |
|
2,418,125 |
|
|
|
150 |
|
|
|
173 |
|
|
|
Total Gynesonics, Inc. |
|
|
9,595,178 |
|
|
|
1,941 |
|
|
|
543 |
|
|
|
|||
Subtotal: Surgical Devices (0.04%)* |
|
|
|
|
1,941 |
|
|
|
543 |
|
|
|
|||||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Impossible Foods, Inc. |
|
Equity |
5/10/2019 |
Preferred Series E-1 |
|
188,611 |
|
|
|
2,000 |
|
|
|
3,430 |
|
|
|
Modumetal, Inc. |
|
Equity |
6/1/2015 |
Common Stock |
|
1,035 |
|
|
|
500 |
|
|
|
— |
|
|
|
NantEnergy, LLC (p.k.a. Fluidic, Inc.) |
|
Equity |
8/31/2013 |
Common Units |
|
59,665 |
|
|
|
102 |
|
|
|
— |
|
|
|
Pineapple Energy LLC |
|
Equity |
12/10/2020 |
Class A Units |
|
3,000,000 |
|
|
|
4,767 |
|
|
|
591 |
|
|
(6) |
Pivot Bio, Inc. |
|
Equity |
6/28/2021 |
Preferred Series D |
|
593,080 |
|
|
|
4,500 |
|
|
|
3,164 |
|
|
|
Proterra, Inc. |
|
Equity |
5/28/2015 |
Common Stock |
|
457,841 |
|
|
|
543 |
|
|
|
4,043 |
|
|
(4) |
Subtotal: Sustainable and Renewable Technology (0.86%)* |
|
|
|
|
12,412 |
|
|
|
11,228 |
|
|
|
|||||
Total: Equity Investments (14.12%)* |
|
|
|
|
|
|
|
$ |
142,219 |
|
|
$ |
184,710 |
|
|
|
|
Warrant Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Spring Mobile Solutions, Inc. |
|
Warrant |
4/19/2013 |
Common Stock |
|
2,834,375 |
|
|
$ |
418 |
|
|
$ |
— |
|
|
|
Subtotal: Communications & Networking (0.00%)* |
|
|
|
|
418 |
|
|
|
— |
|
|
|
|||||
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Grove Collaborative, Inc. |
|
Warrant |
4/30/2021 |
Common Stock |
|
83,625 |
|
|
|
433 |
|
|
|
326 |
|
|
|
Penumbra Brands, LLC (p.k.a. Gadget Guard) |
|
Warrant |
6/3/2014 |
Common Stock |
|
1,662,441 |
|
|
|
228 |
|
|
|
— |
|
|
|
TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) |
|
Warrant |
7/16/2013 |
Preferred Series B |
|
206,185 |
|
|
|
1,101 |
|
|
|
2,181 |
|
|
|
The Neat Company |
|
Warrant |
8/13/2014 |
Common Stock |
|
54,054 |
|
|
|
365 |
|
|
|
— |
|
|
|
Whoop, Inc. |
|
Warrant |
6/27/2018 |
Preferred Series C |
|
686,270 |
|
|
|
18 |
|
|
|
1,847 |
|
|
|
Subtotal: Consumer & Business Products (0.33%)* |
|
|
|
|
2,145 |
|
|
|
4,354 |
|
|
|
|||||
Drug Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.) |
|
Warrant |
9/30/2015 |
Common Stock |
|
110,882 |
|
|
|
74 |
|
|
|
— |
|
|
|
BioQ Pharma Incorporated |
|
Warrant |
10/27/2014 |
Common Stock |
|
459,183 |
|
|
|
1 |
|
|
|
62 |
|
|
|
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) |
|
Warrant |
8/28/2014 |
Common Stock |
|
3,929 |
|
|
|
390 |
|
|
|
1 |
|
|
(4) |
Subtotal: Drug Delivery (0.00%)* |
|
|
|
|
465 |
|
|
|
63 |
|
|
|
|||||
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Acacia Pharma Inc. |
|
Warrant |
6/29/2018 |
Common Stock |
|
201,330 |
|
|
|
305 |
|
|
|
6 |
|
|
(4)(5)(10) |
ADMA Biologics, Inc. |
|
Warrant |
12/21/2012 |
Common Stock |
|
89,750 |
|
|
|
295 |
|
|
|
1 |
|
|
(4) |
See notes to consolidated financial statements
25
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Albireo Pharma, Inc. |
|
Warrant |
6/8/2020 |
Common Stock |
|
5,311 |
|
|
$ |
61 |
|
|
$ |
42 |
|
|
(4)(10) |
Axsome Therapeutics, Inc. |
|
Warrant |
9/25/2020 |
Common Stock |
|
15,541 |
|
|
|
681 |
|
|
|
142 |
|
|
(4)(10) |
Brickell Biotech, Inc. |
|
Warrant |
2/18/2016 |
Common Stock |
|
9,005 |
|
|
|
119 |
|
|
|
— |
|
|
(4) |
Cellarity, Inc. |
|
Warrant |
12/8/2021 |
Preferred Series B |
|
100,000 |
|
|
|
287 |
|
|
|
287 |
|
|
(14) |
Century Therapeutics |
|
Warrant |
9/14/2020 |
Common Stock |
|
16,112 |
|
|
|
37 |
|
|
|
64 |
|
|
(4) |
Concert Pharmaceuticals, Inc. |
|
Warrant |
6/8/2017 |
Common Stock |
|
61,273 |
|
|
|
178 |
|
|
|
3 |
|
|
(4)(10) |
Dermavant Sciences Ltd. |
|
Warrant |
5/31/2019 |
Common Stock |
|
223,642 |
|
|
|
101 |
|
|
|
354 |
|
|
(10)(12) |
enGene, Inc. |
|
Warrant |
12/30/2021 |
Preferred Series 3 Class C |
|
84,714 |
|
|
|
64 |
|
|
|
64 |
|
|
(5)(10) |
Evofem Biosciences, Inc. |
|
Warrant |
6/11/2014 |
Common Stock |
|
7,806 |
|
|
|
266 |
|
|
|
— |
|
|
(4) |
Genocea Biosciences, Inc. |
|
Warrant |
4/24/2018 |
Common Stock |
|
41,176 |
|
|
|
165 |
|
|
|
1 |
|
|
(4) |
Motif Bio PLC |
|
Warrant |
1/27/2020 |
Common Stock |
|
121,337,041 |
|
|
|
282 |
|
|
|
— |
|
|
(10) |
Myovant Sciences, Ltd. |
|
Warrant |
10/16/2017 |
Common Stock |
|
73,710 |
|
|
|
460 |
|
|
|
267 |
|
|
(4)(10) |
Paratek Pharmaceuticals, Inc. |
|
Warrant |
6/27/2017 |
Common Stock |
|
432,240 |
|
|
|
546 |
|
|
|
427 |
|
|
(4) |
Phathom Pharmaceuticals, Inc. |
|
Warrant |
9/17/2021 |
Common Stock |
|
64,687 |
|
|
|
848 |
|
|
|
307 |
|
|
(4)(10)(14)(15) |
Scynexis, Inc. |
|
Warrant |
5/14/2021 |
Common Stock |
|
90,887 |
|
|
|
188 |
|
|
|
142 |
|
|
(4) |
Stealth Bio Therapeutics Corp. |
|
Warrant |
6/30/2017 |
Common Stock |
|
500,000 |
|
|
|
158 |
|
|
|
— |
|
|
(4)(10) |
TG Therapeutics, Inc. |
|
Warrant |
2/28/2019 |
Common Stock |
|
231,613 |
|
|
|
1,033 |
|
|
|
2,172 |
|
|
(4)(10)(12) |
Tricida, Inc. |
|
Warrant |
3/27/2019 |
Common Stock |
|
31,352 |
|
|
|
280 |
|
|
|
20 |
|
|
(4) |
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) |
|
Warrant |
6/15/2020 |
Common Units |
|
102,216 |
|
|
|
256 |
|
|
|
441 |
|
|
|
X4 Pharmaceuticals, Inc. |
|
Warrant |
3/18/2019 |
Common Stock |
|
108,334 |
|
|
|
673 |
|
|
|
2 |
|
|
(4) |
Yumanity Therapeutics, Inc. |
|
Warrant |
12/20/2019 |
Common Stock |
|
15,414 |
|
|
|
110 |
|
|
|
3 |
|
|
(4) |
Subtotal: Drug Discovery & Development (0.36%)* |
|
|
|
|
7,393 |
|
|
|
4,745 |
|
|
|
|||||
Electronics & Computer Hardware |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
908 Devices, Inc. |
|
Warrant |
3/15/2017 |
Common Stock |
|
49,078 |
|
|
|
101 |
|
|
|
618 |
|
|
(4) |
Skydio, Inc. |
|
Warrant |
11/8/2021 |
Common Stock |
|
124,451 |
|
|
|
557 |
|
|
|
422 |
|
|
|
Subtotal: Electronics & Computer Hardware (0.08%)* |
|
|
|
|
658 |
|
|
|
1,040 |
|
|
|
|||||
Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Capella Space |
|
Warrant |
10/21/2021 |
Common Stock |
|
176,200 |
|
|
|
207 |
|
|
|
139 |
|
|
(14) |
InMobi Inc. |
|
Warrant |
11/19/2014 |
Common Stock |
|
65,587 |
|
|
|
82 |
|
|
|
— |
|
|
(10) |
Netbase Solutions, Inc. |
|
Warrant |
8/22/2017 |
Preferred Series 1 |
|
60,000 |
|
|
|
356 |
|
|
|
418 |
|
|
|
Subtotal: Information Services (0.04%)* |
|
|
|
|
645 |
|
|
|
557 |
|
|
|
|||||
Internet Consumer & Business Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aria Systems, Inc. |
|
Warrant |
5/22/2015 |
Preferred Series G |
|
231,535 |
|
|
|
74 |
|
|
|
— |
|
|
|
Carwow LTD |
|
Warrant |
12/14/2021 |
Common Stock |
|
174,163 |
|
|
|
164 |
|
|
|
160 |
|
|
(5)(10) |
Cloudpay, Inc. |
|
Warrant |
4/10/2018 |
Preferred Series B |
|
6,763 |
|
|
|
54 |
|
|
|
348 |
|
|
(5)(10) |
First Insight, Inc. |
|
Warrant |
5/10/2018 |
Preferred Series B |
|
75,917 |
|
|
|
96 |
|
|
|
105 |
|
|
|
Houzz, Inc. |
|
Warrant |
10/29/2019 |
Common Stock |
|
529,661 |
|
|
|
20 |
|
|
|
116 |
|
|
|
Interactions Corporation |
|
Warrant |
6/16/2015 |
Preferred Series G-3 |
|
68,187 |
|
|
|
204 |
|
|
|
505 |
|
|
|
Landing Holdings Inc. |
|
Warrant |
3/12/2021 |
Common Stock |
|
11,806 |
|
|
|
116 |
|
|
|
141 |
|
|
(14) |
Lendio, Inc. |
|
Warrant |
3/29/2019 |
Preferred Series D |
|
127,032 |
|
|
|
39 |
|
|
|
84 |
|
|
|
LogicSource |
|
Warrant |
3/21/2016 |
Preferred Series C |
|
79,625 |
|
|
|
30 |
|
|
|
210 |
|
|
|
Rhino Labs, Inc. |
|
Warrant |
3/12/2021 |
Common Stock |
|
13,106 |
|
|
|
470 |
|
|
|
77 |
|
|
(14) |
RumbleON, Inc. |
|
Warrant |
4/30/2018 |
Common Stock |
|
5,139 |
|
|
|
88 |
|
|
|
33 |
|
|
(4) |
SeatGeek, Inc. |
|
Warrant |
6/12/2019 |
Common Stock |
|
1,379,761 |
|
|
|
842 |
|
|
|
1,140 |
|
|
|
ShareThis, Inc. |
|
Warrant |
12/14/2012 |
Preferred Series C |
|
493,502 |
|
|
|
547 |
|
|
|
— |
|
|
|
Skyword, Inc. |
|
Warrant |
8/23/2019 |
Preferred Series B |
|
444,444 |
|
|
|
83 |
|
|
|
7 |
|
|
|
Snagajob.com, Inc. |
|
Warrant |
4/20/2020 |
Common Stock |
|
600,000 |
|
|
|
16 |
|
|
|
121 |
|
|
(12) |
|
|
Warrant |
6/30/2016 |
Preferred Series A |
|
1,800,000 |
|
|
|
782 |
|
|
|
171 |
|
|
(12) |
|
|
Warrant |
8/1/2018 |
Preferred Series B |
|
1,211,537 |
|
|
|
62 |
|
|
|
90 |
|
|
(12) |
Total Snagajob.com, Inc. |
|
|
3,611,537 |
|
|
|
860 |
|
|
|
382 |
|
|
|
|||
Tapjoy, Inc. |
|
Warrant |
7/1/2014 |
Preferred Series D |
|
748,670 |
|
|
|
317 |
|
|
|
443 |
|
|
|
The Faction Group LLC |
|
Warrant |
11/3/2014 |
Preferred Series AA |
|
8,076 |
|
|
|
234 |
|
|
|
650 |
|
|
|
See notes to consolidated financial statements
26
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Thumbtack, Inc. |
|
Warrant |
5/1/2018 |
Common Stock |
|
190,953 |
|
|
$ |
552 |
|
|
$ |
786 |
|
|
|
Xometry, Inc. |
|
Warrant |
5/9/2018 |
Common Stock |
|
87,784 |
|
|
|
47 |
|
|
|
3,038 |
|
|
(4) |
Zepz (p.k.a. Worldremit Group Limited) |
|
Warrant |
2/11/2021 |
Preferred Series D |
|
77,215 |
|
|
|
129 |
|
|
|
1,962 |
|
|
(5)(10)(15) |
|
|
Warrant |
8/27/2021 |
Preferred Series E |
|
1,868 |
|
|
|
26 |
|
|
|
25 |
|
|
(5)(10)(15) |
Total Zepz (p.k.a. Worldremit Group Limited) |
|
|
79,083 |
|
|
|
155 |
|
|
|
1,987 |
|
|
|
|||
Subtotal: Internet Consumer & Business Services (0.78%)* |
|
|
|
|
4,992 |
|
|
|
10,212 |
|
|
|
|||||
Media/Content/Info |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Zoom Media Group, Inc. |
|
Warrant |
12/21/2012 |
Preferred Series A |
|
1,204 |
|
|
|
348 |
|
|
|
— |
|
|
|
Subtotal: Media/Content/Info (0.00%)* |
|
|
|
|
348 |
|
|
|
— |
|
|
|
|||||
Medical Devices & Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Aspire Bariatrics, Inc. |
|
Warrant |
1/28/2015 |
Common Stock |
|
22,572 |
|
|
|
455 |
|
|
|
— |
|
|
|
Flowonix Medical Incorporated |
|
Warrant |
11/3/2014 |
Preferred Series AA |
|
155,325 |
|
|
|
363 |
|
|
|
— |
|
|
(12) |
|
|
Warrant |
9/21/2018 |
Preferred Series BB |
|
725,806 |
|
|
|
351 |
|
|
|
— |
|
|
|
Total Flowonix Medical Incorporated |
|
|
881,131 |
|
|
|
714 |
|
|
|
— |
|
|
|
|||
Intuity Medical, Inc. |
|
Warrant |
12/29/2017 |
Preferred Series B-1 |
|
3,076,323 |
|
|
|
294 |
|
|
|
264 |
|
|
|
Medrobotics Corporation |
|
Warrant |
3/13/2013 |
Preferred Series E |
|
455,539 |
|
|
|
370 |
|
|
|
— |
|
|
|
Outset Medical, Inc. |
|
Warrant |
9/27/2013 |
Common Stock |
|
62,794 |
|
|
|
401 |
|
|
|
1,797 |
|
|
(4) |
SonaCare Medical, LLC |
|
Warrant |
9/28/2012 |
Preferred Series A |
|
6,464 |
|
|
|
188 |
|
|
|
— |
|
|
|
Tela Bio, Inc. |
|
Warrant |
3/31/2017 |
Common Stock |
|
15,712 |
|
|
|
61 |
|
|
|
13 |
|
|
(4) |
Subtotal: Medical Devices & Equipment (0.16%)* |
|
|
|
|
2,483 |
|
|
|
2,074 |
|
|
|
|||||
Semiconductors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Achronix Semiconductor Corporation |
|
Warrant |
6/26/2015 |
Preferred Series D-2 |
|
750,000 |
|
|
|
99 |
|
|
|
1,950 |
|
|
|
Fungible Inc. |
|
Warrant |
12/16/2021 |
Common Stock |
|
800,000 |
|
|
|
751 |
|
|
|
751 |
|
|
(14) |
Subtotal: Semiconductors (0.21%)* |
|
|
|
|
850 |
|
|
|
2,701 |
|
|
|
|||||
Software |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Bitsight Technologies, Inc. |
|
Warrant |
11/18/2020 |
Common Stock |
|
29,691 |
|
|
|
284 |
|
|
|
1,272 |
|
|
|
Brain Corporation |
|
Warrant |
10/4/2021 |
Common Stock |
|
194,629 |
|
|
|
165 |
|
|
|
132 |
|
|
(14) |
CloudBolt Software, Inc. |
|
Warrant |
9/30/2020 |
Common Stock |
|
211,342 |
|
|
|
117 |
|
|
|
85 |
|
|
|
Cloudian, Inc. |
|
Warrant |
11/6/2018 |
Common Stock |
|
477,454 |
|
|
|
71 |
|
|
|
33 |
|
|
|
Couchbase, Inc. |
|
Warrant |
4/25/2019 |
Common Stock |
|
105,350 |
|
|
|
462 |
|
|
|
1,343 |
|
|
(4)(19) |
Dashlane, Inc. |
|
Warrant |
3/11/2019 |
Common Stock |
|
560,536 |
|
|
|
404 |
|
|
|
415 |
|
|
|
Delphix Corp. |
|
Warrant |
10/8/2019 |
Common Stock |
|
718,898 |
|
|
|
1,594 |
|
|
|
3,275 |
|
|
(15) |
Demandbase, Inc. |
|
Warrant |
8/2/2021 |
Common Stock |
|
483,248 |
|
|
|
404 |
|
|
|
443 |
|
|
|
DNAnexus, Inc. |
|
Warrant |
3/21/2014 |
Preferred Series C |
|
909,091 |
|
|
|
97 |
|
|
|
102 |
|
|
|
Evernote Corporation |
|
Warrant |
9/30/2016 |
Common Stock |
|
62,500 |
|
|
|
106 |
|
|
|
65 |
|
|
|
Fuze, Inc. |
|
Warrant |
6/30/2017 |
Preferred Series F |
|
256,158 |
|
|
|
89 |
|
|
|
— |
|
|
|
Lightbend, Inc. |
|
Warrant |
2/14/2018 |
Preferred Series D |
|
89,685 |
|
|
|
131 |
|
|
|
— |
|
|
|
Mixpanel, Inc. |
|
Warrant |
9/30/2020 |
Common Stock |
|
82,362 |
|
|
|
252 |
|
|
|
906 |
|
|
|
Nuvolo Technologies Corporation |
|
Warrant |
3/29/2019 |
Common Stock |
|
50,000 |
|
|
|
88 |
|
|
|
283 |
|
|
|
Poplicus, Inc. |
|
Warrant |
5/28/2014 |
Common Stock |
|
132,168 |
|
|
|
— |
|
|
|
— |
|
|
|
Pymetrics, Inc. |
|
Warrant |
9/15/2020 |
Common Stock |
|
150,943 |
|
|
|
77 |
|
|
|
218 |
|
|
|
RapidMiner, Inc. |
|
Warrant |
11/28/2017 |
Preferred Series C-1 |
|
4,982 |
|
|
|
24 |
|
|
|
54 |
|
|
|
Reltio, Inc. |
|
Warrant |
6/30/2020 |
Common Stock |
|
69,120 |
|
|
|
215 |
|
|
|
637 |
|
|
|
Signpost, Inc. |
|
Warrant |
1/13/2016 |
Series Junior 1 Preferred |
|
474,019 |
|
|
|
314 |
|
|
|
— |
|
|
|
SingleStore, Inc. (p.k.a. memsql, Inc.) |
|
Warrant |
4/28/2020 |
Preferred Series D |
|
312,596 |
|
|
|
103 |
|
|
|
704 |
|
|
|
Tact.ai Technologies, Inc. |
|
Warrant |
2/13/2020 |
Common Stock |
|
1,041,667 |
|
|
|
206 |
|
|
|
162 |
|
|
|
Udacity, Inc. |
|
Warrant |
9/25/2020 |
Common Stock |
|
486,359 |
|
|
|
218 |
|
|
|
345 |
|
|
|
ZeroFox, Inc. |
|
Warrant |
5/7/2020 |
Preferred Series C-1 |
|
648,350 |
|
|
|
101 |
|
|
|
603 |
|
|
|
Zimperium, Inc. |
|
Warrant |
7/2/2021 |
Common Stock |
|
20,563 |
|
|
|
72 |
|
|
|
56 |
|
|
|
Subtotal: Software (0.85%)* |
|
|
|
|
5,594 |
|
|
|
11,133 |
|
|
|
|||||
See notes to consolidated financial statements
27
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)
Portfolio Company |
|
Type of |
Acquisition Date (4) |
Series (3) |
Shares |
|
|
Cost (2) |
|
|
Value |
|
|
Footnotes |
|||
Surgical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Gynesonics, Inc. |
|
Warrant |
2/8/2012 |
Preferred Series C |
|
151,123 |
|
|
$ |
67 |
|
|
$ |
6 |
|
|
|
TransMedics Group, Inc. (p.k.a Transmedics, Inc.) |
|
Warrant |
11/7/2012 |
Common Stock |
|
64,440 |
|
|
|
139 |
|
|
|
480 |
|
|
(4) |
Subtotal: Surgical Devices (0.04%)* |
|
|
|
|
206 |
|
|
|
486 |
|
|
|
|||||
Sustainable and Renewable Technology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Agrivida, Inc. |
|
Warrant |
6/20/2013 |
Preferred Series D |
|
471,327 |
|
|
|
120 |
|
|
|
— |
|
|
|
Fulcrum Bioenergy, Inc. |
|
Warrant |
9/13/2012 |
Preferred Series C-1 |
|
280,897 |
|
|
|
274 |
|
|
|
699 |
|
|
|
Halio, Inc. (p.k.a. Kinestral Technologies, Inc.) |
|
Warrant |
4/22/2014 |
Preferred Series A |
|
325,000 |
|
|
|
155 |
|
|
|
249 |
|
|
|
|
|
Warrant |
4/7/2015 |
Preferred Series B |
|
131,883 |
|
|
|
63 |
|
|
|
86 |
|
|
|
Total Halio, Inc. (p.k.a. Kinestral Technologies, Inc.) |
|
|
456,883 |
|
|
|
218 |
|
|
|
335 |
|
|
|
|||
Polyera Corporation |
|
Warrant |
12/11/2012 |
Preferred Series C |
|
311,609 |
|
|
|
338 |
|
|
|
— |
|
|
|
Subtotal: Sustainable and Renewable Technology (0.08%)* |
|
|
|
|
950 |
|
|
|
1,034 |
|
|
|
|||||
Total: Warrant Investments (2.93%)* |
|
|
|
$ |
27,147 |
|
|
$ |
38,399 |
|
|
|
|||||
Total: Investments in Securities (185.91%)* |
|
|
|
$ |
2,388,952 |
|
|
$ |
2,432,708 |
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Investment Funds & Vehicles |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Forbion Growth Opportunities Fund I C.V. |
|
Investment Funds & Vehicles |
11/16/2020 |
|
|
|
|
|
2,032 |
|
|
|
1,814 |
|
|
(5)(10)(16) |
|
Total: Investments in Investment Funds & Vehicles (0.14%)* |
|
|
|
$ |
2,032 |
|
|
$ |
1,814 |
|
|
|
|||||
Total: Investments (186.05%)* |
|
|
|
$ |
2,390,984 |
|
|
$ |
2,434,522 |
|
|
|
|||||
* Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
See notes to consolidated financial statements
28
HERCULES CAPITAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Description of Business
Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.
The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a Regulated Investment Company (“RIC”) under Subchapter M of the Code (see “Note 6 - Income Taxes”).
The Company does not currently use Commodity Futures Trading Commission (“CFTC”) derivatives. However, to the extent that it uses CFTC derivatives in the future, it intends to do so below prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a "commodity pool operator" under the CEA.
Hercules Capital IV, L.P. (“HC IV”) is our wholly owned Delaware limited partnership that was formed in December 2010. HC IV received a license to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020. SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC (“HTM”), is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV.
The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). These subsidiaries are taxable entities and are not consolidated with Hercules for income tax purposes. The Company's taxable subsidiaries may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.
In May 2020, Hercules Adviser LLC (the “Adviser Subsidiary”) was formed as a wholly owned Delaware limited liability subsidiary of the Company to provide investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary receives fee income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”).
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency.
29
As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated.
Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.
A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.
To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.
The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. As of March 31, 2022, the Company held no interests in a VIE.
Fair Value Measurements
The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value.
30
The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.
Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.
Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.
Valuation of Investments
The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.
As of March 31, 2022, approximately 96.3% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors (the “Board”). Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.
In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by or under the direction of the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by or under the direction of the Board.
As part of the overall process, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. The Board is ultimately, and solely, responsible for determining the fair value of the Company’s investments in good faith. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The Company determines the fair value of each individual investment and records changes in fair value as unrealized appreciation or depreciation.
31
The Company's quarterly multi-step valuation process each quarter, which the Board has approved, is as described below:
Debt Investments
The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820.
In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.
The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date.
The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.
The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost.
When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.
32
Equity Securities and Warrants
Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.
At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors.
Investment Funds & Vehicles
The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.
Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of March 31, 2022, the Company held $451 thousand (Cost basis $456 thousand) of foreign cash. As of December 31, 2021, the Company held $95 thousand (Cost basis $93 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions.
Other Assets
Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivables.
Escrow Receivables
Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. As of both March 31, 2022 and December 31, 2021, there were no material past due escrow receivables. The approximate fair value in accordance with ASC Topic 820 of the escrow receivable balance as of March 31, 2022 and December 31, 2021 was $0.7 million and $0.6 million, respectively.
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in right of use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based
33
on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.
Income Recognition
The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $48.1 million of unamortized fees as of March 31, 2022, of which approximately $40.0 million was included as an offset to the cost basis of its current debt investments and approximately $8.1 million was deferred contingent upon the occurrence of a funding or milestone. As of December 31, 2021, the Company had approximately $42.9 million of unamortized fees, of which approximately $36.5 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $6.4 million was deferred contingent upon the occurrence of a funding or milestone.
The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default, waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $0.3 million and $1.6 million in one-time fee income during the three months ended March 31, 2022 and 2021, respectively.
In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of March 31, 2022, the Company had approximately $37.2 million in exit fees receivable, of which approximately $32.9 million was included as a component of the cost basis of its current debt investments and approximately $4.3 million was a deferred receivable related to expired commitments. As of December 31, 2021, the Company had approximately $35.0 million in exit fees receivable, of which approximately $29.6 million was included as a component of the cost basis of its current debt investments and approximately $5.4 million was a deferred receivable related to expired commitments.
The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $5.0 million and $2.6 million in PIK income during the three months ended March 31, 2022 and 2021, respectively.
To maintain the Company’s RIC status for taxation purposes, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments.
In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three months ended March 31, 2022 and 2021.
34
Equity Offering Expenses
The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.
Debt
The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statement of Operations within net realized gains (losses) as a “Loss on debt extinguishment”.
Debt Issuance Costs
Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest, debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.
Stock Based Compensation
The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.
Income Taxes
The Company intends to operate so as to qualify to be subject to tax as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized.
As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance Requirement, as defined below. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).
Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.
35
We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and net realized securities gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Also, tax legislation requires that income be recognized for tax purposes no later than when recognized for financial reporting purposes, with certain exceptions.
Earnings Per Share (“EPS”)
Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.
Comprehensive Income
The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did not have other comprehensive income for the three months ended March 31, 2022 or 2021. The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.
Distributions
Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions. During the three months ended March 31, 2022, the Company issued 60,326 shares, of common stock to stockholders in connection with the dividend reinvestment plan. During the three months ended March 31, 2021, the Company issued 66,997 shares, of common stock to stockholders in connection with the dividend reinvestment plan.
Segments
The Company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single reportable segment.
36
3. Fair Value of Financial Instruments
Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2022 and December 31, 2021.
(in thousands) |
|
Balance as of |
|
|
Quoted Prices in |
|
|
Significant |
|
|
Significant |
|
||||
Description |
|
2022 |
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
||||
Other assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Escrow Receivables |
|
$ |
660 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
660 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Investments |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Senior Secured Debt |
|
$ |
2,337,510 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,337,510 |
|
Unsecured Debt |
|
|
53,832 |
|
|
|
— |
|
|
|
— |
|
|
|
53,832 |
|
Preferred Stock |
|
|
57,502 |
|
|
|
— |
|
|
|
— |
|
|
|
57,502 |
|
Common Stock |
|
|
102,682 |
|
|
|
64,328 |
|
|
|
17,880 |
|
|
|
20,474 |
|
Warrants |
|
|
37,897 |
|
|
|
— |
|
|
|
7,531 |
|
|
|
30,366 |
|
|
|
$ |
2,589,423 |
|
|
$ |
64,328 |
|
|
$ |
25,411 |
|
|
$ |
2,499,684 |
|
Investment Funds & Vehicles measured at Net Asset Value (1) |
|
|
2,911 |
|
|
|
|
|
|
|
|
|
|
|||
Total Investments excluding cash equivalents |
|
$ |
2,592,334 |
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Investments including cash equivalents |
|
$ |
2,592,334 |
|
|
|
|
|
|
|
|
|
|
|||
(in thousands) |
|
Balance as of |
|
|
Quoted Prices in |
|
|
Significant |
|
|
Significant |
|
||||
Description |
|
2021 |
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
||||
Other assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Escrow Receivables |
|
$ |
561 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
561 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Investments |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Senior Secured Debt |
|
$ |
2,156,709 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,156,709 |
|
Unsecured Debt |
|
|
52,890 |
|
|
|
— |
|
|
|
— |
|
|
|
52,890 |
|
Preferred Stock |
|
|
69,439 |
|
|
|
— |
|
|
|
— |
|
|
|
69,439 |
|
Common Stock |
|
|
115,271 |
|
|
|
84,460 |
|
|
|
8,843 |
|
|
|
21,968 |
|
Warrants |
|
|
38,399 |
|
|
|
— |
|
|
|
10,922 |
|
|
|
27,477 |
|
|
|
$ |
2,432,708 |
|
|
$ |
84,460 |
|
|
$ |
19,765 |
|
|
$ |
2,328,483 |
|
Investment Funds & Vehicles measured at Net Asset Value (1) |
|
|
1,814 |
|
|
|
|
|
|
|
|
|
|
|||
Total Investments excluding cash equivalents |
|
$ |
2,434,522 |
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Investments including cash equivalents |
|
$ |
2,434,522 |
|
|
|
|
|
|
|
|
|
|
|||
37
The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2022 and 2021.
(in thousands) |
Balance as of |
|
Net Realized |
|
Net Change in |
|
Purchases (5) |
|
Sales |
|
Repayments (6) |
|
Gross |
|
Gross |
|
Balance as of |
|
|||||||||
Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Senior Secured Debt |
$ |
2,156,709 |
|
$ |
(2,010 |
) |
$ |
(8,696 |
) |
$ |
292,683 |
|
$ |
— |
|
$ |
(97,672 |
) |
$ |
— |
|
$ |
(3,504 |
) |
$ |
2,337,510 |
|
Unsecured Debt |
|
52,890 |
|
|
— |
|
|
(259 |
) |
|
1,201 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
53,832 |
|
Preferred Stock |
|
69,439 |
|
|
2,867 |
|
|
(6,513 |
) |
|
2,903 |
|
|
(4,772 |
) |
|
— |
|
|
— |
|
|
(6,422 |
) |
|
57,502 |
|
Common Stock |
|
21,968 |
|
|
— |
|
|
2,241 |
|
|
— |
|
|
— |
|
|
— |
|
|
207 |
|
|
(3,942 |
) |
|
20,474 |
|
Warrants |
|
27,477 |
|
|
19 |
|
|
114 |
|
|
3,824 |
|
|
(1,068 |
) |
|
— |
|
|
— |
|
|
— |
|
|
30,366 |
|
Other Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Escrow Receivable |
|
561 |
|
|
277 |
|
|
— |
|
|
167 |
|
|
(345 |
) |
|
— |
|
|
— |
|
|
— |
|
|
660 |
|
Total |
$ |
2,329,044 |
|
$ |
1,153 |
|
$ |
(13,113 |
) |
$ |
300,778 |
|
$ |
(6,185 |
) |
$ |
(97,672 |
) |
$ |
207 |
|
$ |
(13,868 |
) |
$ |
2,500,344 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
(in thousands) |
Balance as of |
|
Net Realized |
|
Net Change in |
|
Purchases (5) |
|
Sales |
|
Repayments (6) |
|
Gross |
|
Gross |
|
Balance as of |
|
|||||||||
Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Senior Secured Debt |
$ |
2,079,465 |
|
$ |
(986 |
) |
$ |
8,712 |
|
$ |
293,287 |
|
$ |
— |
|
$ |
(219,330 |
) |
$ |
— |
|
$ |
— |
|
$ |
2,161,148 |
|
Unsecured Debt |
|
14,970 |
|
|
— |
|
|
(647 |
) |
|
9,591 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
23,914 |
|
Preferred Stock |
|
58,981 |
|
|
— |
|
|
(9,751 |
) |
|
2,687 |
|
|
(230 |
) |
|
— |
|
|
— |
|
|
— |
|
|
51,687 |
|
Common Stock |
|
27,398 |
|
|
— |
|
|
12,372 |
|
|
3,336 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
43,106 |
|
Warrants |
|
21,483 |
|
|
(410 |
) |
|
7,690 |
|
|
791 |
|
|
(159 |
) |
|
— |
|
|
— |
|
|
— |
|
|
29,395 |
|
Other Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Escrow Receivable |
|
65 |
|
|
567 |
|
|
— |
|
|
— |
|
|
(567 |
) |
|
— |
|
|
— |
|
|
— |
|
|
65 |
|
Total |
$ |
2,202,362 |
|
$ |
(829 |
) |
$ |
18,376 |
|
$ |
309,692 |
|
$ |
(956 |
) |
$ |
(219,330 |
) |
$ |
— |
|
$ |
— |
|
$ |
2,309,315 |
|
For the three months ended March 31, 2022, approximately $7.3 million in net unrealized depreciation and $2.2 million in net unrealized appreciation relating to assets still held at the reporting date were recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $8.0 million and $0.3 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.
For the three months ended March 31, 2021, approximately $9.2 million in net unrealized depreciation and $12.4 million in net unrealized appreciation relating to assets still held at the reporting date were recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $7.1 million and $7.1 million in net unrealized appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.
The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of March 31, 2022 and December 31, 2021. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.
38
Investment Type - Level 3 |
Fair Value as of |
|
|
Valuation |
Unobservable Input (1) |
Range |
Weighted |
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals |
$ |
267,330 |
|
|
Originated Within 4-6 Months |
Origination Yield |
9.88% - 13.03% |
10.85% |
|
|
637,715 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
10.21% - 14.36% |
11.77% |
|
|
|
|
|
Premium/(Discount) |
(0.75%) - 0.75% |
0.00% |
|
|
|
1,880 |
|
|
Liquidation |
Collateral Recoverability |
0.00% - 25.00% |
25.00% |
|
|
|
|
|
|
|
|
|
Technology |
|
94,896 |
|
|
Originated Within 4-6 Months |
Origination Yield |
10.11% - 12.50% |
11.66% |
|
|
663,272 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
9.17% - 15.42% |
11.73% |
|
|
|
|
|
Premium/(Discount) |
(0.25%) - 1.00% |
0.14% |
|
|
|
20,725 |
|
|
Convertible Note Analysis |
Probability weighting of alternative outcomes |
1.00% - 35.00% |
32.90% |
|
|
|
|
|
|
|
|
|
Sustainable and Renewable Technology |
|
2,986 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
10.88% |
10.88% |
|
|
|
|
|
Premium/(Discount) |
0.50% |
0.50% |
|
|
|
|
|
|
|
|
|
|
Lower Middle Market |
|
71,045 |
|
|
Originated Within 4-6 Months |
Origination Yield |
10.81% - 11.51% |
11.06% |
|
|
159,157 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
10.44% - 16.32% |
10.99% |
|
|
|
|
|
Premium/(Discount) |
(1.50%) - 1.50% |
(0.64%) |
|
|
|
8,347 |
|
|
Liquidation (3) |
Probability weighting of alternative outcomes |
20.00% - 80.00% |
80.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Where Fair Value Approximates Cost |
||||
|
|
242,405 |
|
|
Debt Investments originated within 3 months |
|
|
|
|
|
33,930 |
|
|
Imminent Payoffs (4) |
|
|
|
|
|
187,654 |
|
|
Debt Investments Maturing in Less than One Year |
|||
|
$ |
2,391,342 |
|
|
Total Level 3 Debt Investments |
|||
Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
39
Investment Type - Level 3 |
Fair Value as of |
|
|
Valuation Techniques/Methodologies |
Unobservable Input (1) |
Range |
Weighted |
|
Pharmaceuticals |
$ |
206,461 |
|
|
Originated Within 4-6 Months |
Origination Yield |
11.23% - 12.84% |
11.40% |
|
|
451,587 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
9.69% - 13.89% |
11.34% |
|
|
|
|
|
Premium/(Discount) |
(0.50%) - 0.75% |
0.06% |
|
|
|
|
|
|
|
|
|
|
Technology |
|
109,904 |
|
|
Originated Within 4-6 Months |
Origination Yield |
11.12% - 11.68% |
11.39% |
|
|
654,320 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
8.98% - 14.54% |
11.64% |
|
|
|
|
|
Premium/(Discount) |
(0.50%) - 0.75% |
0.12% |
|
|
|
2,608 |
|
|
Liquidation (3) |
Probability weighting of alternative outcomes |
20.00% - 50.00% |
40.48% |
|
|
20,425 |
|
|
Convertible Note Analysis |
Probability weighting of alternative outcomes |
1.00% - 35.00% |
32.95% |
|
|
|
|
|
|
|
|
|
Sustainable and Renewable Technology |
|
247 |
|
|
Convertible Note Analysis |
Probability weighting of alternative outcomes |
40.00% - 60.00% |
51.84% |
|
|
7,500 |
|
|
Expected Realizable Value (4) |
Probability weighting of alternative outcomes |
100% - 100% |
100.00% |
|
|
|
|
|
|
|
|
|
Lower Middle Market |
|
3,100 |
|
|
Originated Within 4-6 Months |
Origination Yield |
5.17% - 5.17% |
5.17% |
|
|
81,566 |
|
|
Market Comparable Companies |
Hypothetical Market Yield |
12.23% - 16.01% |
13.22% |
|
|
|
|
|
Premium/(Discount) |
0.00% - 1.50% |
0.43% |
|
|
|
90,504 |
|
|
Expected Realizable Value (4) |
Probability weighting of alternative outcomes |
30.00% - 70.00% |
57.74% |
|
|
|
|
|
Hypothetical Market Yield |
10.64% - 10.64% |
10.64% |
|
|
|
|
|
|
Premium/(Discount) |
(1.00%) - (1.00%) |
(1.00%) |
|
|
|
8,269 |
|
|
Liquidation (3) |
Probability weighting of alternative outcomes |
20.00% - 80.00% |
80.00% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Where Fair Value Approximates Cost |
||||
|
|
441,524 |
|
|
Debt Investments originated within 3 months |
|
|
|
|
|
131,584 |
|
|
Debt Investments Maturing in Less than One Year |
|||
|
$ |
2,209,599 |
|
|
Total Level 3 Debt Investments |
|||
Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
40
Investment Type - Level 3 Equity and Warrant Investments |
|
Fair Value as of |
|
|
Valuation Techniques/ |
|
Unobservable Input (1) |
|
Range |
|
Weighted Average (5) |
|
Equity Investments |
|
$ |
27,805 |
|
|
Market Comparable Companies |
|
EBITDA Multiple (2) |
|
17.5x - 17.5x |
|
17.5x |
|
|
|
|
|
|
|
Revenue Multiple (2) |
|
0.8x - 14.2x |
|
8.1x |
|
|
|
|
|
|
|
|
Tangible Book Value Multiple (2) |
|
2.3x - 2.3x |
|
2.3x |
|
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
16.42% - 30.96% |
|
24.47% |
|
|
|
|
21,109 |
|
|
Market Adjusted OPM Backsolve |
|
Market Equity Adjustment (4) |
|
(93.81%) - 68.62% |
|
8.75% |
|
|
|
14,544 |
|
|
Discounted Cash Flow |
|
Discount Rate (7) |
|
17.74% - 26.99% |
|
22.18% |
|
|
|
— |
|
|
Liquidation |
|
Revenue Multiple (2) |
|
2.1x - 2.1x |
|
2.1x |
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
84.00% - 84.00% |
|
84.00% |
|
|
|
|
14,518 |
|
|
Other (6) |
|
|
|
|
|
|
Warrant Investments |
|
|
14,354 |
|
|
Market Comparable Companies |
|
EBITDA Multiple (2) |
|
17.5x - 17.9x |
|
17.5x |
|
|
|
|
|
|
|
Revenue Multiple (2) |
|
0.8x - 8.0x |
|
4.7x |
|
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
16.42% - 32.75% |
|
23.13% |
|
|
|
|
11,525 |
|
|
Market Adjusted OPM Backsolve |
|
Market Equity Adjustment (4) |
|
(92.25%) - 68.62% |
|
(3.81%) |
|
|
|
4,487 |
|
|
Other(6) |
|
|
|
|
|
|
Total Level 3 |
|
$ |
108,342 |
|
|
|
|
|
|
|
|
|
41
Investment Type - Level 3 Equity and Warrant Investments |
|
Fair Value as of |
|
|
Valuation Techniques/ |
|
Unobservable Input (1) |
|
Range |
|
Weighted Average (5) |
|
Equity Investments |
|
$ |
26,587 |
|
|
Market Comparable Companies |
|
EBITDA Multiple (2) |
|
20.6x - 20.6x |
|
20.6x |
|
|
|
|
|
|
|
Revenue Multiple (2) |
|
1.0x - 18.4x |
|
11.8x |
|
|
|
|
|
|
|
|
Tangible Book Value Multiple (2) |
|
2.5x - 2.5x |
|
2.5x |
|
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
18.81% - 34.69% |
|
25.53% |
|
|
|
|
24,910 |
|
|
Market Adjusted OPM Backsolve |
|
Market Equity Adjustment (4) |
|
(88.67%) - 47.22% |
|
0.81% |
|
|
|
11,990 |
|
|
Discounted Cash Flow |
|
Discount Rate (7) |
|
15.93% - 25.30% |
|
20.46% |
|
|
|
— |
|
|
Liquidation |
|
Revenue Multiple (2) |
|
2.1x - 2.1x |
|
2.1x |
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
84.00% - 84.00% |
|
84.00% |
|
|
|
|
27,920 |
|
|
Other (6) |
|
|
|
|
|
|
Warrant Investments |
|
|
14,517 |
|
|
Market Comparable Companies |
|
EBITDA Multiple (2) |
|
20.6x - 26.0x |
|
20.7x |
|
|
|
|
|
|
|
Revenue Multiple (2) |
|
0.6x - 9.5x |
|
4.5x |
|
|
|
|
|
|
|
|
Discount for Lack of Marketability (3) |
|
18.81% - 37.35% |
|
26.93% |
|
|
|
|
11,914 |
|
|
Market Adjusted OPM Backsolve |
|
Market Equity Adjustment (4) |
|
(88.67%) - 47.22% |
|
(7.76%) |
|
|
|
1,046 |
|
|
Other(6) |
|
|
|
|
|
|
Total Level 3 Warrant and Equity Investments |
|
$ |
118,884 |
|
|
|
|
|
|
|
|
|
The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company is recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.
As of March 31, 2022, the 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $25.95 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit. The fair values of the SBA debentures, July 2024 Notes, February 2025 Notes, June 2025 Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the Union Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of March 31, 2022.
42
The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of March 31, 2022 and December 31, 2021:
|
|
March 31, 2022 |
|
|||||||||||||||||
(in thousands) |
|
Carrying |
|
|
Approximate |
|
|
Identical Assets |
|
|
Observable Inputs |
|
|
Unobservable Inputs |
|
|||||
Description |
|
Value |
|
|
Fair Value |
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
|||||
SBA Debentures |
|
$ |
169,296 |
|
|
$ |
167,181 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
167,181 |
|
July 2024 Notes |
|
|
104,311 |
|
|
|
104,632 |
|
|
|
— |
|
|
|
— |
|
|
|
104,632 |
|
February 2025 Notes |
|
|
49,665 |
|
|
|
48,862 |
|
|
|
— |
|
|
|
— |
|
|
|
48,862 |
|
June 2025 Notes |
|
|
69,474 |
|
|
|
68,791 |
|
|
|
— |
|
|
|
— |
|
|
|
68,791 |
|
March 2026 A Notes |
|
|
49,629 |
|
|
|
48,606 |
|
|
|
— |
|
|
|
— |
|
|
|
48,606 |
|
March 2026 B Notes |
|
|
49,596 |
|
|
|
48,695 |
|
|
|
— |
|
|
|
— |
|
|
|
48,695 |
|
September 2026 Notes |
|
|
320,622 |
|
|
|
290,584 |
|
|
|
— |
|
|
|
— |
|
|
|
290,584 |
|
January 2027 Notes |
|
|
343,606 |
|
|
|
322,719 |
|
|
|
— |
|
|
|
— |
|
|
|
322,719 |
|
2033 Notes |
|
|
38,745 |
|
|
|
41,520 |
|
|
|
— |
|
|
|
41,520 |
|
|
|
— |
|
Union Bank Facility |
|
|
100,000 |
|
|
|
100,000 |
|
|
|
— |
|
|
|
— |
|
|
|
100,000 |
|
SMBC Facility |
|
|
29,051 |
|
|
|
29,051 |
|
|
|
— |
|
|
|
— |
|
|
|
29,051 |
|
Total |
|
$ |
1,323,995 |
|
|
$ |
1,270,641 |
|
|
$ |
— |
|
|
$ |
41,520 |
|
|
$ |
1,229,121 |
|
|
|
December 31, 2021 |
|
|||||||||||||||||
(in thousands) |
|
Carrying |
|
|
Approximate |
|
|
Identical Assets |
|
|
Observable Inputs |
|
|
Unobservable Inputs |
|
|||||
Description |
|
Value |
|
|
Fair Value |
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
|||||
SBA Debentures |
|
$ |
145,498 |
|
|
$ |
151,471 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
151,471 |
|
2022 Notes |
|
|
149,563 |
|
|
|
152,906 |
|
|
|
— |
|
|
|
152,906 |
|
|
|
— |
|
July 2024 Notes |
|
|
104,238 |
|
|
|
110,496 |
|
|
|
— |
|
|
|
— |
|
|
|
110,496 |
|
February 2025 Notes |
|
|
49,637 |
|
|
|
51,983 |
|
|
|
— |
|
|
|
— |
|
|
|
51,983 |
|
June 2025 Notes |
|
|
69,433 |
|
|
|
72,031 |
|
|
|
— |
|
|
|
— |
|
|
|
72,031 |
|
March 2026 A Notes |
|
|
49,605 |
|
|
|
52,646 |
|
|
|
— |
|
|
|
— |
|
|
|
52,646 |
|
March 2026 B Notes |
|
|
49,570 |
|
|
|
52,751 |
|
|
|
— |
|
|
|
— |
|
|
|
52,751 |
|
September 2026 Notes |
|
|
320,376 |
|
|
|
315,495 |
|
|
|
— |
|
|
|
— |
|
|
|
315,495 |
|
2033 Notes |
|
|
38,718 |
|
|
|
42,672 |
|
|
|
— |
|
|
|
42,672 |
|
|
|
— |
|
2022 Convertible Notes |
|
|
229,740 |
|
|
|
236,049 |
|
|
|
— |
|
|
|
236,049 |
|
|
|
— |
|
Union Bank Facility |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
SMBC Facility |
|
|
29,925 |
|
|
|
29,925 |
|
|
|
— |
|
|
|
— |
|
|
|
29,925 |
|
Total |
|
$ |
1,236,303 |
|
|
$ |
1,268,425 |
|
|
$ |
— |
|
|
$ |
431,627 |
|
|
$ |
836,798 |
|
4. Investments
Control and Affiliate Investments
As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds.
43
The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three months ended March 31, 2022 and 2021.
(in thousands) |
|
|
|
|
|
|
Three Months Ended March 31, 2022 |
|
||||||||||||||
Portfolio Company |
|
Type |
|
Fair Value as of March 31, 2022 |
|
|
Interest Income |
|
|
Fee Income |
|
|
Net Change in Unrealized Appreciation (Depreciation) |
|
|
Realized Gain (Loss) |
|
|||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Coronado Aesthetics, LLC |
|
Control |
|
$ |
614 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
49 |
|
|
$ |
— |
|
Gibraltar Business Capital, LLC |
|
Control |
|
|
42,622 |
|
|
|
834 |
|
|
|
16 |
|
|
|
(1,227 |
) |
|
|
— |
|
Hercules Adviser LLC |
|
Control |
|
|
24,694 |
|
|
|
111 |
|
|
|
— |
|
|
|
2,554 |
|
|
|
— |
|
Tectura Corporation |
|
Control |
|
|
8,347 |
|
|
|
170 |
|
|
|
— |
|
|
|
78 |
|
|
|
— |
|
Total Control Investments |
|
$ |
76,277 |
|
|
$ |
1,115 |
|
|
$ |
16 |
|
|
$ |
1,454 |
|
|
$ |
— |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Black Crow AI, Inc. |
|
Affiliate |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(120 |
) |
|
$ |
3,772 |
|
Pineapple Energy LLC |
|
Affiliate |
|
|
4,830 |
|
|
|
1,047 |
|
|
|
— |
|
|
|
873 |
|
|
|
— |
|
Total Affiliate Investments |
|
$ |
4,830 |
|
|
$ |
1,047 |
|
|
$ |
— |
|
|
$ |
753 |
|
|
$ |
3,772 |
|
||
Total Control & Affiliate Investments |
|
$ |
81,107 |
|
|
$ |
2,162 |
|
|
$ |
16 |
|
|
$ |
2,207 |
|
|
$ |
3,772 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
(in thousands) |
|
|
|
|
|
|
Three Months Ended March 31, 2021 |
|
||||||||||||||
Portfolio Company |
|
Type |
|
Fair Value as of March 31, 2021 |
|
|
Interest Income |
|
|
Fee Income |
|
|
Net Change in Unrealized Appreciation (Depreciation) |
|
|
Realized Gain (Loss) |
|
|||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Gibraltar Business Capital, LLC |
|
Control |
|
$ |
50,301 |
|
|
$ |
629 |
|
|
$ |
8 |
|
|
$ |
(8,090 |
) |
|
$ |
— |
|
Hercules Adviser LLC |
|
Control |
|
|
9,869 |
|
|
|
— |
|
|
|
— |
|
|
|
9,869 |
|
|
|
— |
|
Tectura Corporation |
|
Control |
|
|
8,523 |
|
|
|
170 |
|
|
|
— |
|
|
|
(77 |
) |
|
|
— |
|
Total Control Investments |
|
$ |
68,693 |
|
|
$ |
799 |
|
|
$ |
8 |
|
|
$ |
1,702 |
|
|
$ |
— |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Black Crow AI, Inc. |
|
Affiliate |
|
$ |
1,255 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
2,040 |
|
|
$ |
— |
|
Pineapple Energy LLC |
|
Affiliate |
|
|
8,409 |
|
|
|
1 |
|
|
|
— |
|
|
|
29 |
|
|
|
— |
|
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) |
|
Affiliate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
40 |
|
|
|
— |
|
Total Affiliate Investments |
|
$ |
9,664 |
|
|
$ |
1 |
|
|
$ |
— |
|
|
$ |
2,109 |
|
|
$ |
— |
|
||
Total Control & Affiliate Investments |
|
$ |
78,357 |
|
|
$ |
800 |
|
|
$ |
8 |
|
|
$ |
3,811 |
|
|
$ |
— |
|
||
Portfolio Composition
The following table shows the fair value of the Company’s portfolio of investments by asset class as of March 31, 2022 and December 31, 2021:
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
(in thousands) |
Investments at |
|
|
Percentage of |
|
|
Investments at |
|
|
Percentage of |
|
||||
Senior Secured Debt |
$ |
2,337,510 |
|
|
|
90.1 |
% |
|
$ |
2,156,709 |
|
|
|
88.6 |
% |
Unsecured Debt |
|
53,832 |
|
|
|
2.1 |
% |
|
|
52,890 |
|
|
|
2.2 |
% |
Preferred Stock |
|
57,502 |
|
|
|
2.2 |
% |
|
|
69,439 |
|
|
|
2.8 |
% |
Common Stock |
|
102,682 |
|
|
|
4.0 |
% |
|
|
115,271 |
|
|
|
4.7 |
% |
Warrants |
|
37,897 |
|
|
|
1.5 |
% |
|
|
38,399 |
|
|
|
1.6 |
% |
Investment Funds & Vehicles |
|
2,911 |
|
|
|
0.1 |
% |
|
|
1,814 |
|
|
|
0.1 |
% |
Total |
$ |
2,592,334 |
|
|
|
100.0 |
% |
|
$ |
2,434,522 |
|
|
|
100.0 |
% |
A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2022 and December 31, 2021 is shown as follows:
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||||||||||
(in thousands) |
Investments at |
|
|
Percentage of |
|
|
Investments at |
|
|
Percentage of |
|
||||
United States |
$ |
2,299,377 |
|
|
|
88.7 |
% |
|
$ |
2,138,184 |
|
|
|
87.8 |
% |
United Kingdom |
|
165,532 |
|
|
|
6.4 |
% |
|
|
169,407 |
|
|
|
7.0 |
% |
Netherlands |
|
84,181 |
|
|
|
3.3 |
% |
|
|
82,925 |
|
|
|
3.4 |
% |
Canada |
|
27,625 |
|
|
|
1.1 |
% |
|
|
27,673 |
|
|
|
1.1 |
% |
Israel |
|
8,930 |
|
|
|
0.3 |
% |
|
|
8,980 |
|
|
|
0.4 |
% |
Ireland |
|
5,499 |
|
|
|
0.2 |
% |
|
|
5,459 |
|
|
|
0.2 |
% |
Germany |
|
1,190 |
|
|
|
0.0 |
% |
|
|
1,894 |
|
|
|
0.1 |
% |
Total |
$ |
2,592,334 |
|
|
|
100.0 |
% |
|
$ |
2,434,522 |
|
|
|
100.0 |
% |
44
The following table shows the fair value of the Company’s portfolio by industry sector as of March 31, 2022 and December 31, 2021:
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||||||||||
(in thousands) |
Investments at |
|
|
Percentage of |
|
|
Investments at |
|
|
Percentage of |
|
||||
Drug Discovery & Development |
$ |
993,554 |
|
|
|
38.2 |
% |
|
$ |
967,383 |
|
|
|
39.7 |
% |
Software |
|
653,770 |
|
|
|
25.2 |
% |
|
|
585,622 |
|
|
|
24.1 |
% |
Internet Consumer & Business Services |
|
456,542 |
|
|
|
17.6 |
% |
|
|
395,506 |
|
|
|
16.3 |
% |
Healthcare Services, Other |
|
118,692 |
|
|
|
4.6 |
% |
|
|
121,003 |
|
|
|
5.0 |
% |
Communications & Networking |
|
105,811 |
|
|
|
4.1 |
% |
|
|
105,490 |
|
|
|
4.3 |
% |
Diversified Financial Services |
|
67,854 |
|
|
|
2.6 |
% |
|
|
65,073 |
|
|
|
2.7 |
% |
Information Services |
|
60,848 |
|
|
|
2.4 |
% |
|
|
74,417 |
|
|
|
3.1 |
% |
Consumer & Business Products |
|
29,778 |
|
|
|
1.2 |
% |
|
|
28,099 |
|
|
|
1.2 |
% |
Manufacturing Technology |
|
27,532 |
|
|
|
1.1 |
% |
|
|
14,995 |
|
|
|
0.6 |
% |
Sustainable and Renewable Technology |
|
27,470 |
|
|
|
1.1 |
% |
|
|
39,387 |
|
|
|
1.6 |
% |
Medical Devices & Equipment |
|
24,112 |
|
|
|
0.9 |
% |
|
|
12,612 |
|
|
|
0.5 |
% |
Semiconductors |
|
20,982 |
|
|
|
0.8 |
% |
|
|
22,498 |
|
|
|
0.9 |
% |
Electronics & Computer Hardware |
|
4,357 |
|
|
|
0.2 |
% |
|
|
1,040 |
|
|
|
0.0 |
% |
Surgical Devices |
|
831 |
|
|
|
0.0 |
% |
|
|
1,029 |
|
|
|
0.0 |
% |
Drug Delivery |
|
201 |
|
|
|
0.0 |
% |
|
|
368 |
|
|
|
0.0 |
% |
Total |
$ |
2,592,334 |
|
|
|
100.0 |
% |
|
$ |
2,434,522 |
|
|
|
100.0 |
% |
No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of March 31, 2022 or December 31, 2021.
Unconsolidated Subsidiaries
In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of March 31, 2022 and March 31, 2021, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.
Concentrations of Credit Risk
The Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development", "Software”, “Internet Consumer & Business Services”, “Healthcare Services, Other”, and “Communications & Networking" sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.
Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies.
For the three months ended March 31, 2022 and the year ended December 31, 2021, the Company’s ten largest portfolio companies represented approximately 31.6% and 30.5% of the total fair value of the Company’s investments in portfolio companies, respectively. As of March 31, 2022 and December 31, 2021, the Company had seven and six portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of March 31, 2022, the Company had five equity investments representing approximately 44.7% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2021, the Company had six equity investments which represented approximately 49.6% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of such investments.
45
Investment Collateral
In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. As of March 31, 2022, approximately 72.9% of the Company’s debt investments at fair value were in a senior secured first lien position, with 36.9% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 29.2% secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property, and 6.8% of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with a security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 24.8% of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, and 2.3% were unsecured.
As of December 31, 2021, approximately 77.0% of the Company’s debt investments at fair value were in a senior secured first lien position, with 37.5% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 31.6% secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property and 7.9% of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 20.6% of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, and 2.4% were unsecured.
5. Debt
As of March 31, 2022 and December 31, 2021, the Company had the following available and outstanding debt:
|
March 31, 2022 |
|
December 31, 2021 |
|
||||||||||||||
(in thousands) |
Total Available |
|
Principal |
|
Carrying Value (1) |
|
Total Available |
|
Principal |
|
Carrying Value (1) |
|
||||||
SBA Debentures |
$ |
175,000 |
|
$ |
175,000 |
|
$ |
169,296 |
|
$ |
175,000 |
|
$ |
150,500 |
|
$ |
145,498 |
|
2022 Notes |
|
— |
|
|
— |
|
|
— |
|
|
150,000 |
|
|
150,000 |
|
|
149,563 |
|
July 2024 Notes |
|
105,000 |
|
|
105,000 |
|
|
104,311 |
|
|
105,000 |
|
|
105,000 |
|
|
104,238 |
|
February 2025 Notes |
|
50,000 |
|
|
50,000 |
|
|
49,665 |
|
|
50,000 |
|
|
50,000 |
|
|
49,637 |
|
June 2025 Notes |
|
70,000 |
|
|
70,000 |
|
|
69,474 |
|
|
70,000 |
|
|
70,000 |
|
|
69,433 |
|
March 2026 A Notes |
|
50,000 |
|
|
50,000 |
|
|
49,629 |
|
|
50,000 |
|
|
50,000 |
|
|
49,605 |
|
March 2026 B Notes |
|
50,000 |
|
|
50,000 |
|
|
49,596 |
|
|
50,000 |
|
|
50,000 |
|
|
49,570 |
|
September 2026 Notes |
|
325,000 |
|
|
325,000 |
|
|
320,622 |
|
|
325,000 |
|
|
325,000 |
|
|
320,376 |
|
January 2027 Notes |
|
350,000 |
|
|
350,000 |
|
|
343,606 |
|
|
— |
|
|
— |
|
|
— |
|
2033 Notes |
|
40,000 |
|
|
40,000 |
|
|
38,745 |
|
|
40,000 |
|
|
40,000 |
|
|
38,718 |
|
2022 Convertible Notes |
|
— |
|
|
— |
|
|
— |
|
|
230,000 |
|
|
230,000 |
|
|
229,740 |
|
Union Bank Facility (2)(3) |
|
400,000 |
|
|
100,000 |
|
|
100,000 |
|
|
400,000 |
|
|
— |
|
|
— |
|
SMBC Facility (2) (3) |
|
100,000 |
|
|
29,051 |
|
|
29,051 |
|
|
100,000 |
|
|
29,925 |
|
|
29,925 |
|
Total |
$ |
1,715,000 |
|
$ |
1,344,051 |
|
$ |
1,323,995 |
|
$ |
1,745,000 |
|
$ |
1,250,425 |
|
$ |
1,236,303 |
|
Debt issuance costs, net of accumulated amortization, were as follows as of March 31, 2022 and December 31, 2021:
(in thousands) |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
SBA Debentures |
|
$ |
5,704 |
|
|
$ |
5,002 |
|
2022 Notes |
|
|
— |
|
|
|
300 |
|
July 2024 Notes |
|
|
689 |
|
|
|
762 |
|
February 2025 Notes |
|
|
335 |
|
|
|
363 |
|
June 2025 Notes |
|
|
526 |
|
|
|
567 |
|
March 2026 A Notes |
|
|
371 |
|
|
|
395 |
|
March 2026 B Notes |
|
|
404 |
|
|
|
430 |
|
September 2026 Notes |
|
|
4,378 |
|
|
|
4,624 |
|
January 2027 Notes |
|
|
6,394 |
|
|
|
— |
|
2033 Notes |
|
|
1,255 |
|
|
|
1,282 |
|
2022 Convertible Notes |
|
|
— |
|
|
|
149 |
|
Union Bank Facility (1) |
|
|
1,001 |
|
|
|
1,239 |
|
SMBC Facility (1) |
|
|
893 |
|
|
|
922 |
|
Total |
|
$ |
21,950 |
|
|
$ |
16,035 |
|
46
For the three months ended March 31, 2022, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows:
|
|
Three Months Ended March 31, 2022 |
|
|||||||||||||
(in thousands) |
|
Interest expense(1) |
|
Amortization of debt issuance cost (loan fees) |
|
Unused facility and other fees (loan fees) |
|
Total interest expense and fees |
|
Cash paid for interest expense |
|
|||||
SBA Debentures |
|
$ |
550 |
|
$ |
140 |
|
$ |
— |
|
$ |
690 |
|
$ |
749 |
|
2022 Notes |
|
|
1,011 |
|
|
50 |
|
|
— |
|
|
1,061 |
|
|
2,293 |
|
July 2024 Notes |
|
|
1,252 |
|
|
74 |
|
|
— |
|
|
1,326 |
|
|
2,504 |
|
February 2025 Notes |
|
|
535 |
|
|
29 |
|
|
— |
|
|
564 |
|
|
1,070 |
|
June 2025 Notes |
|
|
754 |
|
|
40 |
|
|
— |
|
|
794 |
|
|
— |
|
March 2026 A Notes |
|
|
563 |
|
|
24 |
|
|
— |
|
|
587 |
|
|
1,125 |
|
March 2026 B Notes |
|
|
569 |
|
|
26 |
|
|
— |
|
|
595 |
|
|
1,138 |
|
September 2026 Notes |
|
|
2,174 |
|
|
204 |
|
|
— |
|
|
2,378 |
|
|
4,266 |
|
January 2027 Notes |
|
|
2,395 |
|
|
161 |
|
|
— |
|
|
2,556 |
|
|
— |
|
2033 Notes |
|
|
625 |
|
|
27 |
|
|
— |
|
|
652 |
|
|
625 |
|
2022 Convertible Notes |
|
|
923 |
|
|
149 |
|
|
— |
|
|
1,072 |
|
|
5,004 |
|
Wells Facility |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Union Bank Facility |
|
|
114 |
|
|
237 |
|
|
567 |
|
|
918 |
|
|
— |
|
SMBC Facility |
|
|
182 |
|
|
49 |
|
|
65 |
|
|
296 |
|
|
236 |
|
Total |
|
$ |
11,647 |
|
$ |
1,210 |
|
$ |
632 |
|
$ |
13,489 |
|
$ |
19,010 |
|
For the three months ended March 31, 2021, the components of interest expense and related fees and cash paid for interest expense for debt were as follows:
|
|
Three Months Ended March 31, 2021 |
|
|||||||||||||
(in thousands) |
|
Interest expense(1) |
|
Amortization of debt issuance cost (loan fees) |
|
Unused facility and other fees (loan fees) |
|
Total interest expense and fees |
|
Cash paid for interest expense |
|
|||||
SBA Debentures |
|
$ |
592 |
|
$ |
215 |
|
$ |
— |
|
$ |
807 |
|
$ |
1,553 |
|
2022 Notes |
|
|
1,776 |
|
|
90 |
|
|
— |
|
|
1,866 |
|
|
— |
|
July 2024 Notes |
|
|
1,252 |
|
|
74 |
|
|
— |
|
|
1,326 |
|
|
2,504 |
|
February 2025 Notes |
|
|
535 |
|
|
28 |
|
|
— |
|
|
563 |
|
|
1,070 |
|
April 2025 Notes(2) |
|
|
985 |
|
|
95 |
|
|
— |
|
|
1,080 |
|
|
984 |
|
June 2025 Notes |
|
|
755 |
|
|
41 |
|
|
— |
|
|
796 |
|
|
— |
|
March 2026 A Notes |
|
|
562 |
|
|
22 |
|
|
— |
|
|
584 |
|
|
750 |
|
March 2026 B Notes |
|
|
170 |
|
|
8 |
|
|
— |
|
|
178 |
|
|
— |
|
September 2026 Notes |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
2033 Notes |
|
|
625 |
|
|
27 |
|
|
— |
|
|
652 |
|
|
625 |
|
2027 Asset-Backed Notes(2) |
|
|
1,775 |
|
|
646 |
|
|
— |
|
|
2,421 |
|
|
1,837 |
|
2028 Asset-Backed Notes(2) |
|
|
2,892 |
|
|
333 |
|
|
— |
|
|
3,225 |
|
|
2,929 |
|
2022 Convertible Notes |
|
|
2,683 |
|
|
223 |
|
|
— |
|
|
2,906 |
|
|
5,031 |
|
Wells Facility(2) |
|
|
— |
|
|
44 |
|
|
156 |
|
|
200 |
|
|
— |
|
Union Bank Facility |
|
|
148 |
|
|
326 |
|
|
472 |
|
|
946 |
|
|
75 |
|
Total |
|
$ |
14,750 |
|
$ |
2,172 |
|
$ |
628 |
|
$ |
17,550 |
|
$ |
17,358 |
|
As of March 31, 2022 and December 31, 2021, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company’s debt.
47
SBA Debentures
The Company reported the following SBA debentures outstanding principal balances as of March 31, 2022 and December 31, 2021:
(in thousands) |
|
Maturity Date |
|
Interest Rate (1) |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
March 26, 2021 |
|
September 1, 2031 |
|
1.58% |
|
$ |
37,500 |
|
|
$ |
37,500 |
|
June 25, 2021 |
|
September 1, 2031 |
|
1.58% |
|
|
16,200 |
|
|
|
16,200 |
|
July 28, 2021 |
|
September 1, 2031 |
|
1.58% |
|
|
5,400 |
|
|
|
5,400 |
|
August 20, 2021 |
|
September 1, 2031 |
|
1.58% |
|
|
5,400 |
|
|
|
5,400 |
|
October 21, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
14,000 |
|
|
|
14,000 |
|
November 1, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
21,000 |
|
|
|
21,000 |
|
November 15, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
5,200 |
|
|
|
5,200 |
|
November 30, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
20,800 |
|
|
|
20,800 |
|
December 20, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
10,000 |
|
|
|
10,000 |
|
December 23, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
10,000 |
|
|
|
10,000 |
|
December 28, 2021 |
|
March 1, 2032 |
|
3.21% |
|
|
5,000 |
|
|
|
5,000 |
|
January 14, 2022 |
|
March 1, 2032 |
|
3.21% |
|
|
4,500 |
|
|
|
— |
|
January 21, 2022 |
|
March 1, 2032 |
|
3.21% |
|
|
20,000 |
|
|
|
— |
|
Total SBA Debentures |
|
|
|
|
|
$ |
175,000 |
|
|
$ |
150,500 |
|
SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs compliance with SBA regulations. Our SBIC was in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of March 31, 2022 and December 31, 2021.
HC IV received its license to operate as a SBIC on October 27, 2020. The license has a 10-year term. Through the license, HC IV has access to $175.0 million of capital through the SBA debenture program, that is in addition to the Company’s regulatory capital commitment of $87.5 million to HC IV. As of March 31, 2022, HC IV has issued a total of $175.0 million in SBA guaranteed debentures and has paid the SBA commitment fees and facility fees of approximately $1.75 million and $4.2 million, respectively.
As of March 31, 2022, the Company held investments in HC IV in 17 companies with a fair value of approximately $267.4 million, accounting for approximately 10.3% of the Company’s total investment portfolio. Further, HC IV held approximately $270.8 million in tangible assets which accounted for approximately 10.1% of the Company’s total assets as of March 31, 2022.
2022 Notes
On October 23, 2017, the Company issued $150.0 million in aggregate principal amount of 4.625% interest-bearing unsecured notes that mature on October 23, 2022 (the “2022 Notes”), unless repurchased in accordance with their terms. Interest on the 2022 Notes is due semiannually in arrears on April 23 and October 23 of each year, commencing on April 23, 2018. On February 22, 2022, pursuant to the redemption terms of the 2025 Notes indenture, the Company fully repaid the aggregate outstanding $150.0 million of principal and $2.3 million of accrued interest. In addition, the Company paid $3.3 million of prepayment premium fees, which together with the accelerated recognition of $0.3 million of debt issuance costs was recognized as a realized loss on extinguishment of the debt.
2022 Convertible Notes
On January 25, 2017, the Company issued $230.0 million in aggregate principal amount of 4.375% interest-bearing unsecured notes due on February 1, 2022 (the “2022 Convertible Notes”), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2022 Convertible Notes. The $230.0 million issued aggregate principal of the 2022 Convertible Notes includes an additional $30.0 million aggregate principal amount issued pursuant to the initial purchaser’s exercise in full of its overallotment option. Interest on the 2022 Convertible Notes is due semiannually in arrears on February 1 and August 1 of each year. On February 1, 2022, the Company fully repaid the aggregate outstanding $230.0 million principal, $5.0 million of accrued interest and fees, and issued 981,169 shares related to noteholders who elected to convert pursuant to the redemption terms of the 2022 Convertible Notes indenture.
48
July 2024 Notes
On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the July 2024 Notes is due semiannually. The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
February 2025 Notes
On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is due semiannually. The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
June 2025 Notes
On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering pursuant to the 2025 Note Purchase Agreement. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
March 2026 A Notes
On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.5% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes is due semiannually. The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
March 2026 B Notes
On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. The sale of the March 2026 B Notes generated net proceeds of approximately $49.5 million. Aggregate offering expenses in connection with the transaction, including fees and commissions, were approximately $0.5 million. Interest on the March 2026 B Notes is due semiannually. The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
September 2026 Notes
On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. The issuance of the September 2026 Notes generated net proceeds of approximately $320.1 million. The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $4.1 million of costs and $0.8 million related to the discount. Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year, commencing on March 16, 2022. The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture.
January 2027 Notes
On January 20, 2022, the Company issued $350.0 million in aggregate principal amount of 3.375% interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Notes”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. The issuance of the January 2027 Notes generated net proceeds of approximately $343.4 million.
49
The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $4.1 million of costs and $2.5 million related to the discount. Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year, commencing on July 20, 2022. The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.
2033 Notes
On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes Indenture after October 30, 2023.
Credit Facilities
As of March 31, 2022 and December 31, 2021, the Company has two available credit facilities, the Union Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the three months ended March 31, 2022 and year ended December 31, 2021, the weighted average interest rate was 2.68% and 2.54%, respectively, and the average debt outstanding under the Credit Facilities was $44.3 million and $28.8 million, respectively.
Union Bank Facility
On February 20, 2020, the Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “Union Bank Facility”) with MUFG Union Bank, as the arranger and administrative agent, and the lenders party to the Union Bank Facility from time to time. The Union Bank Facility replaced the Company’s credit facility (the “2019 Union Bank Facility”) entered into on February 20, 2019 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. The 2019 Union Bank Facility replaced the Company’s credit facility (the “Prior Union Bank Facility”) entered into on May 5, 2016 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. Any references to amounts related to the Union Bank Facility prior to February 20, 2020 were incurred and relate to the Prior Union Bank Facility or the 2019 Union Bank Facility, as applicable.
Under the Union Bank Facility, the lenders have made commitments of $400.0 million. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $200.0 million, funded by existing or additional lenders and with the agreement of MUFG Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings. Debt under the Union Bank Facility generally bears interest at a rate per annum equal to LIBOR plus 2.50%. The Union Bank Facility matures on February 22, 2024, unless sooner terminated in accordance with its terms. The Union Bank Facility is secured by all of the assets of Hercules Funding IV. The Union Bank Facility requires payment of a non-use fee during the revolving credit availability period as follows: (i) 0.50% if less than or equal to 50% utilization; (ii) 0.375% if more than 50% utilization but less than or equal to 80% utilization; and (iii) 0.20% if more than 80% is utilized.
The Union Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of $723.0 million.
The Union Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.
SMBC Facility
On November 9, 2021, the Company entered into a revolving credit agreement with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. The SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies in an initial aggregate amount of up to $100.0 million. The
50
SMBC Facility also has an accordion feature that allows for an increase in the total commitments of up to $150.0 million, subject to certain conditions. Additionally, the SMBC Facility provides for the issuance of letters of credit on the account of the Company or its designee in U.S. dollars and certain agreed upon foreign currencies in an aggregate face amount not to exceed $15.0 million. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder. Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026.
Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. Interest under the SMBC Facility for (i) loans for which the Company elects the base rate option, (A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, is payable at an “alternate base rate” (which is the greater of (x) zero and (y) the highest of (a) the prime rate as published in the print edition of The Wall Street Journal, Money Rates Section, (b) the federal funds effective rate plus 0.5% and (c) the one-month Eurocurrency rate plus 1% per annum) plus 0.875% per annum and (B) if the borrowing base is less than the product of 1.60 and the revolving credit exposure, the alternate base rate plus 1.00% per annum; (ii) loans for which the Company elects the Eurocurrency option, (A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to the Eurocurrency rate plus 1.875% per annum and (B) if the borrowing base is less than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to the Eurocurrency rate plus 2.00% per annum; and (iii) loans for which the Company elects the RFR option, (A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to RFR plus 1.9934% per annum and (B) if the borrowing base is less than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to RFR plus 2.1193% per annum. The SMBC Facility will be subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company will be required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility.
The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.
6. Income Taxes
To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.
As previously noted, federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Also, tax legislation requires that income be recognized for tax purposes no later than when recognized for financial reporting purposes, with certain exceptions.
As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years (the “Excise Tax Avoidance Requirement”). The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).
51
Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.
The Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal corporate tax rates based on its taxable income.
Taxable income for the three months ended March 31, 2022, was approximately $33.2 million or $0.28 per share. Taxable net realized gains for the same period were $3.7 million or approximately $0.03 per share. Taxable income for the three months ended March 31, 2021, was approximately $34.9 million or $0.31 per share. Taxable net realized gains for the same period were $8.8 million or approximately $0.08 per share.
For the three months ended March 31, 2022, the Company paid approximately $7.1 million of income tax, including excise tax, and had $0.8 million of accrued but unpaid tax expense as of March 31, 2022. For the three months ended March 31, 2021, the Company paid approximately $3.5 million of income tax, including excise tax, and had $1.0 million accrued but unpaid tax expense as of March 31, 2021.
The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
During the three months ended March 31, 2022, the Company declared and paid distributions of $0.48 per share. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s taxable year generally based upon its taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. If the Company had determined the tax attributes of its distributions taxable year-to-date as of March 31, 2022, 100% would be from its current and accumulated earnings and profits. However, there can be no certainty to stockholders that this determination is representative of what the actual tax attributes of the Company’s fiscal year of 2022 distributions to stockholders will be.
7. Stockholders’ Equity
On July 2, 2020, the Company entered into an At-The-Market (“ATM”) equity distribution agreement with JMP Securities LLC (“JMP”) (the “2020 Equity Distribution Agreement”). The 2020 Equity Distribution Agreement provides that the Company may offer and sell up to 16.5 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.
During the three months ended March 31, 2022, the Company sold approximately 4.9 million shares of common stock under the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $85.2 million, including $0.9 million of offering expenses. During the three months ended March 31, 2021, there were no shares sold under the 2020 Equity Distribution Agreement.
The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2022, approximately 10.7 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.
52
The Company has issued stock options for common stock subject to future issuance, of which 171,239 and 210,569 were outstanding as of March 31, 2022 and December 31, 2021, respectively.
8. Equity Incentive Plans
The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018, and authorize us to issue up to 18.7 million shares of common stock and 300,000 shares of restricted stock under the 2018 Plan and Director Plan, respectively. Unless earlier terminated by the Board, the 2018 Plan and Director Plan will terminate on May 12, 2028. Outstanding awards issued under plans that precede the 2018 Plan and Director Plan remain outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with their terms.
The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.
The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended March 31, 2022, and 2021, the Company recognized $4.4 million, and $2.7 million of stock based compensation expense in the Consolidated Statement of Operations, respectively. As of March 31, 2022, and 2021, approximately $22.2 million and $20.9 million of total unrecognized compensation costs expected to be recognized over the next 2.1 and 2.1 years, respectively.
Service-Vesting Awards
The Company grants equity-based awards which have service conditions, and generally begin to vest one-third after one year after the date of grant and ratably over the succeeding 2 years in accordance with the individual award terms (the “Service Vesting Awards”). The grant date fair value of Service Vesting Awards granted during the three months ended March 31, 2022, and 2021, were approximately $10.4 million, and $10.7 million, respectively.
The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the three months ended March 31, 2022, and 2021, are summarized below:
|
|
Three months ended March 31, |
|
|
|||||||||||
|
|
2022 |
|
|
2021 |
|
|
||||||||
|
|
Shares |
|
Weighted Average Grant Date |
|
|
Shares |
|
Weighted Average Grant Date |
|
|
||||
Unvested Shares Beginning of Period |
|
|
1,037,848 |
|
$ |
14.51 |
|
|
|
989,100 |
|
$ |
13.69 |
|
|
Granted |
|
|
593,745 |
|
$ |
17.49 |
|
|
|
731,662 |
|
$ |
14.73 |
|
|
Vested (1) |
|
|
(331,049 |
) |
$ |
14.41 |
|
|
|
(301,053 |
) |
$ |
13.85 |
|
|
Forfeited |
|
|
(9,619 |
) |
$ |
15.93 |
|
|
|
(39,841 |
) |
$ |
14.37 |
|
|
Unvested Shares End of Period |
|
|
1,290,925 |
|
$ |
15.90 |
|
|
|
1,379,868 |
|
$ |
14.25 |
|
|
(1) With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.
In addition to the restricted stock equity based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the periods ended March 31, 2022 and 2021, was approximately $10,000 and $6,000, respectively. During the periods ended March 31, 2022 and 2021, approximately $15,000, and $7,000, of share-based cost due to stock option grants was expensed, respectively.
53
Performance-Vesting Awards
The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date using a Monte-Carlo simulation multiplied by the target payout level and is recognized over the service period. For each of the three months ended March 31, 2022, and 2021, there were 487,409 shares of unvested Performance Awards and there were no Performance Awards granted or vested during either period. For certain Performance Awards, distribution equivalent units (“DEUs”) will accrue in the form of additional shares, but will not be paid unless the Performance Awards to which such DEUs relate actually vest. No DEUs have been issued during the periods ended March 31, 2022, or 2021.
Liability Classified Awards
The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). The remaining maximum total potential value of the Liability Awards granted is $11.2 million, which assumes all performance conditions are met for each Liability award. If the performance conditions are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The awards are recorded as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statement of Assets and Liabilities.
Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. As of March 31, 2022, the Company determined that the weighted average expected probability of the performance conditions being met within each Liability Award was 100%. The expected probability is re-evaluated each period, and may be adjusted to reflect changes in this assumption. These other Liability Awards vest over a three year service term.
As of March 31, 2022, all Liability Awards are unvested and there was approximately $3.8 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 2.0 years. For the three months ended March 31, 2022, there was approximately $1.3 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $7.0 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. No Liability Awards vested during the periods presented.
As of March 31, 2021, all Liability Awards are unvested and there was approximately $1.6 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 1.1 years. For the three months ended March 31, 2021, there was approximately $0.3 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $4.3 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. No Liability Awards vested during the periods presented.
54
9. Earnings Per Share
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:
|
|
Three Months Ended March 31, |
|
|||||
(in thousands, except per share data) |
|
2022 |
|
|
2021 |
|
||
Numerator |
|
|
|
|
|
|
||
Net (decrease) increase in net assets resulting from operations |
|
$ |
(3,336 |
) |
|
$ |
64,163 |
|
Less: Distributions declared-common and restricted shares |
|
|
(57,882 |
) |
|
|
(42,795 |
) |
(Over-)Undistributed earnings |
|
|
(61,218 |
) |
|
|
21,368 |
|
Undistributed earnings-common shares |
|
|
(61,218 |
) |
|
|
21,145 |
|
Add: Distributions declared-common shares |
|
|
57,261 |
|
|
|
42,349 |
|
Numerator for basic and diluted change in net assets per common share |
|
$ |
(3,957 |
) |
|
$ |
63,494 |
|
|
|
|
|
|
|
|
||
Denominator |
|
|
|
|
|
|
||
Basic weighted average common shares outstanding |
|
|
118,296 |
|
|
|
114,304 |
|
Common shares issuable |
|
|
— |
|
|
|
499 |
|
Weighted average common shares outstanding assuming dilution |
|
|
118,296 |
|
|
|
114,803 |
|
|
|
|
|
|
|
|
||
Change in net assets per common share |
|
|
|
|
|
|
||
Basic |
|
$ |
(0.03 |
) |
|
$ |
0.56 |
|
Diluted |
|
$ |
(0.03 |
) |
|
$ |
0.55 |
|
In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share. For the three months ended March 31, 2022, as the Company had a net loss, the effect of unvested stock options, restricted stock units and awards, and Performance Awards were anti-dilutive, and therefore have been excluded from the calculation of diluted loss per share.
As disclosed in “Note 5 – Debt”, on February 1, 2022, the Company fully repaid the 2022 Convertible Notes. As these notes were fully repaid, there is no dilutive impact for the current period ended March 31, 2022. For the three months ended March 31, 2021, the effect of the 2022 Convertible Notes under the treasury stock method was anti-dilutive and, accordingly, was excluded from the calculation of diluted earnings per share.
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three months ended March 31, 2022, and 2021, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:
|
|
Three months ended March 31, |
|
|||||
Anti-dilutive Securities |
|
2022 |
|
|
2021 |
|
||
2022 Convertible Notes |
|
|
— |
|
|
|
816,703 |
|
Unvested common stock options |
|
|
31,354 |
|
|
|
177 |
|
Unvested restricted stock units |
|
|
32,697 |
|
|
— |
|
|
Unvested restricted stock awards |
|
|
— |
|
|
|
1,449 |
|
Unvested Performance Awards |
|
|
547,626 |
|
|
— |
|
|
As of both March 31, 2022 and December 31, 2021, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.
55
10. Financial Highlights
Following is a schedule of financial highlights for the three months ended March 31, 2022 and 2021:
|
Three Months Ended March 31, |
|
|||||
|
2022 |
|
|
2021 |
|
||
Per share data (1): |
|
|
|
|
|
||
Net asset value at beginning of period |
$ |
11.22 |
|
|
$ |
11.26 |
|
Net investment income |
|
0.30 |
|
|
|
0.30 |
|
Net realized gain (loss) |
|
(0.02 |
) |
|
|
0.07 |
|
Net unrealized appreciation (depreciation) |
|
(0.31 |
) |
|
|
0.19 |
|
Total from investment operations |
|
(0.03 |
) |
|
|
0.56 |
|
Net increase (decrease) in net assets from capital share transactions (1) |
|
0.08 |
|
|
|
(0.11 |
) |
Distributions of net investment income (6) |
|
(0.48 |
) |
|
|
(0.37 |
) |
Stock-based compensation expense included in investment income (2) |
|
0.03 |
|
|
|
0.02 |
|
Net asset value at end of period |
$ |
10.82 |
|
|
$ |
11.36 |
|
|
|
|
|
|
|
||
Ratios and supplemental data (in thousands, except per share data): |
|
|
|
|
|
||
Per share market value at end of period |
$ |
18.07 |
|
|
$ |
16.03 |
|
Total return (3) |
|
11.97 |
% |
|
|
13.64 |
% |
Shares outstanding at end of period |
|
123,194 |
|
|
|
115,768 |
|
Weighted average number of common shares outstanding |
|
118,296 |
|
|
|
114,304 |
|
Net assets at end of period |
$ |
1,333,448 |
|
|
$ |
1,315,394 |
|
Ratio of total expense to average net assets (4) |
|
8.82 |
% |
|
|
10.57 |
% |
Ratio of net investment income before investment gains and losses to average net assets (4) |
|
10.75 |
% |
|
|
10.69 |
% |
Portfolio turnover rate (5) |
|
3.81 |
% |
|
|
9.09 |
% |
Weighted average debt outstanding |
$ |
1,341,941 |
|
|
$ |
1,287,712 |
|
Weighted average debt per common share |
$ |
11.34 |
|
|
$ |
11.27 |
|
11. Commitments and Contingencies
The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. A portion of these unfunded contractual commitments as of March 31, 2022, are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect its financial condition or business outlook. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones.
As of March 31, 2022, and December 31, 2021, the Company had approximately $371.3 million and $286.8 million, respectively, of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. These amounts also exclude unfunded commitments related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions".
The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.
56
As of March 31, 2022, and December 31, 2021, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:
(in thousands) |
|
Unfunded Commitments (1) as of |
|
|||||
Portfolio Company |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
Debt Investments: |
|
|
|
|
|
|
||
Phathom Pharmaceuticals, Inc. |
|
$ |
43,250 |
|
|
$ |
43,250 |
|
Thumbtack, Inc. |
|
|
40,000 |
|
|
|
— |
|
Vida Health |
|
|
40,000 |
|
|
|
— |
|
Skydio, Inc. |
|
|
37,500 |
|
|
|
37,500 |
|
Syndax Pharmaceutics Inc. |
|
|
30,000 |
|
|
|
30,000 |
|
Blue Sprig Pediatrics, Inc. |
|
|
20,000 |
|
|
|
30,000 |
|
Dashlane, Inc. |
|
|
20,000 |
|
|
|
19,300 |
|
G1 Therapeutics, Inc. |
|
|
19,375 |
|
|
|
19,375 |
|
Equality Health, LLC |
|
|
17,500 |
|
|
|
17,500 |
|
Brain Corporation |
|
|
15,000 |
|
|
|
20,000 |
|
Carbon Health Technologies, Inc. |
|
|
11,625 |
|
|
|
11,625 |
|
RVShare, LLC |
|
|
10,500 |
|
|
|
13,500 |
|
BridgeBio Pharma, Inc. |
|
|
10,000 |
|
|
|
— |
|
Nuvolo Technologies Corporation |
|
|
10,000 |
|
|
|
— |
|
Tarsus Pharmaceuticals, Inc. |
|
|
8,250 |
|
|
|
— |
|
MacroFab, Inc. |
|
|
7,000 |
|
|
|
— |
|
Veem, Inc. |
|
|
5,000 |
|
|
|
— |
|
Better Therapeutics, Inc. |
|
|
4,000 |
|
|
|
4,000 |
|
Ceros, Inc. |
|
|
3,845 |
|
|
|
3,845 |
|
Demandbase, Inc. |
|
|
3,750 |
|
|
|
9,375 |
|
Yipit, LLC |
|
|
2,250 |
|
|
|
2,250 |
|
Khoros (p.k.a Lithium Technologies) |
|
|
1,812 |
|
|
|
1,812 |
|
ThreatConnect, Inc. |
|
|
1,600 |
|
|
|
1,600 |
|
Ikon Science Limited |
|
|
1,050 |
|
|
|
1,050 |
|
3GTMS, LLC |
|
|
833 |
|
|
|
1,583 |
|
Agilence, Inc. |
|
|
800 |
|
|
|
800 |
|
Mobile Solutions Services |
|
|
743 |
|
|
|
424 |
|
Cybermaxx Intermediate Holdings, Inc. |
|
|
471 |
|
|
|
471 |
|
Enmark Systems, Inc. |
|
|
457 |
|
|
|
457 |
|
Annex Cloud |
|
|
386 |
|
|
|
— |
|
ShadowDragon, LLC |
|
|
333 |
|
|
|
333 |
|
Gryphon Networks Corp. |
|
|
268 |
|
|
|
268 |
|
Cytracom Holdings LLC |
|
|
225 |
|
|
|
225 |
|
ePayPolicy Holdings, LLC |
|
|
— |
|
|
|
250 |
|
Bicycle Therapeutics PLC |
|
|
— |
|
|
|
10,000 |
|
Logicworks |
|
|
— |
|
|
|
2,000 |
|
Pineapple Energy LLC |
|
|
— |
|
|
|
120 |
|
Total Unfunded Debt Commitments: |
|
|
367,823 |
|
|
|
282,913 |
|
|
|
|
|
|
|
|
||
Investment Funds & Vehicles:(2) |
|
|
|
|
|
|
||
Forbion Growth Opportunities Fund I C.V. |
|
|
3,457 |
|
|
|
3,839 |
|
Total Unfunded Commitments in Investment Funds & Vehicles: |
|
|
3,457 |
|
|
|
3,839 |
|
|
|
|
|
|
|
|
||
Total Unfunded Commitments |
|
$ |
371,280 |
|
|
$ |
286,752 |
|
57
The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type:
(in thousands) |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
Unfunded Debt Commitments: |
|
|
|
|
|
|
||
Expiring during: |
|
|
|
|
|
|
||
2022 |
|
$ |
251,811 |
|
|
$ |
199,681 |
|
2023 |
|
|
28,750 |
|
|
|
43,675 |
|
2024 |
|
|
73,550 |
|
|
|
25,800 |
|
2025 |
|
|
1,801 |
|
|
|
2,232 |
|
2026 |
|
|
11,525 |
|
|
|
11,525 |
|
2027 |
|
|
386 |
|
|
|
— |
|
Total Unfunded Debt Commitments |
|
|
367,823 |
|
|
|
282,913 |
|
|
|
|
|
|
|
|
||
Unfunded Commitments in Investment Funds & Vehicles: |
|
|
|
|
|
|
||
Expiring during: |
|
|
|
|
|
|
||
2030 |
|
|
3,457 |
|
|
|
3,839 |
|
Total Unfunded Commitments in Investment Funds & Vehicles |
|
|
3,457 |
|
|
|
3,839 |
|
Total Unfunded Commitments |
|
$ |
371,280 |
|
|
$ |
286,752 |
|
The following tables provide the Company’s contractual obligations as of March 31, 2022 and December 31, 2021:
As of March 31, 2022: |
|
Payments due by period (in thousands) |
|
|||||||||||||||||
Contractual Obligations (1) |
|
Total |
|
|
Less than 1 year |
|
|
1 - 3 years |
|
|
3 - 5 years |
|
|
After 5 years |
|
|||||
Debt (2)(3) |
|
$ |
1,344,051 |
|
|
$ |
— |
|
|
$ |
255,000 |
|
|
$ |
874,051 |
|
|
$ |
215,000 |
|
Lease and License Obligations (4) |
|
|
8,683 |
|
|
|
3,299 |
|
|
|
2,741 |
|
|
|
1,816 |
|
|
|
827 |
|
Total |
|
$ |
1,352,734 |
|
|
$ |
3,299 |
|
|
$ |
257,741 |
|
|
$ |
875,867 |
|
|
$ |
215,827 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
As of December 31, 2021: |
|
Payments due by period (in thousands) |
|
|||||||||||||||||
Contractual Obligations (1) |
|
Total |
|
|
Less than 1 year |
|
|
1 - 3 years |
|
|
3 - 5 years |
|
|
After 5 years |
|
|||||
Debt (5)(3) |
|
$ |
1,250,425 |
|
|
$ |
380,000 |
|
|
$ |
105,000 |
|
|
$ |
574,925 |
|
|
$ |
190,500 |
|
Lease and License Obligations (4) |
|
|
8,283 |
|
|
|
3,120 |
|
|
|
2,958 |
|
|
|
1,427 |
|
|
|
778 |
|
Total |
|
$ |
1,258,708 |
|
|
$ |
383,120 |
|
|
$ |
107,958 |
|
|
$ |
576,352 |
|
|
$ |
191,278 |
|
Certain premises are leased or licensed under agreements which expire at various dates through December 2028. For the three months ended March 31, 2022, total rent expense, including short-term leases, amounted to approximately $0.8 million. For the three months ended March 31, 2021, total rent expense, including short-term leases, amounted to approximately $0.8 million. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.
The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of March 31, 2022, and 2021:
(in thousands) |
|
Three Months Ended March 31, 2022 |
|
|
Three Months Ended March 31, 2021 |
|
||
Total operating lease cost |
|
$ |
703 |
|
|
$ |
738 |
|
Cash paid for amounts included in the measurement of lease liabilities |
|
$ |
594 |
|
|
$ |
578 |
|
|
|
As of March 31, 2022 |
|
|
As of March 31, 2021 |
|
||
Weighted-average remaining lease term (in years) |
|
|
4.26 |
|
|
|
3.94 |
|
Weighted-average discount rate |
|
|
4.74 |
% |
|
|
5.43 |
% |
58
The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of March 31, 2022:
(in thousands) |
|
As of March 31, 2022 |
|
|
2022 |
|
$ |
2,372 |
|
2023 |
|
|
2,305 |
|
2024 |
|
|
653 |
|
2025 |
|
|
693 |
|
Thereafter |
|
|
1,512 |
|
Total lease payments |
|
|
7,535 |
|
Less: imputed interest |
|
|
(659 |
) |
Total operating lease liability |
|
$ |
6,876 |
|
The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.
12. Related Party Transactions
As disclosed in “Note 2 – Summary of Significant Accounting Policies”, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. Refer to “Note 4 – Investments” for information related to income, gains and losses recognized related to the Company’s investment.
In 2021, the Adviser Subsidiary entered into investment management agreements with its privately-offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds and may receive incentive fees based on the performance of the Adviser Funds. Additionally, the Company entered into a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary will utilize human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology) of the Company. Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended March 31, 2022, are net of expenses allocated to the Adviser Subsidiary of $1.4 million. As of March 31, 2022, the Adviser Subsidiary owed the Company $0.1 million related to settlement of investment assignments to the Adviser Funds. The Company’s total expenses for the three months ended March 31, 2021, are net of expenses allocated to the Adviser Subsidiary of $0.9 million. As of March 31, 2021, there was $1.0 million receivable from the Adviser Subsidiary.
In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. During the three months ended March 31, 2022, $108.1 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds. During the three months ended March 31, 2022, fundings of $61.1 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $27.0 million from the Adviser Funds relating to the assigned investments during the three months ended March 31, 2022.
During the three months ended March 31, 2021, $63.8 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds. During the three months ended March 31, 2021, fundings of $48.3 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $48.0 million from the Adviser Funds relating to the assigned investments during the three months ended March 31, 2021.
13. Recent Accounting Pronouncements
In March 2022, the FASB issued ASU 2022-02, “Financial Instruments Credit Losses (Topic 326)”, which is intended to address issues identified during the post-implementation review of ASU 2016-13, “Finance Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The amendment, among other things, eliminates the accounting guidance for troubled debt restructurings by creditors in Subtopic 310-40, “Receivables Troubled Debt Restructurings by Creditors”, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. The new guidance is effective for interim and annual periods beginning after December 15, 2022. The Company does not anticipate the new standard to have a material impact to the consolidated financial statements and related disclosures.
59
14. Subsequent Events
Distribution Declaration
On April 27, 2022, the Board declared a cash distribution of $0.33 per share to be paid on May 24, 2022 to stockholders of record as of May 17, 2022. In addition to the cash distribution, and as part of the declared supplemental cash distribution of $0.60 per share to be paid in four quarterly distributions of $0.15, the Board declared a supplemental cash distribution of $0.15 per share to be paid on May 24, 2022 to stockholders of record as of May 17, 2022. Including the $0.15 per share supplemental cash distribution paid to stockholders of record as of March 9, 2022, the Board has declared a total of $0.30 per share of the $0.60 per share supplemental cash distribution declared on February 16, 2022.
Equity Offering
During April 2022, through its ATM program, the Company sold approximately 0.7 million shares of common stock for $13.3 million of net proceeds.
60
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:
You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.
The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A— “Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A— “Risk Factors” of our annual report on Form 10-K filed with the SEC on February 22, 2022 and under “Forward-Looking Statements” of this Item 2.
61
Use of Non-GAAP Measures
Throughout this MD&A, we present our financial condition and results of operations in the way we believe will be most meaningful and representative of our business results. Some of the measurements we use are “non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for “generally accepted accounting principles” in the United States. The non-GAAP financial measures we present may not be comparable to similarly-named measures reported by other companies.
Overview
We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. Our goal is to be the leading structured debt financing provider for venture capital-backed and institutional-backed companies in a variety of technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at various stages of their development.
We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United Kingdom.
We have elected to be treated for tax purposes as RIC under Subchapter M of the Code. As a RIC, we generally will not be subject to U.S. federal income tax on the portion of our investment company taxable income and net capital gain (i.e., net realized long-term capital gains in excess of net realized short-term capital losses) that we distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes to stockholders with respect to that taxable year. We will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed taxable income and capital gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year subject to certain requirements as defined for RICs. In order to qualify as a RIC requires that we must comply with provisions contained in Subchapter M of the Code. For example, as a RIC we must earn 90% or more of our gross income during each taxable year from qualified sources, typically referred to as “good income,” as well as satisfy certain quarterly asset diversification and annual income distribution requirements.
We have established Hercules Adviser LLC, a wholly owned registered investment adviser subsidiary. The Adviser Subsidiary provides investment advisory and related services to the Advisor Funds and External Parties. The Adviser Subsidiary is not consolidated for reporting purposes as noted in “Note 1 Description of Business”. In addition to the Adviser Subsidiary, we have established other wholly owned subsidiaries which are consolidated for reporting. However, certain of these subsidiaries are not consolidated for income tax purposes and may generate income tax expense or benefit, as well as tax assets and liabilities as a result of their ownership of certain portfolio investments.
Our primary business objectives are to increase our net income, net investment income, and NAV by investing in debt, typically with warrants or equity, of venture capital-backed and institutional-backed companies in a variety of technology-related industries at attractive current yields and the potential for equity appreciation and realized gains. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital appreciation from our warrant and equity investments. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations. We invest primarily in private companies but also have investments in public companies.
We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase or convert into common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We also invest in “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position. In addition to our debt investments, we regularly engage in discussions with third parties with respect to various potential transactions to explore all
62
alternatives. Through such alternatives we may acquire an investment, a portfolio of investments, an entire company, or sell portions of our portfolio on an opportunistic basis.
We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions which may include, depending on the transaction and without limitation, the approval of our Board, required regulatory or third-party consents, and/or the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.
Portfolio and Investment Activity
The total fair value of our investment portfolio was approximately $2.6 billion and $2.4 billion as of March 31, 2022 and December 31, 2021, respectively. The fair value of our debt investment portfolio as of March 31, 2022 was approximately $2.4 billion, compared to a fair value of approximately $2.2 billion at December 31, 2021. The fair value of the equity portfolio as of March 31, 2022 was approximately $160.2 million, compared to a fair value of approximately $184.7 million as of December 31, 2021. The fair value of the warrant portfolio as of March 31, 2022 was approximately $37.9 million, compared to a fair value of approximately $38.4 million as of December 31, 2021.
Portfolio Activity
Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. From time to time, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.
Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.
During the three months ended March 31, 2022, Hercules and the Adviser Funds directly committed or originated an aggregate total of $615.2 million of investment commitments. Of the aggregated total directly committed or originated by Hercules and the Adviser Funds, $108.1 million of investment commitments were directly committed or originated by the Adviser Funds. Of the aggregate total direct fundings or originations, $61.1 million of debt, equity, and warrant fundings during the period, were assigned to, directly funded or originated by the Adviser Funds.
During the three months ended March 31, 2021, Hercules and the Adviser Funds directly committed or originated an aggregate total of $531.0 million of investment commitments. Of the aggregated total directly committed or originated by Hercules and the Adviser Funds, $63.8 million of investment commitments were directly committed or originated by the Adviser Funds. Of the aggregate total direct fundings or originations, $48.3 million of debt, equity, and warrant fundings during the period, were assigned to, directly funded or originated by the Adviser Funds.
63
Our portfolio activity for the three months ended March 31, 2022 and March 31, 2021 was comprised of the following:
(in millions) |
|
March 31, 2022 |
|
|
March 31, 2021 |
|
||
Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds (1) |
|
|
|
|
|
|
||
New portfolio company |
|
$ |
448.9 |
|
|
$ |
398.0 |
|
Existing portfolio company |
|
|
163.3 |
|
|
|
127.7 |
|
Sub-total |
|
$ |
612.2 |
|
|
$ |
525.7 |
|
Less: Debt commitments assigned to or directly committed by the Adviser Funds (3) |
|
|
(107.6 |
) |
|
|
(63.0 |
) |
Net Total Debt Commitments |
|
$ |
504.6 |
|
|
$ |
462.7 |
|
Gross Debt Fundings by Hercules Capital and the Adviser Funds (2) |
|
|
|
|
|
|
||
New portfolio company |
|
$ |
245.0 |
|
|
$ |
255.2 |
|
Existing portfolio company |
|
|
103.2 |
|
|
|
94.0 |
|
Sub-total |
|
$ |
348.2 |
|
|
$ |
349.2 |
|
Less: Debt fundings assigned to or directly funded by the Adviser Funds (3) |
|
|
(60.6 |
) |
|
|
(47.5 |
) |
Net Total Debt Fundings |
|
$ |
287.6 |
|
|
$ |
301.7 |
|
Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds |
|
|
|
|
|
|
||
New portfolio company |
|
$ |
— |
|
|
$ |
3.2 |
|
Existing portfolio company |
|
|
3.4 |
|
|
|
2.9 |
|
Sub-total |
|
$ |
3.4 |
|
|
$ |
6.1 |
|
Less: Equity fundings assigned to or directly funded by the Adviser Funds (3) |
|
|
(0.5 |
) |
|
|
(0.8 |
) |
Net Total Equity and Investments Funds and Vehicle Fundings |
|
$ |
2.9 |
|
|
$ |
5.3 |
|
Unfunded Contractual Commitments (4) |
|
|
|
|
|
|
||
Total |
|
$ |
371.3 |
|
|
$ |
257.9 |
|
Non-Binding Term Sheets |
|
|
|
|
|
|
||
New portfolio company |
|
$ |
564.8 |
|
|
$ |
101.1 |
|
Existing portfolio company |
|
|
80.7 |
|
|
|
126.3 |
|
Total |
|
$ |
645.5 |
|
|
$ |
227.4 |
|
We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the three months ended March 31, 2022, we received approximately $96.2 million in aggregate principal repayments. Of the approximately $96.2 million of aggregate principal repayments, approximately $11.3 million were scheduled principal payments and approximately $84.9 million were early principal repayments related to 10 portfolio companies.
Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable and escrow receivables) as of and for the three months ended March 31, 2022 and March 31, 2021 was as follows:
(in millions) |
|
March 31, 2022 |
|
|
March 31, 2021 |
|
||
Beginning portfolio |
|
$ |
2,434.5 |
|
|
$ |
2,354.1 |
|
New fundings and restructures |
|
|
351.6 |
|
|
|
355.3 |
|
Fundings allocated to the Advisor Funds(1) |
|
|
(61.1 |
) |
|
|
(48.4 |
) |
Warrants not related to current period fundings |
|
|
0.7 |
|
|
|
0.6 |
|
Principal payments received on investments |
|
|
(11.3 |
) |
|
|
(18.3 |
) |
Early payoffs |
|
|
(84.9 |
) |
|
|
(191.5 |
) |
Accretion of loan discounts and paid-in-kind principal |
|
|
12.8 |
|
|
|
10.6 |
|
Net acceleration of loan discounts and loan fees due to early payoff or restructure |
|
|
(1.5 |
) |
|
|
(9.5 |
) |
New loan fees |
|
|
(3.2 |
) |
|
|
(5.0 |
) |
Sale of investments |
|
|
(8.8 |
) |
|
|
(12.5 |
) |
Gain (loss) on investments due to sales or write offs |
|
|
1.2 |
|
|
|
7.2 |
|
Net change in unrealized appreciation (depreciation) |
|
|
(37.7 |
) |
|
|
21.8 |
|
Ending portfolio |
|
$ |
2,592.3 |
|
|
$ |
2,464.4 |
|
As of March 31, 2022, we held debt, warrants, or equity positions in one company that has filed a registration statement on Form S-1 with the SEC in contemplation of a potential initial public offering, and four companies that have filed definitive agreements for reverse merger initial public offerings with special purpose acquisition companies. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.
64
The following table presents certain selected information regarding our debt investment portfolio as of March 31, 2022 and December 31, 2021:
|
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||
Number of portfolio companies with debt outstanding |
|
|
97 |
|
|
|
92 |
|
Percentage of debt bearing a floating rate |
|
|
94.7 |
% |
|
|
94.0 |
% |
Percentage of debt bearing a fixed rate |
|
|
5.3 |
% |
|
|
6.0 |
% |
Weighted average core yield (1) |
|
|
11.1 |
% |
|
|
11.4 |
% |
Weighted average effective yield (2) |
|
|
11.5 |
% |
|
|
12.9 |
% |
Prime rate at the end of the period |
|
|
3.5 |
% |
|
|
3.3 |
% |
Income from Portfolio
We generate revenue in the form of interest income, primarily from our investments in debt securities, and fee income, which is primarily comprised of commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies. Our investments generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below that range. As of March 31, 2022, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 7.0% to approximately 14.5%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.
Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.
Loan origination and commitment fees are generally received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. We had approximately $48.1 million of unamortized fees as of March 31, 2022, of which approximately $40.0 million was included as an offset to the cost basis of our current debt investments and approximately $8.1 million was deferred contingent upon the occurrence of a funding or milestone. As of December 31, 2021, we had approximately $42.9 million of unamortized fees, of which approximately $36.5 million was included as an offset to the cost basis of our current debt investments and approximately $6.4 million was deferred contingent upon the occurrence of a funding or milestone.
Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of March 31, 2022, we had approximately $37.2 million in exit fees receivable, of which approximately $32.9 million was included as a component of the cost basis of our current debt investments and approximately $4.3 million was a deferred receivable related to expired commitments. As of December 31, 2021, we had approximately $35.0 million in exit fees receivable, of which approximately $29.6 million was included as a component of the cost basis of our current debt investments and approximately $5.4 million was a deferred receivable related to expired commitments.
We have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. We recorded approximately $5.0 million and $2.6 million in PIK income during the three months ended March 31, 2022 and 2021, respectively.
Portfolio Yield
We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-GAAP financial measures. In particular, we evaluate performance through monitoring the
65
portfolio yields as we consider them to be effective indicators, for both management and stockholders, of the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described below:
|
|
March 31, 2022 |
|
|
March 31, 2021 |
|
||
Total Yield |
|
|
10.7 |
% |
|
|
11.9 |
% |
Effective Yield |
|
|
11.5 |
% |
|
|
13.2 |
% |
Core Yield (Non-GAAP) |
|
|
11.1 |
% |
|
|
11.6 |
% |
We believe that these measures are useful for our stockholders as it provides the yield of our portfolio to allow a more meaningful comparison with our competitors. As noted above, Core Yield, a Non-GAAP financial measure, is derived by dividing Core investment income, as defined above, by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding. The reconciliation to calculate “Core investment income” from GAAP basis 'Total investment income' are as follows:
(in thousands) |
|
March 31, 2022 |
|
|
March 31, 2021 |
|
||
GAAP Basis: |
|
|
|
|
|
|
||
Total investment income |
|
$ |
65,157 |
|
|
$ |
68,759 |
|
Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events, but including income from expired commitments |
|
|
(2,248 |
) |
|
|
(8,149 |
) |
Non-GAAP Basis: |
|
|
|
|
|
|
||
Core investment income |
|
$ |
62,909 |
|
|
$ |
60,610 |
|
We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate significantly from period to period, thereby allowing for a more meaningful comparison over time.
Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar Non-GAAP financial measures used by other companies.
Another financial measure that we monitor is the total return for our investors, was approximately 12.0% and 13.6% during the three months ended March 31, 2022 and 2021, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.
66
Portfolio Composition
Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, consolidation and product and market extension opportunities.
The following table presents the fair value of the Company’s portfolio by industry sector as of March 31, 2022 and December 31, 2021:
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||||||||||
(in thousands) |
Investments at |
|
|
Percentage of |
|
|
Investments at |
|
|
Percentage of |
|
||||
Drug Discovery & Development |
$ |
993,554 |
|
|
|
38.2 |
% |
|
$ |
967,383 |
|
|
|
39.7 |
% |
Software |
|
653,770 |
|
|
|
25.2 |
% |
|
|
585,622 |
|
|
|
24.1 |
% |
Internet Consumer & Business Services |
|
456,542 |
|
|
|
17.6 |
% |
|
|
395,506 |
|
|
|
16.3 |
% |
All other industries (1) |
|
488,468 |
|
|
|
19.0 |
% |
|
|
486,011 |
|
|
|
19.9 |
% |
Total |
$ |
2,592,334 |
|
|
|
100.0 |
% |
|
$ |
2,434,522 |
|
|
|
100.0 |
% |
Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated in several portfolio companies.
For the three months ended March 31, 2022 and the year ended December 31, 2021, our ten largest portfolio companies represented approximately 31.6% and 30.5% of the total fair value of our investments in portfolio companies, respectively. As of March 31, 2022 and December 31, 2021, we had seven and six investments that represented 5% or more of our net assets, respectively. As of March 31, 2022, we had five equity investments representing approximately 44.7% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. As of December 31, 2021, we had six equity investments which represented approximately 49.6% of the total fair value of our equity investment portfolio, and each represented 5% or more of the total fair value of our equity investments. No single portfolio investment represented more than 10% of the fair value of our total investments as of March 31, 2022 and December 31, 2021.
As of March 31, 2022 and December 31, 2021, approximately 94.7% and 94.0% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime, LIBOR, SOFR, or BSBY-based interest rate floor, respectively. Changes in interest rates, including Prime, LIBOR, SOFR, BSBY rates, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates.
Our investments in structured debt have detachable equity enhancement features, typically in the form of warrants or other equity securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of March 31, 2022, we held warrants in 103 portfolio companies, with a fair value of approximately $37.9 million. The fair value of our warrant portfolio decreased by approximately $0.5 million, as compared to a fair value of $38.4 million as of December 31, 2021, primarily related to the decrease in fair value of the portfolio companies.
Our existing warrant holdings would require us to invest approximately $70.3 million to exercise such warrants as of March 31, 2022. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.02x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in the event that warrants are terminated or expire unexercised.
Portfolio Grading
We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the
67
distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2022 and December 31, 2021, respectively:
(in thousands) |
|
March 31, 2022 |
|
|
December 31, 2021 |
|
||||||||||||||
Investment Grading |
|
Number of Companies |
|
Debt Investments |
|
|
Percentage of |
|
|
Number of Companies |
|
Debt Investments |
|
|
Percentage of |
|
||||
1 |
|
16 |
|
$ |
468,973 |
|
|
|
19.6 |
% |
|
15 |
|
$ |
408,975 |
|
|
|
18.5 |
% |
2 |
|
53 |
|
|
1,280,321 |
|
|
|
53.6 |
% |
|
47 |
|
|
1,208,323 |
|
|
|
54.7 |
% |
3 |
|
26 |
|
|
631,821 |
|
|
|
26.4 |
% |
|
28 |
|
|
581,424 |
|
|
|
26.3 |
% |
4 |
|
2 |
|
|
10,227 |
|
|
|
0.4 |
% |
|
1 |
|
|
8,269 |
|
|
|
0.4 |
% |
5 |
|
0 |
|
|
— |
|
|
|
0.0 |
% |
|
1 |
|
|
2,608 |
|
|
|
0.1 |
% |
|
|
97 |
|
$ |
2,391,342 |
|
|
|
100.0 |
% |
|
92 |
|
$ |
2,209,599 |
|
|
|
100.0 |
% |
As of March 31, 2022, our debt investments had a weighted average investment grading of 2.10 on a cost basis, as compared to 2.10 as of December 31, 2021. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans, and therefore have been downgraded until their funding is complete or their operations improve.
As the COVID-19 pandemic and other macro-economic events (such as the ongoing war in Ukraine) cause disruption to markets and businesses, we are continuing to monitor and work with the management teams and stakeholders of our portfolio companies to navigate the significant market, operational, and economic challenges created by these events. This includes continuing to proactively assess and manage potential risks across our debt investment portfolio.
Non-accrual Investments
The following table shows the amortized cost of our performing and non-accrual investments as of March 31, 2022 and December 31, 2021:
|
|
As of March 31, |
|
|
As of December 31, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
||||||||||
(in millions) |
|
Amortized Cost |
|
|
Percentage of Total Portfolio at Amortized Cost |
|
|
Amortized Cost |
|
|
Percentage of Total Portfolio at Amortized Cost |
|
||||
Performing |
|
$ |
2,573 |
|
|
|
99.5 |
% |
|
$ |
2,367 |
|
|
|
99.0 |
% |
Non-accrual |
|
|
13 |
|
|
|
0.5 |
% |
|
|
24 |
|
|
|
1.0 |
% |
Total Investments |
|
$ |
2,586 |
|
|
|
100.0 |
% |
|
$ |
2,391 |
|
|
|
100.0 |
% |
Debt investments are placed on non-accrual status when it is probable that principal, interest, or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay our current and future contractual obligations. We may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
COVID-19 Developments
The COVID-19 pandemic, which began in late 2019, has and threatens to continue to create market volatility and disruption in the U.S. and across the global capital markets. We are continuing to closely monitor the impact of COVID-19 on all aspects of our business, including impacts to our portfolio companies, employees, due diligence and underwriting processes, and financial markets. With the rollout of vaccination programs in the U.S. and globally, several countries, as well as certain states in the U.S., have lifted or reduced certain travel restrictions, business restrictions, and other quarantine measures. This has contributed to a positive economic recovery since 2020, especially in the U.S. Although the economic recovery and rollout of vaccination programs are promising, the potential exists for new COVID-19 variants to impede the global economic recovery. For example, the Delta and Omicron variants have caused a surge in the reported number of cases, hospitalizations and deaths related to the COVID-19 pandemic. These surges have led to the re-introduction of such restrictions and business shutdowns in certain states within the United States and globally. Although some states and municipalities have begun to eliminate restrictions related to COVID-19, there remains the potential for new COVID-19 variants to cause the reintroduction of such restrictions in the future.
As a result of the pressures on liquidity and financial results to certain of our portfolio companies caused by the COVID-19 pandemic, portfolio companies may draw on most, if not all, of the unfunded portion of any revolving or delayed draw term loans made by us, subject to availability under the terms of such loans. The extent to which the COVID-19 pandemic will continue to affect
68
the financial condition and liquidity of our portfolio companies’ results of operations will depend on future developments, such as the speed and extent of further vaccine distribution and the impact of the COVID-19 variants that might arise, which are highly uncertain and cannot be predicted.
Equally the extent of the impact of the COVID-19 pandemic on our own operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend to a large extent on future developments regarding the duration and severity of the COVID-19, effectiveness of vaccination deployment and the actions taken by governments (including stimulus measures or the lack thereof) and their citizens to contain the COVID-19 or treat its impact, all of which are beyond our control. An extended period of global supply chain and economic disruption, including any resulting inflation, could materially affect our business, results of operations, access to sources of liquidity and financial condition. Given the fluidity of the situation, neither our management nor our Board is able to predict the full impact of COVID-19 on our business, future results of operations, financial position, or cash flows at this time.
Results of Operations
Refer below for a discussion of our operating results for three months ended March 31, 2022 as compared to the same period for 2021.
Investment Income
Total investment income for the three months ended March 31, 2022 was approximately $65.2 million as compared to approximately $68.8 million for the three months ended March 31, 2021. Investment income is primarily composed of interest income earned on our debt investments and fee income from commitments, facilities, and other loan related fees.
Interest Income
The following table summarizes the components of interest income for the three months ended March 31, 2022 and 2021:
|
Three Months Ended March 31, |
|
|||||
(in thousands) |
2022 |
|
|
2021 |
|
||
Contractual interest income |
$ |
49,544 |
|
|
$ |
49,220 |
|
Exit fee interest income |
|
6,726 |
|
|
|
10,817 |
|
PIK interest income |
|
4,975 |
|
|
|
2,561 |
|
Other interest income (1) |
|
1,007 |
|
|
|
1,184 |
|
Total interest income |
$ |
62,252 |
|
|
$ |
63,782 |
|
Interest income for the three months ended March 31, 2022 totaled approximately $62.3 million as compared to approximately $63.8 million for the three months ended March 31, 2021. The decrease in interest income for the three months ended March 31, 2022 as compared to the same period ended March 31, 2021, was primarily attributable to a decline in overall portfolio yields.
Of the $62.3 million in interest income for the three months ended March 31, 2022, approximately $61.1 million represents recurring income from the contractual servicing of our loan portfolio and approximately $1.1 million represent income related to the acceleration of income due to early loan repayments and other one-time events during the period. Of the $63.8 million in interest income for the three months ended March 31, 2021, approximately $58.1 million represents income from recurring interest and approximately $5.7 million represents the acceleration of interest income due to early loan repayments and other one-time events during the period.
The following table shows the PIK-related activity for the three months ended March 31, 2022 and 2021, at cost:
|
|
Three Months Ended March 31, |
|
|||||
(in thousands) |
|
2022 |
|
|
2021 |
|
||
Beginning PIK interest receivable balance |
|
$ |
11,801 |
|
|
$ |
14,817 |
|
PIK interest income during the period |
|
|
4,975 |
|
|
|
2,561 |
|
Payments received from PIK loans |
|
|
(2,081 |
) |
|
|
(1,394 |
) |
Realized gain (loss) |
|
|
(367 |
) |
|
|
— |
|
Ending PIK interest receivable balance |
|
$ |
14,328 |
|
|
$ |
15,984 |
|
The increase in PIK interest income during the three months ended March 31, 2022 as compared to the three months ended March 31, 2021 is due to an increase in the weighted average principal outstanding for loans on accrual which bear PIK interest. PIK accrued (capitalized) to principal but not recorded as income during the three months ended March 31, 2022 and 2021 includes the portion of PIK receivable that is capitalized as principal on the restructuring of loans, as applicable. Payments on PIK loans are
69
normally received only in the event of payoffs. PIK receivable at both March 31, 2022 and March 31, 2021 represented less than 1% of total debt investments.
Fee Income
Fee income from commitment, facility and loan related fees for the three months ended March 31, 2022 totaled approximately $2.9 million, as compared to approximately $5.0 million for the three months ended March 31, 2021. The decrease in fee income for the three months ended March 31, 2022 is primarily due to a decrease in the acceleration of unamortized fees, and one-time fees due to lower volume of early repayments.
Of the $2.9 million, in fee income from commitment, facility, and loan related fees for the three months ended March 31, 2022, approximately $1.8 million represented income from recurring fee amortization, approximately $0.3 million represented the acceleration of unamortized fees from expired commitments and loan amendments, and approximately $0.8 million represented income related to the acceleration of unamortized fees during the period.
Of the $5.0 million in fee income from commitment, facility, and loan related fees for the three months ended March 31, 2021, approximately $1.9 million represented income from recurring fee amortization, and approximately $0.6 million represented the acceleration of unamortized fees from expired commitments, and approximately $2.5 million represented income related to the acceleration of unamortized fees during the period.
In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three months ended March 31, 2022 or 2021.
Operating Expenses
Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, and employee compensation and benefits. Our net operating expenses totaled approximately $29.4 million and $34.2 million during the three months ended March 31, 2022 and 2021, respectively.
Interest and Fees on our Debt
Interest and fees on our debt totaled approximately $13.5 million and $17.6 million for the three months ended March 31, 2022 and 2021, respectively. Our lower weighted average borrowing costs during the three months ended March 31, 2022, resulted in a decline of interest and fee expenses as compared to the three months ended March 31, 2021.
We had a weighted average cost of debt of approximately 4.0% and 5.5% for the three months ended March 31, 2022 and 2021, respectively. The weighted average cost of debt includes interest and fees on our debt, but excludes the impact of fee accelerations due to the extinguishment of debt. The decrease in the weighted average cost of debt for the three months ended March 31, 2022, as compared to 2021, was attributable to our refinancing activities undertaken in the past year.
General and Administrative Expenses and Tax Expenses
General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments, and various other expenses. Our general and administrative expenses increased to $3.8 million from $3.6 million for the three months ended March 31, 2022 and 2021, respectively. The increase in general and administrative expenses for the three months ended March 31, 2022 is primarily attributable to an increase in information technology related expenses. Tax expenses primarily relate to excise tax accruals. Tax expenses were $0.7 million and $1.4 million during the three months ended March 31, 2022 and 2021, respectively.
Employee Compensation
Employee compensation and benefits totaled approximately $8.3 million, for the three months ended March 31, 2022 as compared to approximately $9.8 million, for the three months ended March 31, 2021. The decrease between the three months ended March 31, 2022 and 2021 was primarily due to a decrease in variable compensation.
Employee stock-based compensation totaled approximately $4.4 million, for the three months ended March 31, 2022 as compared to approximately $2.7 million, for the three months ended March 31, 2021. The increase between the comparative periods was primarily attributable to the issuance of additional stock-based compensation awards and higher weighted average grant date fair value.
70
Expenses allocated to the Adviser Subsidiary
In March 2021, we entered into a shared services agreement with the Adviser Subsidiary (the “Sharing Agreement”), pursuant to which the Adviser Subsidiary utilizes our human capital resources, including deal professional, finance, and administrative functions, as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of shared services to the Adviser Subsidiary. Our total net operating expenses for the three months ended March 31, 2022 and 2021, are net of expenses allocated to the Adviser Subsidiary of $1.4 million and $0.9 million, respectively. As of March 31, 2022 and 2021, $0.1 million and $1.0 million remained receivable from the Adviser Subsidiary related to the expenses allocated during the period.
Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation
Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event debt is extinguished before its stated maturity. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
A summary of net realized gains and losses for the three months ended March 31, 2022 and 2021 is as follows:
|
Three Months Ended March 31, |
|
|||||
(in thousands) |
2022 |
|
|
2021 |
|
||
Realized gains |
$ |
5,044 |
|
|
$ |
9,504 |
|
Realized losses |
|
(3,739 |
) |
|
|
(1,734 |
) |
Realized loss on debt extinguishment |
|
(3,686 |
) |
|
|
— |
|
Net realized gains (losses) |
$ |
(2,381 |
) |
|
$ |
7,770 |
|
During the three months ended March 31, 2022, we recognized net realized losses of $2.4 million on the portfolio. The net realized loss was comprised of gross realized gains of $5.0 million primarily from the sale of our equity position in Black Crow AI, Inc. Our gains were partially offset by gross realized losses of $3.7 million primarily from the write-off of our investments in Regent Education and Medrobotics Corporation during the period. In addition, as part of the retirement of the 2022 Notes we incurred a $3.7 million loss on debt extinguishment, which was related to fees, accrued interest, and the acceleration of debt issuance costs amortization. The $3.7 million is included as a realized loss within the “Loss on debt extinguishment” on the Consolidated Statement of Operations for the three months ended March 31, 2022.
During the three months ended March 31, 2021, we recognized net realized gains of $7.8 million on the portfolio. The net realized gains was comprised of gross realized gains of $9.5 million primarily from the sale of DoorDash, Inc. and TransMedics Group, Inc. Our gains were partially offset by gross realized losses of $1.7 million primarily from the write-off of our investment in Sebacia, Inc. during the period. There were no debt extinguishment losses recognized during the three months ended March 31, 2021.
The net change in unrealized appreciation and depreciation on investments is based on the fair value of each investment determined in good faith by our Board. The following table summarizes the movements in net change in unrealized appreciation or depreciation for the three months ended March 31, 2022 and 2021:
|
For the three months ended March 31, |
|
|||||
(in thousands) |
2022 |
|
|
2021 |
|
||
Gross unrealized appreciation |
$ |
19,540 |
|
|
$ |
57,255 |
|
Gross unrealized depreciation |
|
(57,173 |
) |
|
|
(28,451 |
) |
Reversal of prior period net unrealized appreciation (depreciation) upon a realization event |
|
1,027 |
|
|
|
(6,971 |
) |
Net unrealized appreciation (depreciation) on debt, equity, warrant and fund investments |
|
(36,606 |
) |
|
|
21,833 |
|
Other net unrealized appreciation (depreciation) |
|
(136 |
) |
|
|
— |
|
Total net unrealized appreciation (depreciation) |
$ |
(36,742 |
) |
|
$ |
21,833 |
|
During the three months ended March 31, 2022 and 2021, we recorded approximately $36.7 million of net unrealized depreciation and $21.8 million of net unrealized appreciation on our debt, equity, warrant, and investment funds, respectively. The following table summarizes the key drivers of change in net unrealized appreciation (depreciation) of investments for the three months ended March 31, 2022 and 2021:
71
|
For the three months ended March 31, |
|
|||||||||||||||||
|
2022 |
|
|
2021 |
|
||||||||||||||
(in thousands) |
Debt |
|
Equity, Warrants |
|
Total |
|
|
Debt |
|
Equity, Warrants |
|
Total |
|
||||||
Valuation appreciation (depreciation) |
$ |
(7,963 |
) |
$ |
(29,670 |
) |
$ |
(37,633 |
) |
|
$ |
7,060 |
|
$ |
21,744 |
|
$ |
28,804 |
|
Reversal of prior period net unrealized appreciation (depreciation) upon a realization event |
|
(150 |
) |
|
1,177 |
|
|
1,027 |
|
|
|
1,005 |
|
|
(7,976 |
) |
|
(6,971 |
) |
Other net unrealized appreciation (depreciation) |
|
22 |
|
|
(158 |
) |
|
(136 |
) |
|
|
— |
|
|
— |
|
|
— |
|
Net realized appreciation (depreciation) |
$ |
(8,091 |
) |
$ |
(28,651 |
) |
$ |
(36,742 |
) |
|
$ |
8,065 |
|
$ |
13,768 |
|
$ |
21,833 |
|
Income and Excise Taxes
We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.
Net Change in Net Assets Resulting from Operations and Earnings Per Share
For the three months ended March 31, 2022 and 2021, we had net changes in net assets of approximately $3.3 million decrease and a $64.2 million increase resulting from operations, respectively. The basic and fully diluted net change in net assets per common share were $(0.03) and $0.56 per share and $(0.03) and $0.55 per share for the three months ended March 31, 2022 and 2021, respectively.
Hercules Adviser LLC
Hercules Adviser LLC, the Adviser Subsidiary, receives fee income for the services provided to the Adviser Funds. The Adviser Subsidiary’s contribution to our net investment income is derived from dividend income declared by the Adviser Subsidiary and interest income earned on loans to the Adviser Subsidiary. For the three months ended March 31, 2022 and 2021, no dividends were declared by the Adviser Subsidiary.
The Adviser Subsidiary has entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee and certain incentive fees. The Adviser Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed technology related and life sciences companies.
Financial Condition, Liquidity, Capital Resources and Obligations
Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”), and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiary. This “Financial Condition, Liquidity and Capital Resources” section should be read in conjunction with the “COVID-19 Developments” section above.
During the three months ended March 31, 2022, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt offerings along with borrowings on our credit facilities, and (iv) equity offerings.
72
During the three months ended March 31, 2022, our operating activities used $188.6 million of cash and cash equivalents, compared to $50.4 million used during the three months ended March 31, 2021. This $138.2 million increase in cash used in operating activities was primarily driven by a $113.4 million decrease in principal and fee payments received from investments, and $4.2 million fewer proceeds received from the sale of equity investments, which was coupled with an increase of $16.5 million in purchases of investments (net of assignments to Adviser Funds).
During the three months ended March 31, 2022, our investing activities used approximately $50 thousand of cash, compared to $12 thousand used during the three months ended March 31, 2021. The $38 thousand increase in cash used in investing activities was due to an increase in purchases of capital equipment.
During the three months ended March 31, 2022, our financing activities provided $114.9 million of cash, compared to $100.4 million used in financing activities during the three months ended March 31, 2021. The $215.2 million decrease of cash flows used in financing activities was primarily due to $535.5 million of new debt issuances related to the issuance of our January 2027 Notes, additional SBA Debenture borrowings, and increased utilization of our Credit Facilities. The debt issuances were primarily used to repay the $230.0 million of 2022 Convertible Notes and $150.0 million to retire the 2022 Notes, during the three months ended March 31, 2022, compared to the three months ended March 31, 2021. Additionally, we distributed $56.9 million in dividends during the three months ended March 31, 2022, which increased from $41.8 million compared to during the three months ended March 31, 2021. Lastly, we issued $85.2 million of ATM equity (net of offering costs) during the three months ended March 31, 2022. We did not issue any common stock issued during the three months ended March 31, 2021.
As of March 31, 2022, our net assets totaled $1.3 billion, with a NAV per share of $10.82. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.
Available liquidity and capital resources as of March 31, 2022
As of March 31, 2022, we had $430.3 million in available liquidity, including $59.3 million in cash and cash equivalents. We had available borrowing capacity of $70.9 million under the SMBC Facility and $300.0 million under the Union Bank Facility. In addition, the Credit Facilities each have accordion provisions through which the available borrowing capacity can be increased by an aggregate $250.0 million.
The 1940 Act permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of March 31, 2022, our asset coverage ratio under our regulatory requirements as a BDC was 213.8% excluding our SBA debentures. Our exemptive order from the SEC allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 199.0% as of March 31, 2022.
As of March 31, 2022, we had $129.1 million outstanding under our Credit Facilities, which are floating interest rate obligations. As of March 31, 2022, the remaining $1,215.0 million of debt outstanding are all fixed interest rate debt obligations.
During the three months ended March 31, 2022, we issued $350 million in aggregate principal amount of January 2027 Notes, which generated net proceeds of approximately $343.4 million. The net proceeds from the January 2027 Notes generated was primarily used to repay the 2022 Convertible Notes and to retire the 2022 Notes. In addition, we borrowed the remaining $24.5 million of capital available through our SBIC, and issued $85.2 million of common shares through ATM equity offerings.
Lastly, as of March 31, 2022, $3.1 million of cash was classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain of the Company’s financing transactions. Refer to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our debt obligations.
As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of recent macro-economic events, including the COVID-19 pandemic, war in Ukraine, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.
73
Equity Offerings
On July 2, 2020, we entered into an ATM equity distribution agreement with JMP (the “2020 Equity Distribution Agreement”). The 2020 Equity Distribution Agreement provides that we may offer and sell up to 16.5 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.
During the three months ended March 31, 2022, the Company sold 4.9 million shares of common stock. As of March 31, 2022, approximately 10.7 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement. During the three months ended March 31, 2021, the Company did not sell any shares of common stock under the 2020 Equity Distribution Agreement.
Commitments and Obligations
Our significant cash requirements generally relate to our debt obligations. As of March 31, 2022, we had $1,344.1 million of debt outstanding, which includes $255.0 million within 1 to 3 years, and $1,089.1 million beyond 3 years. In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet.
Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our unfunded commitments.
As of March 31, 2022, we had approximately $371.3 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in a private equity fund. This excludes $39.7 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments.
As of March 31, 2022, we also had approximately $695.5 million of non-binding term sheets outstanding to twelve new companies and five existing companies, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.
The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.
Indemnification Agreements
We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act. We and our executives and directors are covered by Directors and
74
Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.
Distributions
Our Board maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% - 100% of our taxable quarterly income or potential annual income for a particular taxable year. In addition, at the end of our taxable year, our Board may choose to pay additional special distributions, so that we may distribute approximately all of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable year as part of any future distribution payments.
Distributions from our taxable income (including gains) to a stockholder generally will be treated as a dividend for U.S. federal income tax purposes to the extent of such stockholder’s allocable share of our current or accumulated earnings and profits. Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of a stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. As a result, any determination of the tax attributes of our distributions made on a quarterly basis may not be representative of the actual tax attributes of our distributions for a full taxable year.
Of the distributions declared during the year ended December 31, 2021, 100% were distributions derived from our current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2022 distributions to stockholders will actually be.
We maintain an “opt out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board authorizes, and we declare, a cash distribution, then our stockholders who have not “opted out” of our dividend reinvestment plan will have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions.
Shortly after the close of each calendar year information identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution, if any) will be provided to our stockholders subject to information reporting. To the extent our taxable earnings fall below the total amount of our distributions for any taxable year, a portion of those distributions may be deemed a tax return of capital to our stockholders.
We expect to qualify to be subject to tax as a RIC under Subchapter M of the Code. In order to be subject to tax as a RIC, we are required to satisfy certain annual gross income and quarterly asset composition tests, as well as make distributions to our stockholders each taxable year treated as dividends for federal income tax purposes of an amount at least equal to 90% of the sum of our investment company taxable income, determined without regard to any deduction for dividends paid, plus our net tax-exempt income, if any. Upon being eligible to be subject to tax as a RIC, we would be entitled to deduct such distributions we pay to our stockholders in determining the overall components of our “taxable income.” Components of our taxable income include our taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses and generally excludes net unrealized appreciation or depreciation as such gains or losses are not included in taxable income until they are realized. In connection with maintaining our ability to be subject to tax as a RIC, among other things, we have made and intend to continue to make the requisite distributions to our stockholders each taxable year, which generally should relieve us from corporate-level U.S. federal income taxes.
As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance Requirement. We will not be subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).
Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from our taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.
75
We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our debt. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.
We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
Critical Accounting Policies and Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.
For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation Measurements, Income Recognition, and Income Taxes. The valuation of investments is our most significant critical estimate. The most significant input to this estimate is the yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming no other changes:
(in thousands) |
|
Change in unrealized |
|
|
Basis Point Change |
|
appreciation (depreciation) |
|
|
(100) |
|
$ |
29,154 |
|
(50) |
|
$ |
14,728 |
|
50 |
|
$ |
(14,321 |
) |
100 |
|
$ |
(28,653 |
) |
For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to “Note 3 – Fair Value of Financial Instruments” included in the notes to our consolidated financial statements appearing elsewhere in this report.
76
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including Prime, LIBOR, SOFR, and BSBY rates, to the extent our debt investments include variable interest rates. As of March 31, 2022, approximately 94.7% of the loans in our portfolio had variable rates based on floating Prime, LIBOR, SOFR, or BSBY rates with a floor. As of March 31, 2022, approximately 18.5% of our debt investments have variable rates based on LIBOR. Additionally, all of our LIBOR rate based debt securities have interest rate floors. We are actively considering and discussing the preferred alternative benchmark with our portfolio companies and prioritize the inclusion of LIBOR fallback language in our documentation. The Alternative Reference Rates Committee ("ARRC") has recommended for US based debt securities to use the SOFR rate as the alternative benchmark. Our debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.
Based on our Consolidated Statements of Assets and Liabilities as of March 31, 2022, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt:
(in thousands) |
|
Interest |
|
|
Interest |
|
|
Net |
|
|
|
|
||||
Basis Point Change |
|
Income |
|
|
Expense |
|
|
Income |
|
|
EPS |
|
||||
(75) |
|
$ |
(4,202 |
) |
|
$ |
(329 |
) |
|
$ |
(3,873 |
) |
|
$ |
(0.03 |
) |
(50) |
|
$ |
(4,202 |
) |
|
$ |
(221 |
) |
|
$ |
(3,981 |
) |
|
$ |
(0.03 |
) |
(25) |
|
$ |
(4,081 |
) |
|
$ |
(111 |
) |
|
$ |
(3,970 |
) |
|
$ |
(0.03 |
) |
25 |
|
$ |
4,641 |
|
|
$ |
111 |
|
|
$ |
4,530 |
|
|
$ |
0.04 |
|
50 |
|
$ |
9,307 |
|
|
$ |
221 |
|
|
$ |
9,086 |
|
|
$ |
0.08 |
|
75 |
|
$ |
14,535 |
|
|
$ |
332 |
|
|
$ |
14,203 |
|
|
$ |
0.12 |
|
100 |
|
$ |
19,769 |
|
|
$ |
443 |
|
|
$ |
19,326 |
|
|
$ |
0.16 |
|
200 |
|
$ |
41,753 |
|
|
$ |
885 |
|
|
$ |
40,868 |
|
|
$ |
0.35 |
|
We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three months ended March 31, 2022, we did not engage in interest rate or foreign currency hedging activities.
Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.
Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds may increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio. For additional information regarding the interest rate associated with each of our debt borrowings and Credit Facilities, refer to Item 2 “Financial Condition, Liquidity and Capital Resources” in this quarterly report on Form 10-Q and “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report.
77
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Our chief executive and chief financial officers, under the supervision and with the participation of our management, conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. As of the end of the period covered by this quarterly report on Form 10-Q, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
78
PART II: OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.
ITEM 1A. RISK FACTORS
In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 22, 2022 (the “Annual Report”).
Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.
Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at March 31, 2022 that represent greater than 5% of our net assets:
|
March 31, 2022 |
|
|||||
(in thousands) |
Fair Value |
|
|
Percentage of Net Assets |
|
||
Corium, Inc. |
$ |
133,126 |
|
|
|
10.0 |
% |
Worldremit Group Limited |
$ |
100,930 |
|
|
|
7.6 |
% |
Rocket Lab Global Services, LLC |
$ |
90,873 |
|
|
|
6.8 |
% |
Phathom Pharmaceuticals, Inc. |
$ |
85,772 |
|
|
|
6.4 |
% |
uniQure B.V. |
$ |
79,397 |
|
|
|
6.0 |
% |
Convoy, Inc. |
$ |
77,171 |
|
|
|
5.8 |
% |
Delphix Corp. |
$ |
66,837 |
|
|
|
5.0 |
% |
Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.
The ongoing invasion of Ukraine by Russia and related sanctions have increased global political and economic
uncertainty, which may have a material impact on the Company’s portfolio and the value of your investment in the
Company.
The ongoing invasion of Ukraine by Russia and related sanctions have increased global political and economic uncertainty. In February 2022, Russia invaded Ukraine and, in response, the United States and many other countries placed economic sanctions on certain Russian entities and individuals. Because Russia is a major exporter of oil and natural gas, the invasion and related sanctions have reduced the supply, and increased the price, of energy, which is accelerating inflation and may exacerbate ongoing supply chain issues. There is also the risk of retaliatory actions by Russia against countries which have enacted sanctions, including cyberattacks against financial and governmental institutions, which could result in business disruptions and further economic turbulence. Although the Company has no known material direct exposure to Russia or Ukraine, the broader consequences of the invasion may have a material adverse impact on the Company’s portfolio and the value of your investment in the Company. Because this is an uncertain and evolving situation, its full impact is unknown at this time.
79
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Dividend Reinvestment Plan
During the three months ended March 31, 2022, we issued 60,326 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $1.0 million.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not Applicable
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable
ITEM 5. OTHER INFORMATION
Not Applicable
80
ITEM 6. EXHIBITS
Exhibit |
Description |
|
|
4.1 |
|
|
|
4.2 |
|
|
|
31.1* |
|
|
|
31.2* |
|
|
|
32.1* |
|
|
|
32.2* |
* Filed herewith.
(1) Incorporated by reference to Exhibits 4.1 and 4.2, as applicable, to the Company's Form 8-K (File No. 814-00702), filed on January 21, 2022.
81
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
For the Three Months Ended March 31, 2022 (unaudited)
(in thousands)
Portfolio Company |
|
Investment (1) |
|
Amount of Interest and Fees Credited to Income (2) |
|
|
Realized Gain (Loss) |
|
|
Fair Value as of |
|
|
Gross Additions (3) |
|
|
Gross Reductions (4) |
|
|
Net Change in Unrealized Appreciation/ (Depreciation) |
|
|
Fair Value as of March 31, 2022 |
|
|||||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Majority Owned Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Coronado Aesthetics, LLC (10) |
|
Preferred Stock |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
500 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
86 |
|
|
$ |
586 |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
65 |
|
|
|
— |
|
|
|
— |
|
|
|
(37 |
) |
|
|
28 |
|
Gibraltar Business Capital, LLC (5) |
|
Unsecured Debt |
|
|
850 |
|
|
|
— |
|
|
|
23,212 |
|
|
|
19 |
|
|
|
— |
|
|
|
(274 |
) |
|
|
22,957 |
|
|
|
Preferred Stock |
|
|
— |
|
|
|
— |
|
|
|
19,393 |
|
|
|
— |
|
|
|
— |
|
|
|
(897 |
) |
|
|
18,496 |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
1,225 |
|
|
|
— |
|
|
|
— |
|
|
|
(56 |
) |
|
|
1,169 |
|
Hercules Adviser LLC (6) |
|
Unsecured Debt |
|
|
111 |
|
|
|
— |
|
|
|
8,850 |
|
|
|
1,300 |
|
|
|
— |
|
|
|
— |
|
|
|
10,150 |
|
|
|
Member Units |
|
|
— |
|
|
|
— |
|
|
|
11,990 |
|
|
|
— |
|
|
|
— |
|
|
|
2,554 |
|
|
|
14,544 |
|
Total Majority Owned Control Investments |
|
|
|
$ |
961 |
|
|
$ |
— |
|
|
$ |
65,235 |
|
|
$ |
1,319 |
|
|
$ |
— |
|
|
$ |
1,376 |
|
|
$ |
67,930 |
|
Other Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Tectura Corporation(7) |
|
Senior Debt |
|
$ |
170 |
|
|
$ |
— |
|
|
$ |
8,269 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
78 |
|
|
$ |
8,347 |
|
|
|
Preferred Stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total Other Control Investments |
|
|
|
$ |
170 |
|
|
$ |
— |
|
|
$ |
8,269 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
78 |
|
|
$ |
8,347 |
|
Total Control Investments |
|
$ |
1,131 |
|
|
$ |
— |
|
|
$ |
73,504 |
|
|
$ |
1,319 |
|
|
$ |
— |
|
|
$ |
1,454 |
|
|
$ |
76,277 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Black Crow AI, Inc. (8) |
|
Preferred Stock |
|
$ |
— |
|
|
$ |
3,772 |
|
|
$ |
1,120 |
|
|
$ |
— |
|
|
$ |
(1,000 |
) |
|
$ |
(120 |
) |
|
$ |
— |
|
Pineapple Energy LLC (9) |
|
Senior Debt |
|
|
1,047 |
|
|
|
— |
|
|
|
7,747 |
|
|
|
— |
|
|
|
(4,781 |
) |
|
|
20 |
|
|
|
2,986 |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
591 |
|
|
|
400 |
|
|
|
— |
|
|
|
853 |
|
|
|
1,844 |
|
Total Affiliate Investments |
|
$ |
1,047 |
|
|
$ |
3,772 |
|
|
$ |
9,458 |
|
|
$ |
400 |
|
|
$ |
(5,781 |
) |
|
$ |
753 |
|
|
$ |
4,830 |
|
||
Total Control and Affiliate Investments |
|
$ |
2,178 |
|
|
$ |
3,772 |
|
|
$ |
82,962 |
|
|
$ |
1,719 |
|
|
$ |
(5,781 |
) |
|
$ |
2,207 |
|
|
$ |
81,107 |
|
||
82
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
For the three months ended March 31, 2021 (unaudited)
(in thousands)
Portfolio Company |
|
Investment (1) |
|
Amount of Interest and Fees Credited to Income (2) |
|
|
Realized Gain (Loss) |
|
|
Fair Value as of |
|
|
Gross Additions (3) |
|
|
Gross Reductions (4) |
|
|
Net Change in Unrealized Appreciation/ (Depreciation) |
|
|
Fair Value as of |
|
|||||||
Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Majority Owned Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Gibraltar Business Capital, LLC (5) |
|
Unsecured Debt |
|
$ |
629 |
|
|
$ |
— |
|
|
$ |
14,970 |
|
|
$ |
9,591 |
|
|
$ |
— |
|
|
$ |
(647 |
) |
|
$ |
23,914 |
|
|
|
Preferred Stock |
|
|
— |
|
|
|
— |
|
|
|
31,554 |
|
|
|
— |
|
|
|
— |
|
|
|
(6,942 |
) |
|
|
24,612 |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
2,276 |
|
|
|
— |
|
|
|
— |
|
|
|
(501 |
) |
|
|
1,775 |
|
Hercules Adviser LLC (6) |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9,869 |
|
|
|
9,869 |
|
Total Majority Owned Control Investments |
|
$ |
629 |
|
|
$ |
— |
|
|
$ |
48,800 |
|
|
$ |
9,591 |
|
|
$ |
— |
|
|
$ |
1,779 |
|
|
$ |
60,170 |
|
||
Other Control Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Tectura Corporation (7) |
|
Senior Debt |
|
$ |
170 |
|
|
$ |
— |
|
|
$ |
8,600 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(77 |
) |
|
$ |
8,523 |
|
|
|
Preferred Stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total Other Control Investments |
|
$ |
170 |
|
|
$ |
— |
|
|
$ |
8,600 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(77 |
) |
|
$ |
8,523 |
|
||
Total Control Investments |
|
$ |
799 |
|
|
$ |
— |
|
|
$ |
57,400 |
|
|
$ |
9,591 |
|
|
$ |
— |
|
|
$ |
1,702 |
|
|
$ |
68,693 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Black Crow AI, Inc. (8) |
|
Preferred Stock |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,000 |
|
|
$ |
— |
|
|
$ |
255 |
|
|
$ |
1,255 |
|
|
|
Convertible Debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,208 |
|
|
|
(3,993 |
) |
|
|
1,785 |
|
|
|
— |
|
Pineapple Energy LLC (9) |
|
Senior Debt |
|
|
1 |
|
|
|
— |
|
|
|
7,500 |
|
|
|
40 |
|
|
|
— |
|
|
|
— |
|
|
|
7,540 |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
840 |
|
|
|
— |
|
|
|
— |
|
|
|
29 |
|
|
|
869 |
|
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (10) |
|
Senior Debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(40 |
) |
|
|
40 |
|
|
|
— |
|
|
|
Common Stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total Affiliate Investments |
|
$ |
1 |
|
|
$ |
— |
|
|
$ |
8,340 |
|
|
$ |
3,248 |
|
|
$ |
(4,033 |
) |
|
$ |
2,109 |
|
|
$ |
9,664 |
|
||
Total Control and Affiliate Investments |
|
$ |
800 |
|
|
$ |
— |
|
|
$ |
65,740 |
|
|
$ |
12,839 |
|
|
$ |
(4,033 |
) |
|
$ |
3,811 |
|
|
$ |
78,357 |
|
||
83
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of March 31, 2022 (unaudited)
(in thousands)
Portfolio Company |
|
Industry |
|
Type of Investment (1) |
|
Maturity Date |
|
Interest Rate and Floor |
|
Principal or Shares |
|
|
Cost |
|
|
Value (2) |
|
|||
Control Investments |
|
|||||||||||||||||||
Majority Owned Control Investments |
|
|||||||||||||||||||
Coronado Aesthetics, LLC |
|
Medical Devices & Equipment |
|
Preferred Series A Equity |
|
|
|
|
|
|
5,000,000 |
|
|
$ |
250 |
|
|
$ |
586 |
|
|
|
Medical Devices & Equipment |
|
Common Stock |
|
|
|
|
|
|
180,000 |
|
|
|
— |
|
|
|
28 |
|
Total Coronado Aesthetics, LLC |
|
|
$ |
250 |
|
|
$ |
614 |
|
|||||||||||
Gibraltar Business Capital, LLC |
|
Diversified Financial Services |
|
Unsecured Debt |
|
September 2026 |
|
Interest rate FIXED 14.50% |
|
$ |
15,000 |
|
|
$ |
14,674 |
|
|
$ |
13,628 |
|
|
|
Diversified Financial Services |
|
Unsecured Debt |
|
September 2026 |
|
Interest rate FIXED 11.50% |
|
$ |
10,000 |
|
|
|
9,830 |
|
|
|
9,329 |
|
|
|
Diversified Financial Services |
|
Preferred Series A Equity |
|
|
|
|
|
|
10,602,752 |
|
|
|
26,122 |
|
|
|
18,496 |
|
|
|
Diversified Financial Services |
|
Common Stock |
|
|
|
|
|
|
830,000 |
|
|
|
1,884 |
|
|
|
1,169 |
|
Total Gibraltar Business Capital, LLC |
|
|
$ |
52,510 |
|
|
$ |
42,622 |
|
|||||||||||
Hercules Adviser LLC |
|
|
|
Unsecured Debt |
|
May 2023 |
|
Interest rate FIXED 5.00% |
|
$ |
10,150 |
|
|
$ |
10,150 |
|
|
$ |
10,150 |
|
|
|
|
|
Member Units |
|
|
|
|
|
|
1 |
|
|
|
35 |
|
|
|
14,544 |
|
Total Hercules Adviser LLC |
|
|
$ |
10,185 |
|
|
$ |
24,694 |
|
|||||||||||
Total Majority Owned Control Investments (5.09%)* |
|
|
$ |
62,945 |
|
|
$ |
67,930 |
|
|||||||||||
Other Control Investments |
|
|||||||||||||||||||
Tectura Corporation |
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
PIK Interest 5.00% |
|
$ |
10,680 |
|
|
$ |
240 |
|
|
$ |
— |
|
|
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
Interest rate FIXED 8.25% |
|
$ |
8,250 |
|
|
|
8,250 |
|
|
|
8,250 |
|
|
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
PIK Interest 5.00% |
|
$ |
13,023 |
|
|
|
13,023 |
|
|
|
97 |
|
|
|
Internet Consumer & Business Services |
|
Preferred Series BB Equity |
|
|
|
|
|
|
1,000,000 |
|
|
|
— |
|
|
|
— |
|
|
|
Internet Consumer & Business Services |
|
Common Stock |
|
|
|
|
|
|
414,994,863 |
|
|
|
900 |
|
|
|
— |
|
Total Tectura Corporation |
|
|
$ |
22,413 |
|
|
$ |
8,347 |
|
|||||||||||
Total Other Control Investments (0.63%)* |
|
|
$ |
22,413 |
|
|
$ |
8,347 |
|
|||||||||||
Total Control Investments (5.72%)* |
|
|
$ |
85,358 |
|
|
$ |
76,277 |
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Affiliate Investments |
|
|||||||||||||||||||
Pineapple Energy LLC |
|
Sustainable and Renewable Technology |
|
Senior Secured Debt |
|
December 2024 |
|
PIK Interest 10.00% |
|
$ |
3,000 |
|
|
$ |
3,000 |
|
|
$ |
2,986 |
|
|
|
Sustainable and Renewable Technology |
|
Common Stock |
|
|
|
|
|
|
498,978 |
|
|
|
5,167 |
|
|
|
1,844 |
|
Total Pineapple Energy LLC |
|
|
$ |
8,167 |
|
|
$ |
4,830 |
|
|||||||||||
Total Affiliate Investments (0.36%)* |
|
|
$ |
8,167 |
|
|
$ |
4,830 |
|
|||||||||||
Total Control and Affiliate Investments (6.08%)* |
|
|
$ |
93,525 |
|
|
$ |
81,107 |
|
|||||||||||
* Value as a percent of net assets
84
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of and for the year ended December 31, 2021
(in thousands)
Portfolio Company |
|
Industry |
|
Type of Investment (1) |
|
Maturity Date |
|
Interest Rate and Floor |
|
Principal or Shares |
|
|
Cost |
|
|
Value (2) |
|
|||
Control Investments |
|
|||||||||||||||||||
Majority Owned Control Investments |
|
|
|
|
|
|
|
|
|
|||||||||||
Coronado Aesthetics, LLC |
|
Medical Devices & Equipment |
|
Preferred Series A Equity |
|
|
|
|
|
|
5,000,000 |
|
|
$ |
250 |
|
|
$ |
500 |
|
|
|
Medical Devices & Equipment |
|
Common Stock |
|
|
|
|
|
|
180,000 |
|
|
|
— |
|
|
|
65 |
|
Total Coronado Aesthetics, LLC |
|
|
|
|
$ |
250 |
|
|
$ |
565 |
|
|||||||||
Gibraltar Business Capital, LLC |
|
Diversified Financial Services |
|
Unsecured Debt |
|
September 2026 |
|
Interest rate FIXED 14.50% |
|
$ |
15,000 |
|
|
$ |
14,662 |
|
|
$ |
13,818 |
|
|
|
Diversified Financial Services |
|
Unsecured Debt |
|
September 2026 |
|
Interest rate FIXED 11.50% |
|
$ |
10,000 |
|
|
|
9,823 |
|
|
|
9,394 |
|
|
|
Diversified Financial Services |
|
Preferred Series A Equity |
|
|
|
|
|
|
10,602,752 |
|
|
|
26,122 |
|
|
|
19,393 |
|
|
|
Diversified Financial Services |
|
Common Stock |
|
|
|
|
|
|
830,000 |
|
|
|
1,884 |
|
|
|
1,225 |
|
Total Gibraltar Business Capital, LLC |
|
|
|
|
$ |
52,491 |
|
|
$ |
43,830 |
|
|||||||||
Hercules Adviser LLC |
|
Diversified Financial Services |
|
Unsecured Debt |
|
May 2023 |
|
Interest rate FIXED 5.00% |
|
$ |
8,850 |
|
|
$ |
8,850 |
|
|
$ |
8,850 |
|
|
|
Diversified Financial Services |
|
Member Units |
|
|
|
|
|
|
1 |
|
|
|
35 |
|
|
|
11,990 |
|
Total Hercules Adviser LLC |
|
|
|
|
$ |
8,885 |
|
|
$ |
20,840 |
|
|||||||||
Total Majority Owned Control Investments (4.99%)* |
|
|
|
|
$ |
61,626 |
|
|
$ |
65,235 |
|
|||||||||
Other Control Investments |
|
|
|
|
|
|
|
|
|
|||||||||||
Tectura Corporation |
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
PIK Interest 5.00% |
|
$ |
10,680 |
|
|
$ |
240 |
|
|
$ |
— |
|
|
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
Interest rate FIXED 8.25% |
|
$ |
8,250 |
|
|
|
8,250 |
|
|
|
8,250 |
|
|
|
Internet Consumer & Business Services |
|
Senior Secured Debt |
|
July 2024 |
|
PIK Interest 5.00% |
|
$ |
13,023 |
|
|
|
13,023 |
|
|
|
19 |
|
|
|
Internet Consumer & Business Services |
|
Preferred Series BB Equity |
|
|
|
|
|
|
1,000,000 |
|
|
|
— |
|
|
|
— |
|
|
|
Internet Consumer & Business Services |
|
Common Stock |
|
|
|
|
|
|
414,994,863 |
|
|
|
900 |
|
|
|
— |
|
Total Tectura Corporation |
|
|
|
|
$ |
22,413 |
|
|
$ |
8,269 |
|
|||||||||
Total Other Control Investments (0.63%)* |
|
|
|
|
$ |
22,413 |
|
|
$ |
8,269 |
|
|||||||||
Total Control Investments (5.62%)* |
|
|
|
|
$ |
84,039 |
|
|
$ |
73,504 |
|
|||||||||
Affiliate Investments |
|
|
|
|
|
|
|
|
|
|||||||||||
Black Crow AI, Inc. |
|
Internet Consumer & Business Services |
|
Preferred Series Seed |
|
|
|
|
|
|
872,797 |
|
|
$ |
1,000 |
|
|
$ |
1,120 |
|
Pineapple Energy LLC |
|
Sustainable and Renewable Technology |
|
Senior Secured Debt |
|
December 2023 |
|
PIK Interest 10.00% |
|
$ |
7,500 |
|
|
|
7,500 |
|
|
|
7,500 |
|
|
|
Sustainable and Renewable Technology |
|
Senior Secured Debt |
|
January 2022 |
|
Interest rate FIXED 10.00% |
|
$ |
280 |
|
|
|
280 |
|
|
|
247 |
|
|
|
Sustainable and Renewable Technology |
|
Common Stock |
|
|
|
|
|
|
3,000,000 |
|
|
|
4,767 |
|
|
|
591 |
|
Total Pineapple Energy LLC |
|
|
|
|
$ |
12,547 |
|
|
$ |
8,338 |
|
|||||||||
Total Affiliate Investments (0.72%)* |
|
|
$ |
13,547 |
|
|
$ |
9,458 |
|
|||||||||||
Total Control and Affiliate Investments (6.34%)* |
|
|
$ |
97,586 |
|
|
$ |
82,962 |
|
|||||||||||
* Value as a percent of net assets
85
SIGNATURES
Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
HERCULES CAPITAL, INC. (Registrant) |
|
|
|
Dated: May 5, 2022 |
|
/S/ SCOTT BLUESTEIN |
|
|
Scott Bluestein |
|
|
President, Chief Executive Officer, and Chief Investment Officer |
|
|
|
Dated: May 5, 2022 |
|
/S/ SETH H. MEYER |
|
|
Seth H. Meyer |
|
|
Chief Financial Officer, and Chief Accounting Officer |
86